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ABSTRACT  
The aim of this study was to isolate and characterise equine mesenchymal stromal 
cells from various sources and to compare their biological properties to that of 
dermal fibroblasts. By using multiple conventional methods a comparative analysis 
of the different populations could be made. The results showed that little 
distinguishes mesenchymal stromal cells from dermal fibroblasts, they have the 
same morphology and growth characteristics, the same cell surface markers as 
demonstrated with immunocytochemistry and flow cytometry and the capacity to 
undergo trilineage differentiation into adipo-, chondro- and osteogenic lineages 
essentially becoming fat, cartilage and bone. An allogenic synovial fluid model was 
shown to induce a chondrogenic phenotype in equine mesenchymal stromal cells 
as well as dermal fibroblasts. A bio-activation assay was performed to evaluate 
cytokine production of cell populations after activation with Tumour necrosis factor 
alpha or inflammatory synovial fluid. All of the analysed cell populations 
demonstrated up-regulation of production of the anti-inflammatory cytokines IL-10 
and TGF-β1, after activation with inflammatory synovial fluid, although significant 
values could not be obtained for every source. As for Prostaglandin E2, results were 
obtained for bone marrow stromal cells and dermal fibroblasts populations only. 
Their effects were in opposite; dermal fibroblast reduced the production of 
Prostaglandin E2 post activation. A functional bio-activation assay has shown 
promise as a method to distinguish equine mesenchymal stromal cells from dermal 
fibroblast populations. 
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CHAPTER 1: LITERATURE REVIEW  
1.1 INTRODUCTION 
Mesenchymal stromal cells (MSC) as a cellular-based regenerative treatment option 
have created great interest in the equine industry for the last decade (Clegg 2012). 
Numerous studies have investigated their use for conditions including equine 
osteoarthritis (Broeckx et al. 2014a; Frisbie et al. 2009; McIlwraith et al. 2011) 
tendinopathy (Godwin et al. 2012; Renzi et al. 2013), ulcerative keratitis (Marfe et 
al. 2012) and wound therapy (Spaas et al. 2013a). Musculo-skeletal injuries often 
involve long recovery periods with high re-injury rates, due to the inherent inability 
for functional repair of some of these tissues. A treatment that can repair defective 
cartilage in a joint or aid in the engineering of a new tendon is an enticing prospect 
for researchers and clinicians. 
 
Mesenchymal stromal cells are derived from many sources with adipose tissue and 
bone marrow being the most studied in the equine field. However, several other 
sources are also being explored; among them placental and umbilical cord tissue, 
peripheral blood, tendons, dental pulp and periodontal tissue. The skin dermis is 
also a tissue of mesenchymal origin. Recent studies in human medicine on wound 
healing and skin regeneration are progressively investigating the relationship 
between dermal fibroblasts and stem cells (Brohem et al. 2013; Feisst et al. 2013; 
Lorenz et al. 2008). An important feature of MSC is their differentiation potential 
involves at least three specialised cell types from the mesenchymal tissues; fat, bone 
and cartilage. Stromal cells from bone marrow, umbilical cord (perivascular tissue) 
and also dermally derived fibroblasts have been induced to differentiate into 
adipocytes, chondrocytes and osteocytes. 
  
There are many protocols published for isolation of MSC from the various sources 
and the methods for identification of MSC also varies between studies. The type of 
injuries exhibits significant variability. For example clinical trials that treat 
naturally occurring injuries often only report favourable results consisting of 
outcome variables like “ Return to Full work (RTW)” at various levels and/ or  re-
injury rates during a set follow up period (Herthel 2001; Pacini et al. 2007; Rich 
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2014). However, the assessment is subjective rather than objective which some of 
the authors acknowledge. Other variables like; horse factors, owner factors, 
veterinary factors, husbandry and rehabilitation protocols can be present, which can 
confound the results. Other studies in a controlled laboratory setting can eliminate 
some of these factors. However, there may be other factors at play; the type of injury 
for example; iatrogenic injuries are created for the purpose of the study; surgical or 
collagenase methods are accepted methods to create a lesion, but are these models 
comparable to naturally occurring injuries? The controlled studies have the 
advantage that the animals are euthanised and histology can be performed to further 
quantify the degree and quality of healing that has occurred. The timing of 
euthanasia and histological interpretation varies among studies, which will have an 
impact on the results. All of the above factors make comparison of results difficult 
for the clinician and there are no set guidelines on what source of MSC is preferable 
nor the dose and method of deliverance. The majority of equine MSC studies to 
date have evaluated autologous mesenchymal stromal cells derived from the patient 
itself. However, equine MSCs have also been used for allogenic cellular therapy 
where the cells are derived from a donor (Broeckx et al. 2014a; Ricco et al. 2013; 
Van Loon et al. 2014). This approach reduces the time lag from injury to treatment 
which typically require up to 14-21 days to multiply enough cells for treatment, and 
could provide a cost effective off-the-shelf treatment option. Despite many 
international groups focusing their research on this topic, the understanding of the 
properties and effects of equine MSC are developing more slowly than the clinical 
implementation. Ongoing research is imperative so that MSC can be offered as a 
safe and efficacious treatment modality in equine medicine.  
 
The outline of this literature review is to provide a background of the equine 
industry in New Zealand and wastage associated with musculo-skeletal injury. The 
anatomy and pathophysiology of tendons and synovial joints will be discussed in 
detail as these structures are the main targets for MSC therapy in horses. It will also 
describe and contrast MSC and fibroblasts with respect to i.) physical properties as 
defined with conventional methods, as well as ii.) functionality, which include new 
concepts like immunomodulation. The idea that MSC as well as fibroblasts control 
the inflammatory response is then further explored in the experimental section. If 
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the functionality of MSC and fibroblasts could be defined, there is the potential for 
developing a more efficient stromal cell therapeutic program. 
 
The equine industry in New Zealand 
Lameness due to musculoskeletal injuries (MSI) cause reduced or lost performance 
in equine athletes and have significant negative economic impact to the equine 
industry. The New Zealand racing industry maintains approximately 8900 
Thoroughbreds and 5200 Standardbreds in training for approximately 8-9 months 
a year. In New Zealand a Thoroughbred in training costs $14-20K per annum and 
a Standardbred costs $10-15k per annum. Racing contributes $1.6 billion (0.9% of 
GDP) to the New Zealand economy and directly employs 8,877 people. Export 
revenue of $167 million is generated by the Thoroughbred Racing industry for New 
Zealand with the annual yearling auction sales alone boosting the economy by more 
than $57 million. The returns to owners are $53 million in prize money (NZTR 
Annual report 2014-2015).  
 
Tanner et al. (2012) reported that based on the number of foals born in New 
Zealand, the Thoroughbred breeding industry is ranked 8th in the world and the 
Standardbred breeding industry is ranked 9th. In the 2009/2010 season, 6,488 
Thoroughbred mares were served by 167 stallions resulting in 4,132 foals and 3,981 
Standardbred mares were served by 92 stallions resulting in 2,801 foals (Tanner et 
al., 2012). The latest data obtained from 2015 estimated the Thoroughbred foal crop 
to be 3719 foals, which was up from 3551 foals born in 2014 (NZTR Annual report 
2014-2015). 
 
Animal welfare is a priority for New Zealand Thoroughbred Racing (NZTR). They 
report the number of horses leaving thoroughbred racing and breeding in New 
Zealand each year to be 800 animals. They have introduced a mandatory 
notification system of horse retirement and expanded the partnerships with 
Thoroughbreds in Equestrian Sport (TiES) and Equestrian Sport New Zealand 
(ESNZ) in endeavour to give retired racehorses a career as sport horses. New 
Zealand Standardbred Breeders' Association actively promote “Life After Racing” 
to minimise wastage of horses after their racing career 
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(http://www.harnessracing.co.nz/life-after-racing). They also support The New 
Zealand Standardbred Riding Association, which was formed in 1992 with the aim 
to encourage and promote the ridden Standardbred. 
 Wastage definition 
Wastage can be used as a broad term in the equine industry, describing loss from 
all areas of the supply chain from conception through to racing (Tanner et al. 2012). 
Wastage can be further defined as, “horses purpose-bred for racing which failed to 
race or participate to their full potential” (McCarthy 2009). The effect of wastage 
on the racing industry can be objectively measured through analyses of days lost in 
training, early retirement from racing or death, the cost of diagnosis and treatment 
of injuries, opportunity cost of investment (Bailey et al. 1997; Dyson et al. 2008).  
 Wastage factors and musculoskeletal injuries quantified  
Several studies in the UK have investigated and quantified wastage factors in 
Thoroughbred racing. In 1982 (Jeffcott et al) identified 246 cases of 
musculoskeletal lameness in 163 horses. Fifty-three percent (53%) of horses that 
raced experienced one or more periods of lameness and in 34 cases (13.8%), the 
condition was sufficiently severe to force retirement. This study was followed up 
by Rossdale et al. (1985) who reported the greatest number of days lost to training 
were caused by lameness (67.6%). Similar figures were reported in Australia by 
Bailey et al. (1997), where “sore shins” (dorsal metacarpal disease) was the most 
prevalent MS injury. A later UK study by Wilsher et al. (2006) reported that 
musculoskeletal injuries accounted for 55% of injuries in 2 year olds and 41% of 
injuries in 3 year olds in training. Furthermore, Dyson et al. (2008) reported that 
lameness was the leading cause of days lost from training. Paris and Stout (2010) 
reported 15-25% of horses requiring spelling from training had joint problems, 
while tendon and ligament injuries accounted for 46% of horses requiring spelling. 
Clegg (2012) reported tendon and ligament injuries as the major cause of morbidity 
and premature retirement in racehorses in the UK.  
 
While the horse is unable to race its’ earning potential is lost and the costs of 
rehabilitation are high. Costs include; feeding, stabling, spelling and veterinary 
expenses. Following treatment and rest from training a case controlled study of 400 
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horses in the UK revealed that the re-injury rate of tendon and ligament injury was 
53% (O'Meara et al. 2010).  
 
In an early New Zealand study, a survey by Hamlin and Hopkins (2003) 
investigated trainer-reported health and training-related problems in Standardbred 
horses and found that trainers perceived that horses were more likely to suffer from 
infections and illness than musculoskeletal problems. However, two years later 
Perkins et al. (2005) reported that in New Zealand, out of 1571 horses followed 
during 3,333 training preparations and 392,290 training days, musculoskeletal 
injuries were associated with the end of a training preparation or spell period in 834 
cases; lameness (N=400), shin soreness (N=207), tendon and ligament conditions 
(N=98), injury or laceration (N=56), fractures (N=55), and back disorders (N=18). 
Thus, 97% of these cases involved the limbs. A later study by Bolwell et al. (2011b) 
found similar results; musculoskeletal injury was responsible for 83.3% of 
involuntary interruptions to training in a cohort of 2-year-old Thoroughbred 
racehorses in New Zealand. Wastage can also be quantified by the number of horses 
that fail to enter training. McCarthy (2009) found that approximately 32% of TB 
and SB failed to enter training in New Zealand. In New Zealand, a study that 
followed an entire annual crop of Standardbred foals reported that 51.9% 
(1,575/3,032) failed to start in a race (Tanner et al. 2010).  
 
1.2 INFLAMMATION 
Inflammation is the physiological response by the immune system to tissue trauma 
or infection. The cells of the immune system are involved in tissue healing and 
initiate repair by fibrosis. Figure 1 is a simplified diagram of the stages of the 
inflammatory process 
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Figure 1 Stages of the inflammatory cascade simplified. Time scale for stages in 
weeks after initial injury 
A cascade of local and systemic events and various cell types and their chemical 
messengers (cytokines) are involved in inflammation (Prockop 2013) as depicted89 
in Figure 2.  Prockop (2013) lists four basic components of inflammation i.) 
exogenous or endogenous stimuli for inflammation such as the products of micro-
organisms or injured cells, called “Inducers”, ii.) “Sensors” that consist primarily 
of macrophages and mast cells that are found locally in the tissue, which express 
receptors for Inducers. Their response is to produce a variety of pro-inflammatory 
“Mediators”, iii.) Mediators are chemokines, amines, and eicosanoids released by 
the Sensors, iv.) “Effectors” are adjacent cells in tissues that respond to Mediators 
by amplifying their signals to attract the defence system (WBCs). MSC are a type 
of regulatory cell population which can regulate the generic pathway of 
inflammation by two negative feedback loops, as depicted in Figure 3. 
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Figure 2 Inflammatory pathway showing the flow-on effects from Inducers – 
Sensors – Mediators – Target tissues. Adapted from Prockop (2013). 
 
When MSC are activated by certain mediators like TNFα they upregulate COX2 
expression and the arachidonic acid pathway, which leads to an increase in secretion 
of prostaglandin E2 (PGE2). Which in turn will affect macrophages (Sensors) and 
promote a switch from a pro-inflammatory phenotype to a more poorly defined 
phenotype that will secrete anti-inflammatory mediators like IL-10 and interleukin-
1 (IL-1) receptor antagonist. When MSCs being activated by Mediators secreted 
from Sensors a second negative feedback loop occurs. The activated MSCs increase 
expression of a number of genes, including the anti-inflammatory protein TNFα 
stimulated gene/protein 6 (TSG-6). TSG-6 has multiple anti-inflammatory 
actions on macrophages, and the overall effect is a decrease in the secretion of 
TNFα and other Mediators that target Effectors. MSC also secrete other Mediators 
like indolamine 2,3 dioygenase (IDO), Interleukin-10, Transforming growth factor 
beta (TGF-β), nitric oxide (NO) among others that have direct effects on immune 
cells (Uccelli and Rosbo 2015) cytokines are discussed further in chapter 1.6.2. 
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Figure 3 Schematic overview on MSC function during inflammation and the two 
negative feedback loops via i.) PGE2 as well as ii.) TSG-6 secretion adapted from 
Prockop (2013) 
Acute inflammation is an important part of the equine immune response and needed 
for healing to occur. However, chronic, inappropriate and excessive inflammation 
can lead to further damage (Dakin 2016). For example when a horse presents with 
acute traumatic tendinopathy of the superficial digital flexor tendon, there is 
disruption of tendon fibres and visible area of surrounding haemorrhage leading to 
a clot forming (Dowling et al. 2000). The variables commonly assessed are location, 
lesion type, tendon and lesion cross sectional area and fibre alignment. When hyper 
extension trauma has occurred, the injury will change with time. If the 
inflammatory response is excessive which can happen if the injury is left untreated, 
a distinct core lesion will become visible on an ultrasonographic exam after 3-
5days. An excessive inflammatory response is also present in degenerative joint 
disease (DJD), osteo-arthritis (OA), where excessive inflammation of the synovium 
further exacerbate the initial injury leading to the induction of a chronic disease 
state (McIlwraith et al. 2012) and in autoimmune diseases. 
 
Several cell types in the immune cascade are needed for healing and resolution 
(Dakin 2016). Tissue-specific progenitor cells or “stem cells” reside in the tendon 
and are involved in the process of replenishing cells lost due to natural cell turnover 
but also to assist in the vent of post injury repair (Richardson et al. 2007). The stem 
cells are activated by inflammatory cytokines (TNFα and IL-1β) and then 
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themselves become involved in regulating the cascade as well as re-building the 
tissue (Kamm et al. 2010). In a clinical application the aim is to promote and utilise 
the anti-inflammatory properties of the MSCs as well as their capacity for self-
renewing. In equine tendinopathy, healing by fibrosis (scar tissue formation) is 
considered inferior due to an inherent weakness of the junction between the scar 
tissue and the intact tendon.  
 
For example, Figure 4 illustrate the events seen in tendonopathies; a.) In the acute 
phase swelling, heat and pain is noted on palpation. b.) anatomy of interest c.) there 
is damage to the tendon fibres and cytokine and chemokine release which initiates 
an influx of inflammatory cells to the area and activates resident stromal cells. d.) 
Ultrasonography is not recommend in the first few days post injury as there is 
limited visibility of the damaged tissue. However, for SDFT core lesions; a distinct 
area of decreased echogenicity can be seen on the ultrasonography scan three to 
five days later. This is due to timing of events in the inflammatory process and 
secreted catabolic enzymes that cause further damage to the tendon tissue. 
Excessive inflammation can also cause prolonged discomfort to the animal 
(lameness, swelling, heat and pain). Conservative treatment of tendon injuries 
includes; rest, cooling therapy (cold water hosing or ice-wraps) and non-steroidal 
medication and will be further discussed later.  
 
Figure 4 Superficial Digital flexor tendon injury explained a.) Physical appearance 
“Bowed tendon” b.) Anatomical location of injury c.) Ruptured tendon fibres d.) 
Ultrasonographic appearance, area of decreased echogenicity as seen on a cross 
sectional view (left injured, right normal). Pictures retrieved online 05/10/16  
a.) http://stable equestrian.net/cms/wpcontent/uploads/2015/06/TendonInjuryText.  jpg 
b.) http://www.science-art.com/gallery/24357/24357_4302012164337.jpg   
c.) http://www.missourifoxtrottersatoz.com/images/fiber%20bundles.jpg  
d.)http://www.auntminnieeurope.com/user/images/content_images/sup_ult/2012_12_19_
12_02_17_137_2012_12_19_equine_US.jpg 
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1.3 LAMENESS IN PERFORMANCE HORSES  
Lameness is common in the performance horse as discussed above. This section 
will aim to describe the anatomy and function of tendons and synovial joints as 
these historically have been the targets of MSC therapy. This will provide an 
understanding of the complexity of healing these tissues and why clinicians are 
exploring regenerative treatment options. 
1.3.1 TENDON ANATOMY AND FUNCTION 
Tendons are elastic, dynamic structures that connect muscle to bone. Their function 
is to facilitate movement, absorb shock and support the lower limbs (Thorpe et al. 
2010). Tendons are composed predominantly of water (approximately 70%), of the 
remaining 30% dry matter, the cellular component are made up of tenocytes which 
produce a dense, fibrous extra-cellular matrix of collagen type I (Dowling et al. 
2000). Collagen types II, III, IV and V are also present in normal flexor tendons 
although in smaller quantities and in specific locations. Type II collagen is found 
within enthesious insertions, the specialised interface between tendon and bone and 
regions where the tendon changes direction around a bony prominence 
(Apostolakos et al. 2014). This part of the tendon has a more fibrocartilage-like 
nature that can withstand compressional as well as tensional forces. Types III, IV 
and V are found in basement membranes and endotendon. The function of the 
tendon is reflected in the mechanical properties of the tendon tissue, The collagen 
fibrils are aligned in the direction of force application (Thorpe et al. 2010), the 
fibrils have crimp for elasticity and extensive crosslinking, resulting in high tensile 
strength. The collagen fibril was previously considered to be the primary unit 
contributing to the strength of the tendon, however more recently, the intra- and 
inter-fibril collagen cross-links and electrostatic cross-links provided by the non-
collagenous proteins like proteoglycans have been considered to contribute 
significantly to the tendons’ biomechanical properties (Dowling et al. 2000). The 
collagen fibrils group together to form fibrils, fibres and fascicles, to form a 
functional tendon (Thorpe (2013).  
 
The tenocytes are the cells of the tendon tissue, present only in small numbers in 
the fascicles between the collagen fibrils. Their function is to produce the collagen 
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and proteoglycans and remodel the matrix by secretion of enzymes, matrix 
metalloproteinases, for degradation of injured or defective tendon tissue (Thorpe et 
al. 2010). The cellularity of the superficial digital flexor tendon (SDFT) and the 
common digital extensor tendon (CDET) is greatly reduced up to two years of age, 
then more gradually during ageing (Patterson-Kane et al. 2012) 
 
 
Figure 5 Ultrasound scanning of the equine superficial digital flexor tendon, A.) 
Transverse scanning B.) Longitudinal scanning C.) Core lesion visible (round 
hypoechoic area within the SDFT D.) Fibre disruption (elongated hypoechoic area). 
Images produced by a Sonosite Micro MAXX. 
 
Tendon and ligament injuries are a major cause of lameness in the equine athlete 
and affect horses at all levels, representing a significant animal welfare concern and 
economic loss to the equine industry. Figure 5 is an example of a SDFT core lesion 
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and typical ultrasonograms. General factors implicated causing tendon injuries are 
fatigue, lack of fitness and poor confirmation (Dowling et al., 2002). In a survey of 
Thoroughbred racehorses in Hong Kong between 1992-2004 it was reported that 
the majority of the tendon injuries (97%) occurred in the forelimb tendons (Lam et 
al. 2007). This can be related to high strains placed on the equine forelimbs, which 
carry more than 60% of the total weight of the horse when galloping (Thorpe et al. 
2010). Excessive and repeated loading like jumping and galloping, cause repetitive 
micro damage. This localised damage of fibrils occurs when the tendon reaches 
80% of failure strain. The micro damage is accompanied by increased gene 
expression and production of matrix metalloproteinases in the tendon. (Hosaka et 
al. 2006) showed increased production of MMP-9 and TNF-α in vitro when 
tenocytes where exposed to temperatures over 40°C. The microdamage is 
accumulative and if not repaired by tenocytes it may result in clinical injury (Thorpe 
et al. 2010). Other studies have also proposed that exercise-induced hyperthermia 
is a possible mechanism for tendinopathy (Birch et al., 1997; Patterson-Kane et al., 
2012). Increased temperature occurs within viscoelastic materials as energy is 
released during repeated loading, and hyperthermia is a likely contributor to 
degenerative changes observed in tendinopathies (Youngstrom 2015). Core 
temperatures of 43-45°C have been measured in the Superficial Digital Flexor 
Tendon (SDFT at high speed locomotion (Wilson and Goodship 1994). Tenocytes 
have shown prolonged heat resistance in vitro, however hyperthermic conditions 
may compromise cell metabolism and cause degeneration of matrix components 
and predispose to traumatic injury (Birch et al., 1997). Hosaka et al. (2006) showed 
that exposure of tenocytes to temperatures over 40°C significantly increased the 
production of MMP-9 in vitro, the production of the pro-inflammatory cytokine 
TNF-α was also increased with prolonged exposure 30-60min above 40°C. Birch 
et al., (1997) also described a hypoxic environment in the tendon core, which may 
further compromise cellular activity. Excessive loading may contribute to 
tendinopathy by activation of prostaglandin E2-mediated pathways, reducing 
tendon stem cell population size and encouraging differentiation into non-tenocyte 
lineages (Youngstrom 2015).  
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 Healing and repair  
When a damaged tendon heals naturally, it heals by the formation of a scar and not 
neo-tendon, hence it loses a substantial part of its original strength and elasticity 
(Dakin 2016). Therefore, tendons can be said to recover structurally (reparation) 
but not functionally (regeneration). The importance of inflammation in tendon 
healing is discussed by Dakin (2016), who suggest that excessive and persistent 
inflammation as the main drive for fibrosis. Fibrotic scar tissue consists of collagen 
type III, which is less elastic than normal tendon tissue (collage type I). Scar tissue 
cannot withstand the same loads and stress as the original structure. Tendon injuries 
carry a high risk of re-injury, some studies reporting 75% (range 23-75%) (Clegg 
2012; O'Meara et al. 2010; Renzi et al. 2013) of horses treated conservatively will 
re-injure within 2 years of the original injury. The re-injury occurs because of 
reduced failure strains and forces applied to the junction between scar tissue and 
normal tendon, will cause breakdown sooner compared with a normal healthy 
tendon, due to a decreased failure strain threshold (Thorpe et al. 2010). 
 Treatment options for tendinopathies 
Treatment options for tendon and ligament injuries are many and often a 
combination of several different treatments at the various stages identified in tendon 
healing. i.) An initial period of stall confinement and rest is required to reduce the 
discomfort for the horse and attempt to stabilise the injury by not objecting it to 
further strain. ii.) Physical treatments are performed that aim to reduce swelling of 
the tendon and minimise inflammation and associated pain. These treatments 
include initial cold hosing, ice-boots and bandaging iii.) Anti-inflammatory 
treatments including: systemic non-steroidal anti-inflammatories (NSAIDs), 
topical dimethylsulphoxide (DMSO) and diclofenac. Other substances have been 
used for intra-lesional injections; historically Beta-aminopropionitrile 
fumarate (BAPN) was used (Alves et al. 2001; Dowling et al. 2000), but this is no 
longer practised (Prof C. Riley, personal communication). However, a recent paper 
by Jann et al. (2016) reported a favourable outcome on tendon healing using a 
modified hyaluronic acid gel in an in vivo surgical model  iv.) A rigorous 
rehabilitation program is one of the major factors that affect the outcome of tendon 
healing (Rich 2014). After an initial period of box rest (1-4weeks) the horse is 
allowed hand walking twice daily with increasing times over a 3-4 month period 
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(Renzi et al. 2013). Monitoring with repeat ultra sound scans would determine the 
progression and trotting in a straight line may be introduced after 3-4 months. In 
general the rehabilitation program would be performed for 9-12months before the 
horse can resume to full work. Exposure to even and increasing loads by force is 
required to correctly align and strengthen the newly formed collagen fibres. Many 
practitioners lose control over their race horse patients when they are spelling or 
away from the track. It is imperative that communication and regular follow ups are 
performed to ensure the best outcome for the patient. vi.) Biological treatment 
options are readily available to the equine practitioner and include; platelet rich 
plasma (PRP) (Bosch et al. 2011; Textor 2011) or Interleukin Receptor antagonist 
Protein (IRAP) (Textor 2011), both which are discussed in the following chapter. 
vii.) Miscellaneous Therapies include; low frequency infrared laser and 
extracorporeal shockwave therapy (Dowling et al. 2000). Laser treatments 
performed by lay people are becoming more frequent in New Zealand. A recent 
study by Duesterdieck-Zellmer et al. (2016) showed that only 1% to 20% and 0.1% 
to 4% of energy were absorbed by SDFTs and DDFTs, respectively, depending on 
skin color, skin thickness, and applied wavelength 800 or 970nm. Their results 
indicated that most laser energy directed through equine skin was absorbed or 
scattered by the skin. Further study was performed by Husby (2016) with the 
conclusion that no significant effects was noted on equine fibroblasts in vitro using 
low frequency laser.  
 
Surgical methods which have been described for tendon repair are; superior check 
ligament desmotomy (Dowling et al. 2000). Hu and Bramlage (2014) reported that 
228 of 332 (69%) horses with superficial digital flexor tendonitis of the forelimb 
that were treated with superior check ligament desmotomy successfully returned to 
racing. Pin-firing of tendons has been described by Renzi et al. (2013), where 
thermocautery was applied on the metacarpal flexor area for a few seconds, at an 
interval of 2cm. The procedure was performed under local anaesthesia. Ten months 
after pin-firing treatment, 3 horses (25%) were in training and able to return to their 
previous activity; while the remaining 9 horses (75%) were retired. The method of 
pin-firing is no longer practiced in New Zealand as it is considered unethical.  
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There are no traditional treatment options that reliably and efficiently treat tendon 
injuries hence why a biological therapy that provides anti-inflammatory effects and 
assist in tissue regeneration is a desirable prospect to clinicians. There is also the 
need to understand that no single treatment will alone heal a tendon lesion. Patients 
will need a combination of several treatments like rest, anti-inflammatory 
treatments and rehabilitation as well as biological treatments to achieve the best 
outcome. 
 
1.3.2 JOINT DISEASE AND TREATMENT OPTIONS 
Joint disease is commonly observed in performance horses (Riggs 2006). Together, 
joint injury and joint disease represent a large majority of the equine clinician’s 
caseload (Goodrich and Nixon 2006). To understand the development of disease a 
brief description of joint anatomy and normal function of its components are given.  
 
A synovial joint is composed of several important structures; the synovial 
membrane, articular (hyaline) cartilage and subchondral bone supported by an 
interconnected lattice with predominantly vertical arcades of cancellous bone 
(Goodrich & Nixon 2006). Microscopically, hyaline articular cartilage is composed 
of approximately 75% water, 15% type II collagen, 10% proteoglycans and a small 
number of chondrocytes (2%). Proteoglycans, consists of a large number of highly 
negatively charged polysulphated glycosaminoglycans, which are responsible for 
drawing water molecules into the extracellular matrix and providing compressive 
stiffness. The cartilage act as a shock absorber and the synovial fluid lubricates the 
cartilage surfaces. The synovial membrane and joint capsule are important 
structures that are involved in joint homeostasis (Kidd et al. 2001). 
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Figure 6 A schematic overview of the anatomy of a synovial joint. Retrieved online 
15/10/16 from https://www.horsejournals.com/arthritis-horses-understanding-
treating-joint-disease 
 Arthropathy 
Joint disease is common in horses due to the demands for athletic performance 
(Riggs 2006). Direct trauma to articular cartilage as well as synovitis and other soft 
tissue changes are significant components of the pathogenesis of arthropathy 
(Wayne 1982). Recognition of early changes and appropriate treatment is 
important. In the young, growing horse we see developmental orthopaedic disease 
like osteochondrosis (Pool 1993). In the performance and older horse we see 
osteoarthritis as a major cause of lameness (Kidd et al. 2001). OA is characterised 
by progressive and permanent disease of the cartilage and associated subchondral 
bone and synovial tissues. The cartilage is defective due to trauma or degeneration 
and loses its shock-absorbing ability. Gross findings include fibrillation, erosion 
and wear lines in the articular cartilage (McIlwraith, 1996). The subchondral bone 
is subsequently exposed, inflammatory mediators are constantly produced which 
cause a synovitis with associated pain and discomfort to the horse, expressed as 
lameness. OA is characterised by the presence of a chronic inflammatory disease 
process. Interleukin 1 is proposed to be the major inducer of the development of 
osteoarthritis (McIlwraith et al. 2012). 
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 Conventional treatment options for arthropathies 
Medical treatment methods include physical therapy, use of anti-inflammatory 
drugs, joint lavage, sodium hyaluronate, and synovectomy (McIlwraith et al. 2012). 
When there are cartilage and bony changes, surgical approach is preferable and the 
use of articular cartilage curettage, osteophyte removal, radiation therapy, and 
surgical arthrodesis is appropriate in some cases.  
 
One option to reduce inflammation is by administration of systemic and/or locally 
administered (intra-articular) medication. Practitioners commonly use non-
steroidal medication such as; phenylbutazone, meloxicam or ketoprofen 
systemically. Phenylbutazone has been shown to be clinically effective in treating 
acute synovitis, De Grauw et al. (2014) found that it does not limit inflammation-
induced cartilage catabolism and may transiently reduce collagen anabolism. In 
contrast the same group also studied the effects on meloxicam and found a 
significant suppression of inflammatory synovial fluid biomarkers, decreased MMP 
activity and a decrease in the cartilage turnover (Grauw et al. 2009). This was also 
suggested much earlier by Clegg et al. (1998) who evaluated MMP activity of both 
NSAIDs and several steroids. Intra-articular administered steroidal anti-
inflammatories such as; triamcinolone, betamethasone or methylprednisolone 
acetate are very commonly used to treat osteoarthritis in the horse (Clegg et al. 
1998; Goodrich and Nixon 2006; Souza 2016). In several equine studies of joint 
inflammation (either by osteochondral chip model or chemically induced arthritis), 
corticosteroids improved outward signs of joint inflammation; but articular 
cartilage degeneration and local bone necrosis could be observed histologically 
(Trotter and McIlwraith 1996). However, McIlwraith (2003) and later (Goodrich 
and Nixon 2006) showed no detrimental effects in treated joints, their results could 
possibly be explained due to decreased dosage and exposure intervals compared to 
initial trials by (Trotter and McIlwraith 1996). Interleukin-1 receptor agonist protein 
(IRAP) is also used commonly as an intra-articular therapy in OA to counteract the 
actions of the pro-inflammatory cytokine interleukin-1β (IL-1β), see chapter 4.3.2. 
A recently developed polyacrylamide gel is currently undergoing clinical trials in 
New Zealand and Australia. It is proposed that the 2.5% polyacrylamide gel attach 
to the defective cartilage and the exposed subchondral bone and has visco-elastic 
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properties, thus forming an artificial pseudo cartilage. Tnibar et al. (2015) showed 
a decrease in joint effusion and lameness grade assessed over a 24month period. 
 
Supplementation of drugs or nutraceuticals to enhance the joint environment is of 
commercial significance. Visco-supplementation with non-sulfated glycosamino-
glycans; hyaluronic acid, given intra-articular, intra-muscular, intra-venously or 
orally depending on the preparation. Oral chondroprotectants such as glucosamine 
and/or chondroitin sulphate are thought to promote viscosity of the synovial fluid 
composition and aid in lubrication of the joint (Neil et al. 2005). A recent study by 
Koenig et al. (2014) assessed the effects of intra-venous sodium pentosane 
polysulfate, N-acetyl glucosamine and sodium hyaluronan in horses with induced 
OA. They found no significant effect from the treatment and instead synovial fluid 
total protein concentration and white blood cell count were higher in OA joints of 
treated horses compared with saline treated horses.  
 
1.3.3 BIOLOGICAL TREATMENT OPTIONS  
Biological therapies offer an alternative treatment through the administration of 
cultured and purified cells, or cellular products, which have naturally occurring 
anti-inflammatory and regenerative properties (Richardson et al. 2007).  
 
 Platelet Rich Plasma (PRP) 
Platelet Rich Plasma is a biological treatment option currently used in practice to 
assist healing of core lesions in tendons or ligamentous tears (Bosch et al. 2010). 
This autologous treatment is prepared freshly from the patients’ own blood and 
consists of a highly concentrated solution of platelets (thrombocytes) and growth 
factors. Platelets are cytoplasmic fragments derived from bone marrow 
megakaryocytes and contain several types of growth factors and cytokines that 
might stimulate wound healing (Borena et al. 2015). Platelets activate the 
inflammatory process by releasing cytokines (such as interleukin (IL)-1α, -1β 
and -6 and tumour necrosis factor-alpha (TNF-α), enhance collagen production 
(FGF-2, IGF-1, TGF-β), stimulate fibroblast to myofibroblast transformation 
(TGF-β), initiate angiogenesis (EGF-2. VEGF-A, TGF-β) and promote re-
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epithelialisation (EGF, FGF-2, IGF-1, TGF-α). The aim with the treatment is to 
reduce inflammation and assist healing (Dunkel et al. 2012). PRP can be prepared 
overnight so offers a rapid treatment option at time of injury. This treatment option 
is available in New Zealand; (Arthrex ACP, Arthrex Vet Systems, New Zealand). 
The treatment has to be used fresh as it contains living platelets and 
cryopreservation is not appropriate. The main difficulty in assessing the 
therapeutic effects of PRP is to define which growth factor(s) are responsible 
for the observed effects since the same mixture of growth factors are present in 
the injured tissue and associated with natural scar healing (Borena et al. 2015). 
 
 Interleukin Receptor-Antagonist Protein (IRAP) 
In joints with osteoarthritis activated fibroblasts produce IL-1, which then induce 
an increase in production of collagenase and prostaglandin E2 (Textor 2011). The 
principle behind IRAP is that an antagonist protein (Interleukin 1receptor 
antagonist protein, IL-1Ra) will bind to IL-1 receptor and block the destructive 
effects of IL-1. In osteoarthritic joints, there is not sufficient IL-1Ra produced to 
block the destructive effects of the increased IL-1. The result is inflammation, pain, 
and eventually cartilage destruction. Autologous blood can be collected in specialist 
syringes containing coated glass beads and cultured for 24hours to stimulate IRAP 
production (Hraha et al. 2011). This produces an acellular conditioned serum (ACS) 
which has many components; cytokines, IRAP and growth factors. In the 
commercial kit Arthrex IRAP II, monocytes (a type of white blood cell) bind to the 
glass beads. The cells are then stimulated to produce regenerative and anti-
inflammatory proteins without the addition of drugs. This process takes place over 
an incubation period of 24 hours. Several syringes can be prepared from one blood 
collection and they can be frozen at -20°C and used for repeated treatments. 
 
 Mesenchymal stromal cells (MSC) 
Mesenchymal stem cell therapy is now a readily available option for treatment of 
joint and tendon injuries in the horse. In New Zealand there is a commercial kit 
available for extraction of autologous stromal vascular fraction and autologous as 
well as allogenic bone marrow derived stromal cell treatments are offered at two 
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equine veterinary clinics; (Veterinary Associates Equine and Farm, Karaka and 
EquiBreed NZ Ltd, Te Awamutu). Indeed, there are many peer reviewed reports of 
clinical cases treated with MSCs derived from several sources; adipose tissue 
(Ricco et al. 2013; Rich 2014) , bone marrow (Ferris et al. 2014; Godwin et al. 
2012; Guest et al. 2010b; Herthel 2001; Pacini et al. 2007; Smith et al. 2003)  and 
peripheral blood (Broeckx et al. 2014b).  
 
Improvements have been reported on the rate and quality of tissue regeneration 
compared to conventional treatment (Frisbie and Smith 2010; Renzi et al. 2013; 
Rich 2014). Nixon et al. (2012) discuss in their review the primary role of MSC and 
suggest it to be their indirect effects on tissue homeostasis when used in tendon 
repair. They reported a consistent finding in the equine model to be that the ongoing 
degradation process associated with tendon rupture is diminished after treatment 
with adipose stromal vascular fraction or bone marrow derived MSC. A recent 
study by Rich (2014) included 83 horses treated with autologous stromal fraction 
from fat. All horses also followed a stringent rehabilitation program over 12months. 
This study found that 84.6% horses with fore-limb tendon injuries and 82.1% of 
horses with hind-limb tendon injuries, returned to full work at the same or higher 
level than before injury. The horses did not re-injure within the 12months follow 
up period. An Italian group led by Pacini (2007), showed that 9/11 horses with 
SDFT injuries treated with autologous equine bone marrow derived stem cells 
(BMSC), returned to racing with no re-injuries during the two year follow up 
period. The control group was treated with pin-firing and all horses (15/15) re-
injured within 12 months. Godwin et al., (2011) showed 98% of horses (111/113) 
returned to work after treatment with BMSC, with a lower than average re-injury 
rate of 27.4% reported. The latest studies by Belgian researchers (Broeckx and 
Spaas 2011-2013) investigated peripheral blood derived stem cells (pBSC) as a 
treatment option for tendon or ligament lesions (SDFT or SL) and they found that 
96% (24/25) of the treated horses performed at the same or higher level than before 
the injury. Broeckxs et al., (2013) showed no adverse effects on clinical outcomes 
using allogenic, tenogenic induced peripheral blood derived MSC injected into 
equine tendons. Stem cells have also been isolated from equine tendon tissue (Burk 
et al., 2013, Violini 2009). Violini et al., (2009) and  Youngstrom (2015) suggest 
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that stem cells isolated from tendon, may have an inherited propensity for tendon 
repair and thus prove to be a superior alternative for tendon repair than MSC from 
other sources.   
 
1.4 MESENCHYMAL STEM AND STROMAL CELLS  
Mesenchymal stem cells were first discovered in bone marrow by (Friedenstein et 
al. 1987) and he described ‘‘osteogenic stem cells’’ as “clonal and fibroblastic 
stromal cells that formed adherent colonies in culture and had robust osteogenic 
potential”. These cells were first termed ‘‘mesenchymal stem cells’’ by Caplan 
(1991) and their multi-lineage differentiation potential into bone, cartilage and fat 
was further characterised by Pittenger et al. (1999). Mesenchymal stem cells and 
stromal cells have been isolated from a wide range of species and tissues using 
numerous techniques. The mesenchymal tissue origins are illustrated in Figure 7. 
 
 
 
Figure 7 Mesenchymal stem cell tissue origins.  
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1.4.1 MESENCHYMAL “STEM” AND STROMAL CELLS  
 Definition  
In the human field, the term “MSC” is mainly associated with Mesenchymal Stem 
Cells and these cell lines are characterised by long-term self-renewal (in vivo) and 
trilineage differentiation abilities (in vitro) (Caplan 1991). The International 
Society for Cellular Therapy (ISCT) states that the term “stem cell” should be used 
only for those cells that (i) show long-term survival in vivo, (ii) have self-renewal 
capacities and (iii) possess the ability for tissue re-population with multi lineage 
differentiation (Horwitz and Dominici 2008). According to human definition 
criteria these cells should also i.) Express a specific set of cell surface markers and 
ii.) Have capacity for trilineage differentiation; after specific stimulation become 
adipocytes, chondrocytes and osteoblasts in vitro (De Schauwer et al. 2011; 
Dominici et al. 2006). These criteria are stated in the publication of the Minimal 
Criteria to Define Human MSCs in 2006 by the ISCT (Dominici et al. 2006) and 
set the standards by which human MSCs can be functionally and phenotypically 
defined. 
 
In horses, stem cell differentiation capacity is still poorly understood. There are no 
reports published that provide evidence of long-term self-renewal and full 
differentiation capacity in vivo. In fact a study by Guest et al. (2008) showed less 
than 5% survival of bone marrow derived stem cells injected into damaged 
superficial digital flexor tendons at 10 days post injection. Thus, before long term 
survival in vivo has been established the more general term Mesenchymal Stromal 
Cells (MSC) is deemed to be more appropriate in equine medicine (Penny et al. 
2012; Ulrich et al. 2012). If a standardised method is used for isolation, 
characterisation and definition of equine MSC the clinical application would be 
more predictable and efficacy between studies could be accurately compared. As 
MSCs become better characterised for their in vitro and in vivo capacities, it is 
likely that the definition and nomenclature will continue to evolve (Tessier et al. 
2015). 
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 Mesenchymal stromal cells - cell cycle events 
The cell cycle of MSC is the same as for somatic cells; they undergo mitosis to 
divide into two identical cells. There are two main phases of mitotic division, the 
interphase and the mitotic phase (Colville and Bassert 2002) Figure 8 below is a 
schematic representation of the cell cycle 
 
Figure 8 Simplified view of the cell cycle and mitotic division. G0 = Resting phase 
G1= Preparation increase in cell size S=Synthesis G2= Growth phase M=Mitosis 
and cell division 
The interphase is the time where the cell carries out normal metabolic functions and 
no division occurs. The interphase has been subdivided into three consecutive 
stages. First, the growth one (G1) phase is a period of intense growth and metabolic 
activity. Cells that proceed past the restriction point in the G1 phase enter the S 
phase, whereas those that do not pass the restriction point remain undivided. These 
undivided cells can withdraw from the cell cycle and enter the G0 phase: a state in 
which cells are termed quiescent or dormant (Nakamura-Ishizu et al. 2014). The 
second phase, the synthetic (S) phase involves deoxyribonucleic acid (DNA) 
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synthesis and replication. The third phase is the growth two (G2) phase, which 
involves the synthesis of enzymes and proteins for cell division and growth 
(Freshney, 2010). On completion of interphase the cell enters the mitotic phase. The 
cell will actively divide to produce two daughter cells with identical copies of the 
original cell’s DNA. Mitotic division comprises of five phases; prophase, 
prometaphase, metaphase, anaphase and telophase.  
Quiescence is a property that characterises tissue-resident stem cells and they 
comprise a G0 dormant reserve that can replenish tissues during homeostasis 
(Nakamura-Ishizu et al. 2014). The regulation of stem cell self-renewal must 
balance the regenerative needs of tissues that persist throughout life (Orford and 
Scadden 2008). The non-cycling cells in the G0 phase can either reversibly re-enter 
the cell cycle and remain dormant or divide, or lose the potential to cycle and 
become senescent. The number of times a cell can self-replicate is a genetically 
controlled event known as senescence, which is regulated by several different genes 
(Freshney, 2010). Cells derived from adult mesenchymal tissue can only be 
expanded in culture for a limited number of times before they lose their ability to 
divide. With increasing passages, telomeres become shorter in cultured MSC 
(Mathon and Lloyd 2001). Telomeres are repetitive DNA sequences located at the 
linear ends of the chromosomes, and with each cell division they are not fully 
replicated but become progressively shorter. This corresponds with a decline in the 
differentiation potential of that cell population. 
Cells that commit and become terminally differentiated lose the ability for self-
renewal. A mesenchymal–epithelial transition (MET) is the biological process that 
involves the transition from motile, multipolar or spindle-shaped mesenchymal 
cells to planar arrays of polarised epithelial cells (Li et al. 2011) Figure 9. 
Developmental METs have been studied most extensively in embryogenesis. 
However, MET events are also related to tissue construction and wound healing 
(Jordan et al. 2011). Stem/stromal cells are involved in all of these processes. The 
mechanism in which MET occurs is by upregulation of epithelium-associated genes 
and downregulation of mesenchyme-associated genes, each process has a unique 
signalling pathway to induce MET. Reverse MET so called epithelial- 
mesenchymal transition (EMT) has been categorised into three types; 
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developmental (Type I), fibrosis and wound healing (Type II), and metastatic 
neoplasia (Jordan et al. 2011; Kalluri and Weinberg 2009).  
 
 
Figure 9 Mesenchymal to epithelial transition simplified. 
 
1.4.2 MESENCHYMAL STROMAL CELL CULTURE METHODS. 
There are a myriad of different culture protocols for MSC from various tissue 
sources published in the literature (Freshney 2010; Masters and Stacey 2007). There 
is a need for standardisation of protocols to efficiently compare studies and their 
results.  In brief; The tissue is harvested from the animal using a variety of surgical 
methods suitable for the specific tissue source. After surgical harvest there is further 
processing involved to mechanically and/or enzymatically digest the tissue. Then a 
density gradient step involving a carbohydrate like Ficoll or Percoll or Lymphoprep 
is performed by centrifugation to isolate a heterogeneous suspension of the 
mononuclear cells (MNCs) from that tissue (Pullen et al. 2016). The primary 
cultures of MNCs are cultured in vitro under standard cell culture conditions; in 
polystyrene plastic flasks with tissue culture medium and maintained at 37°C in 5% 
CO2  (Freshney 2010).  
Equine MSC and dermal fibroblasts are multipotent cells that are plastic-adherent 
when maintained under in vitro culture (Radtke et al. 2013; Ranera et al. 2012). The 
cells are commonly grown in polystyrene cell culture flasks (25 to 75cm2) at 37°C 
in 5% CO2 in a humidified incubator. The MSC form colonies initially, which 
develop into a monolayer with time. Daily monitoring where the cells are observed 
for confluence (percentage of cell coverage) is performed. The adherent stromal 
cells have a spindle-like morphology and grow in a monolayer.  
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The culture medium used for in vitro cell culture generally consists of Dulbeccos 
Minimal Eagles Medium (DMEM) at a low (1g/1L) or high (4.5g/1L) concentration 
of glucose, foetal bovine serum between 10-30%, antibiotics (penicillin, 
streptomycin and/or gentamicin), and an antifungal agent (amphotericin B) 
(Freshney 2010).  
In cell culture, nutrients become depleted and metabolic products, which may be 
toxic to cells increase in concentration (Masters and Stacey 2007). Frequency of 
medium change depends on the cell line and the type of medium. It is important to 
relate the changing of the medium to the health of the cells and the timing of the 
experiment. The cells rapidly utilize the nutrients and release metabolites into the 
medium, resulting in a lowering of pH. Buffers are required to standardise pH levels 
(Masters and Stacey 2007). Most mammalian cells grow at pH levels of 7.2–7.4. 
The culture media contain bicarbonate, which requires a 5% carbon dioxide 
atmosphere to maintain the pH at 7.4. HEPES, an organic buffer, is often added to 
medium to reduce the dependence on bicarbonate. Phenol red is added to medium 
for ease of pH detection by eye and ranges in colour, optimal pH 7.4 is red in colour. 
The medium is changed every 3-4days in adherent culture systems (Freshney 2010). 
To avoid stress to the cells, the medium is pre-equilibrated in the incubator at 37 ֩C 
at 5% CO2. All of the spent medium is removed and replaced with new warm 
medium at each change (Masters and Stacey 2007). For comparative purposes, it is 
important to use the same formulation of medium throughout an experiment to 
eliminate variable. Also, when several cell lines are used, it is essential to grow all 
the cells in the same medium to exclude this as a variable.  
When confluence reaches 60-80% the cells are detached by mechanical or 
enzymatic release agents (commonly 0.05% Trypsin EDTA) and counted and sub-
cultured in new culture flasks and/or cryogenically preserved. Purified trypsin is 
used in most laboratories at a concentration of 0.25% (wt/vol) in 0.5 mM EDTA 
(disodium ethylenediaminetetraacetic acid) dissolved in calcium- and magnesium-
free phosphate-buffered saline (Masters and Stacey 2007). Optimum activity of 
trypsin is achieved at 37°C, so pre-warmed trypsin may speed up cell detachment. 
Long incubation times and high trypsin concentrations tend to damage the cells, 
causing them to stick together. For passaging the cells are re-seeded in new flasks 
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for sub-culture, a common cell density is 5.0x103 cells per cm2 when passaging 
MSC. The sub-culture process is an attempt to obtain a homogenous population of 
cells. This population of cells may be morphologically identical but there is great 
likelihood the cells differ in growth kinetics and differentiation potentials. Thus, 
any given cell population are assumed to display some level of heterogenicity 
(Freshney 2010).  
 
During cryopreservation, aliquots of cells are re-suspended in cryogenic media 
consisting of DMEM, foetal bovine serum or autologous equine serum (5-90%) and 
dimethyl sulphoxide (DMSO) (5-10%) as a cryoprotective agent (Redmond 
Hubbard 2014). The MSC are frozen by a controlled freezing protocol at the rate of 
-1°C per minute in a Mr Frosty container (5100-0001, ThermoFisher Scientific, 
NZ). It is good laboratory practice to test all cell lines for Mycoplasma species, 
using testing PCR method, that will yield highly sensitive and specific results 
(Masters and Stacey 2007). Mycoplasma contamination can alter many biochemical 
processes. 
 
Heterogenicity of cell populations combined with the different techniques used to 
isolate, culture and define MSC means that there is large experimental variability, 
inefficient differentiation and often contradictory or incomparable results between 
studies. The question is if there is a functional difference of MSC derived from 
different donors and tissues? An attempt can be done to standardise parameters like 
sex, age and health status, to allow comparison between studies. However, a study 
by Carter‐Arnold et al. (2014) described the in vitro adherence, proliferation and 
potential for differentiation of equine BMSC harvested from middle-aged mares 
(10-13 years old). Thus, they were matched for sex and age. The result of this study 
confirmed than donor-to-donor variation in equine BMSC existed; one out of six 
donors demonstrated a higher rate of proliferation, enhanced ability for passaging 
and superior in vitro differentiation. Comparatively, equine BMSC from two donors 
demonstrated a lower rate of proliferation and lack of osteogenic and chondrogenic 
differentiation. Schnabel et al (2013) showed a large variability in MHC-II 
expression between ten equine donors of bone marrow derived MSC. However, it 
is impossible for different studies to use the same donors and cell populations. And 
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even if matching for sex and age there appear to be variability as per Carter-Arnold 
et al. (2014). Thus, it should be noted that donor-to-donor variability is unavoidable. 
Other external factors like; growth conditions, culture media, environmental 
contamination and operator experience and technique can also affect the outcome 
(Freshney 2010; Ulrich et al. 2012). Many of these factors can be standardised by 
using a standard operating procedure (SOP) to minimise variability. Thus, the main 
cause of variability between studies will ultimately be the individual donors and 
cell lines derived from those.  
 
1.4.3 IMMUNO-PHENOTYPING OF MESENCHYMAL STROMAL 
CELLS 
 Cluster of Differentiation (CD) cell surface markers 
Mesenchymal stromal cells display cell surface antigens termed cluster of 
differentiation markers (CD markers). According to definition criteria, human MSC 
should express the cell surface markers CD73+, CD90+ and CD105+ and lack 
expression of CD14 ̅ or CD11b ̅, CD34 ̅, CD45 ̅, CD79 ̅or CD19 ̅ and MHC-II ̅ 
(Dominici et al. 2006). Besides the markers defined by the ISCT, additional cell 
surface markers including CD29+, CD44+, CD106+ and CD166+, have been 
reported to be expressed by human MSC (Dominici et al. 2006). The cluster of 
differentiation markers on MSCs share many common features with the CD 
markers on endothelial, epithelial and muscle cells. Thus, a panel of antigens is 
necessary to identify a cell as a MSC. The MSCs can be analysed and sorted on the 
basis of their CD markers. The methods used is either immunocytochemistry, where 
fluorescent labelled antibodies are applied to fixed cells and evaluated with 
fluorescent microscopy, or flow cytometry.  
 Flow cytometry  
Flow cytometry has historically been the gold standard for determining the physical 
presence of CD markers (De Schauwer et al. 2011). Flow cytometry technology 
was developed 50 years ago by Mack Fulwyler (Robinson and Roederer 2015). 
Four years later geneticist Leonard Herzenberg used the discovery of mono-clonal 
antibodies by César Milstein and Georges Köhler at Cambridge University, together 
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with the idea of labelling these antibodies with a fluorescent dye to enable cells to 
be viably sorted into different populations. This was the initial work for the 
“fluorescence-activated cell sorting” (FACS) technique. Live cells labelled with 
monoclonal antibodies conjugated to fluorescent dyes, that are maintained in 
suspension are passed in front of a laser detector (Preffer and Dombkowski 2009). 
This allows for rapid and simultaneous analysis of multiple parameters such as size, 
biochemical and antigenicity. Flow cytometry is suitable for cell counting, 
biomarker detection and also cell or particle sorting to purify populations of interest 
(Robinson and Roederer 2015). Its application has been of great use in biological 
research as well as clinical diagnostics, and have led to innumerable advances in 
immunology and cell biology. 
 Polymerase chain reaction  
More recently real-time polymerase chain reaction (RT-PCR) has been used to 
determine the gene expression of the same cell surface markers that traditionally 
have been evaluated by flow cytometry. The timing is important for PCR analysis 
as differentiating MSC show a temporal variation in expression of these specific 
markers (unpublished data Redmond-Hubbard 2014). For example; Wang et al. 
(2015) did a temporal analysis on days 7, 14, 21 and 28 of expression of osteogenic 
gene markers including; osteocalcin, osteopontin, Runt-related transcription factor 
2 (Runx2), alkaline phosphatase and collagen type I. Quantitative reverse 
transcription-polymerase chain reaction, q-PCR was used for the analysis, and they 
reported that human bone marrow derived MSC needed 14days exposure to 
induction media to express osteopontin and Runx-2 genes and at least 21 days 
exposure to induction media to get a significant increase in osteocalcin expression. 
Expression of alkaline phosphatase and collagen type 1 genes reached peak levels 
on day 21.  
 Monoclonal antibodies  
In equine veterinary medicine immuno-phenotyping can be difficult due to the lack 
of commercially available monoclonal “anti-horse” antibodies. Currently there are 
commercially available antibodies for four equine epitopes; CD13, CD44, CD90 
and MHC-II (Burk et al. 2013a; De Schauwer et al. 2011). Studies listed in Table 1 
have reported the immuno-phenotype of equine MSC and use this data as the 
 30 
 
confirmation of stemness of their stromal cell population. De Schauwer and 
colleagues (2011) used a qualitative approach and proposed a standardised set of 
markers of stemness. They performed a large study to validate the cross-reactivity 
of a large number of human and murine antibodies with cell surface markers present 
on equine MSC. They found that many of the anti-human and anti-mouse antibodies 
did not cross react with the equine antigens. For example, none of the anti-
human CD34 antibodies recognised equine CD34, still several studies have 
reported a negative CD34 expression (Iacono et al. 2012; Maia et al. 2013; Radtke 
et al. 2013). Based on this work De Schauwer et al. (2011) derived a distinct panel 
of CD markers that are suitable for the characterisation of equine MSC. Their 
suggestion is that equine MSC should positively express CD29, CD44 and CD90 
and lack expression of CD14, CD79α and MHC-II. They used a human 
mononuclear cells as positive control for CD45 and found that 65.3% of the human 
MNC expressed CD45. They also compared the immuno-phenotype with gene 
expression at mRNA level and found that it can be used to support the findings of 
marker expression, especially when the CD marker was absent or when no suitable 
antibody was available. 
 
Schnabel et al. (2014) immuno-phenotyped equine bone marrow derived stromal 
cells (10 donor horses = 10 BMSC cell lines plus three repeat bone marrow 
aspirates; N=13) as well as one dermal fibroblast (DF) cell line (N=1). They 
evaluated the expression of following CD-markers: MHC-I, MCH-II, CD29, CD44, 
CD90, LFA-1 and negative markers CD45RB and major histocompatibility 
complex I and II (MHC-I/II) with flow cytometry. The major histocompatibility 
complex (MHC) is a set of cell surface proteins essential for the acquired immune 
system to recognise foreign molecules. MHC molecules on the cell surface bind to 
protein fragments derived from invading pathogens and display these to notify T-
cells. Gustafson et al. (2004) showed that the equine MHC is a single gene-dense 
region, similar in structure to the human MHC in contrast to ruminants and pigs, 
which show a disrupted gene sequence. Lymphocyte function-associated antigen 
1, also known as LFA-1 is involved in the binding of T-cells and also on B-
cells, macrophages and neutrophils to the antigen presenting cell. 
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The immuno-phenotype identified by Schnabel et al (2013) was; positive for MHC-
I, MHC-II, CD44, CD29 and CD90 and negative for LFA-1 and CD45. This was 
true for all CD markers but CD90, where one horse (1/10) only had a smaller 
number (30%) of cells expressing this marker. The expression of LFA-1 showed 
greater variability, where 6/10 BMSC lines were positive (>10% cells displayed 
this marker) and the remainder (4/10) were negative. At passage two (P2) 11 out of 
the 13 samples were positive for MHC-II, with only one (1/10) BMSC line was 
completely negative for MHC-II and another cell line (1/10) had very small 
percentage of cells (10.05%) that expressed MHC-II. These results were in contrast 
to De Schauwer et al. (2011) who suggested per definition equine MSC should be 
negative for MHC-II. Schnabel et al. (2014) then hypothesised that cell lines would 
initially be MHC-II positive, but with increasing number of passages (P2-P8) in 
vitro, would lose the expression of this antigen presenting marker. They continued 
to do a temporal study of MHC-II expression of their BMSC cell lines after 
passaging P2-P8. Their results showed heterogenicity in the MHC-II expression 
with 11/13 cell lines being initially positive for MHC-II (>10%) and at passage 8 
this number was reduced to 6/13 cell lines remaining positive for MHC-II. They 
used a modified mixed leukocyte reaction to evaluate the possibility of MSC to 
provoke an immune response. Their results showed that MHC-II-mismatched MSC 
are capable of inciting an immune reaction in vitro and they suggest therefore that 
immuno-phenotyping of MSC is very important when selecting donor animals for 
allogenic stem cell treatments to avoid an undesirable immune reaction in the 
recipient. Pezzanite et al. (2015) injected between 30x106 and 50x106 allogenic 
bone marrow derived stromal cells intra-dermally in the neck of the recipient horses 
and then evaluated the recipients serum for any immune response by using the 
standard two-stage lymphocyte micro-cytotoxicity dye-exclusion test. They found 
that in some cases there was a strong response and cross reactive antibodies were 
formed, thus a repeated treatment could result in an excessive inflammatory 
response. Broeckx et al. (2013) injected allogenic frozen/thawed peripheral blood 
derived stromal cells (Veno-Cell®, Global Stem Cell Technology, Belgium) 
intravenously in six horses and performed a temporal haematological study. The 
concentration of cells was not reported in this study and the carrier fluid was 
DMEM and 10% DMSO. Results showed the cortisol levels (P=0.0490) and 
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number of neutrophils (P=0.0042) were significantly higher, while glucose levels 
were significantly lower (P=0.0330) in all the treated horses. At Day 1, the blood 
thrombocyte levels were significantly higher in the treated group as compared to 
the control group (P<0.0001), however this was a transient change and not noted 
with increasing time. The same authors later performed a study of 291 horses 
receiving allogenic peripheral blood derived stromal cells (Veno-Cell®, Global 
Stem Cell Technology, Belgium) at a concentration of 0.2x106 cells as a single or 
repeated injections as well as one group receiving 1x106 cells (Broeckx et al. 
2014a). No negative side effects were reported in this study, however the horses 
only received a daily clinical exam for ten days and no blood parameters were 
evaluated. 
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MSC 
Source 
Positive marker Negative marker Reference 
AT, BM,  
Muscle, 
Periosteal 
tissue 
CD44, CD90 CD45, CD34 
Radtke, C.L. et al. (2013) 
Am. J. Vet. Res. 74:790. 
BM 
CD44, CD90, 
Vimentin, PCNA 
CD13, CD34 
Maia, L. et al. (2013) 
Microsc. Res. Tech. 76:618. 
Amniotic 
CD44, CD90, 
CD105 
CD19, CD20, CD28, 
CD38, CD62L, CD200, 
CD31, CD62P, CD34, 
CD41a 
Seo, M.-S. et al. (2013) J. 
Vet. Sci. 14:151. 
UCB 
CD29, CD44, 
CD90 
CD45, CD73, CD79 
alpha, CD105, MHC 
Class II 
De Schauwer, C. et 
al. (2013) Equine Vet. 
J. 45:518. 
AT, BM CD29, CD90 -  
Ranera, B. et al. (2012) 
BMC Vet. Res. 8:142. 
PB 
CD29, CD44, 
CD90, CD105 
CD45, CD79 alpha, 
MHC Class II 
Spaas, J.H. et al. (2013) Vet. 
J. 195:107. 
PB 
CD51, CD90, 
CD105 
-  
Dhar, M. et al. (2012) 
Equine Vet. J. 44:600. 
Amniotic, 
UCB, WJ 
CD90, CD44, 
CD105 
CD34, CD14, CD45 
Iacono, E. et al. (2012) 
Reproduction 143:455. 
UCB 
CD29, CD44, 
CD90 
CD79 alpha, MHC-II 
De Schauwer, C. et 
al. (2011) Tissue Eng. Part 
C 17:1061. 
UCB 
CD29, CD44, 
CD90 
MHC-I, MHC-II, CD4, 
CD8, CD11a/18 and 
CD73 
Tessier, L. et al. (2015) 
PLOS ONE | April 22, 2015 
AT,BM, 
UCB, 
UCM 
CD29, CD44, 
CD90, MHC-I 
CD86, F6B, MHC-II Carrade, D. et al (2012)  
Table 1 Results from individual publications examining surface marker expression 
(CD Markers) of equine MSCs derived from various tissue sources 
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 Immunocytochemistry (ICC) 
This technique can be used to visualise proteins and peptides inside cells or on the 
cell surface (Burry 2011). A primary antibody binds to the protein of interest, then 
a secondary antibody conjugated to a fluorophore is used to bind the primary and 
the cells are viewed with a fluorescence microscope set at appropriate wavelength. 
Common fluorophores used are Fluorescein (FITC), AlexaFluor (Invitrogen), 
BODIPY (Invitrogen), APC, RPE, BPE (Phyco-Biotech, Greensea, Prozyme, 
Flogen). The newer proprietary formulations of fluorophores are advertised as 
brighter and both more pH and photo stable. The same cell surface markers as 
discussed previously can also be assessed with ICC. The need for adequate controls 
is very important when performing ICC (Burry 2011). For example; to prove the 
absence of a marker, a positive control from a different cell type that expresses the 
marker, needs to be included to ensure that the marker is functional and that absence 
of fluorescence is not due to poor technique or mismatched epitopes.  
 
Barberini et al. (2014) utilised ICC to distinguish adipose, bone marrow and 
umbilical derived MSC. They found no presence of MHC-II with ICC nor flow 
cytometry. Reed and Johnson (2008) characterised stromal cells from equine 
umbilical cord blood with immunocytochemistry. They evaluated markers of 
stemness, SSEA-1, Oct4, Tra1-60 and Tra1-81. Results demonstrated the presence 
of Oct4 in the nuclei of greater than 90% of the cells. However, this does not provide 
proof of a true stem cell population. 
 Gene expression studies of MSC 
As well as the method of ICC and flowcytometry can assess the protein present 
inside the cell and on the cell surface, MSC can also be evaluated for the actual 
gene expression of the same protein. However, immunophenotyping is hampered 
by the lack of a single specific marker and the limited availability of monoclonal 
anti-horse antibodies (De Schauwer et al. 2011) and there is also no explicit gene 
that can define a MSCs. However, genes often referred to as pluripotency genes or 
“stem cell specific” are; SOX-2, Nanog and Oct-4 (Hackett et al. 2012). These 
genes as well as tissue specific genes; adipose, chondro and osteo-genic genes, are 
often assessed after induction of trilineage differentiation as a confirmation of the 
cell line as a stem cell line. Violini et al. (2009) studied equine BMSC and defined 
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these as stem cells by their expression of markers, Sox-2 and Nanog. The BMSC 
also had the capability to differentiate into tenocytes, which expressed tendon-
related markers; tenomodulin and decorin.  
 
The method for determination of gene expression is by extraction of m-RNA from 
the selected cell line and assessment by western blots or reverse transcription 
polymerase chain reaction (RT-qPCR) (Freshney 2010). Reverse transcription is 
used to generate a single stranded complementary DNA (cDNA) sample that is put 
through a series of thermal cycles to amplify the target sequence. Then the PCR 
product is electrophoresed through an agarose gel and viewed under UV light to 
determine the presence of the DNA of interest. Detection of gene expression on 
mRNA level can be a valuable alternative, although the need still exists to test 
several antibody clones in search for cross-reactivity (De Schauwer et al. 
2011). Often studies use a combination of methods for stromal cell identification, 
however it can be argued that because no specific CD marker or gene have been 
identified these methods are of limited value. Gene expression studies are more 
useful as a tool to identify a change in cells after they have undergone differentiation 
as compared to naïve, undifferentiated cells.  
 
1.4.4 TRILINEAGE DIFFERENTIATION  
Differentiation is a diagnostic method applied to MSCs to assess plasticity and 
ensure the selected cell line fulfil the criteria specified for Stemness of 
Mesenchymal stromal cells (Dominici et al. 2006). Plasticity is defined as the 
capacity of a cell to give rise to one or more lineages. Unipotent cells give rise to 
only one lineage, multipotent cells give rise to more than two lineages, pluripotent 
cells may give rise to several lineages and totipotent cells are able to give rise to all 
known cell types (Freshney, 2010). Mesenchymal stem cells are considered 
multipotent due to their ability to differentiate into more than two lineages. 
Adipogenic (fat), chondrogenic (cartilage) and osteogenic (bone) lineages are the 
most commonly differentiated cell types for confirmation of MSC plasticity, 
although tenogenic (tendon) and myogenic (muscle) (Martinello et al. 2009) and 
neuronal (Hoynowski et al. 2007) differentiation have also been confirmed for 
equine MSCs. However the differentiation potential of MSCs is not guaranteed 
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within a specific population of cells, heterogenicity may still arise even in clonal 
colonies (Baer and Geiger 2012). Clonal colonies of MSCs are grown from a single 
precursor cell in the attempt to preserve a specific cell phenotype and its specialised 
properties (Freshney 2010). Burk et al. (2013b) suggest that cells from certain 
origins have a higher capacity for differentiation into specific tissues. (Youngstrom 
2015) reported that MSC derived from tendon showed a higher capacity for 
tenogenic differentiation than adipose and bone marrow derived MSC. 
 
The process of trilineage differentiation has been evaluated and confirmed for MSC 
derived from many equine tissues including fat (de Mattos Carvalho et al. 2009), 
bone marrow (Parker et al. 2012; Schnabel et al. 2014), peripheral blood (Broeckx 
et al. 2012; Koerner et al. 2006; J. Spaas et al. 2011) , tendon (Burk et al. 2013b; 
Youngstrom 2015), aminiotic fluid (A. B. Lovati et al. 2011; Violini et al. 2012) 
and , umbilical cord blood (T. G. Koch et al. 2007; Mohanty et al. 2014)and 
Whartons’ jelly (Barberini et al. 2014; Cardoso et al. 2012; Hoynowski et al. 2007). 
Only one paper to our knowledge has evaluated trilineage differentiation in a single 
equine skin derived fibroblast cell line (DF) (Schnabel et al. 2014). 
 Adipogenic differentiation 
The MSC are grown 24 or 48well plates and maintained in adipogenic 
differentiation media for 7-14days. The StemPro adipogenic media (Gibco, 
Lifetechnologies) have been used by several studies (Barberini et al. 2014; 
Schnabel et al. 2014; Violini et al. 2012). The detection of adipogenic 
differentiation is achieved through i.) Determination of morphological 
characteristics, ii.) The use of specific stains like Oil-Red-O (Sigma), BODIPY 
(ThermoFisher) and LipidTOX Green (Lifetechnologies) and iii.) Evaluation of 
gene expression in differentiated cells. Peroxisome proliferator-activated receptor 
gamma (PPARγ2) and lipoprotein lipase (LPL) are two adipose specific gene 
markers analysed during differentiation in equine MSCs (Ranera et al. 2012). For 
confirmation of adipogenic differentiation, oil red O is typically used to stain lipid 
vesicles deposited within adipocyte cells (Burk et al. 2013b). The use of BODIPY 
has been reported in one equine study, (Redmond Hubbard 2014). This fluorescent 
stain has been used with human BMSC to confirm intercellular accumulation of 
lipid (Fink and Zachar 2011). The commercial kit; StemPro Adipogenesis 
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Differentiation kit (Gibco, Lifetechnologies) promotes the use of LipidTOX, a 
fluorescent stain.  
 Chondrogenic differentiation 
There are several methods described for chondrogenic differentiation. The basic 
principle is to create a high density cell pellet either by i.) micromass culture (Greco 
et al. 2011) or ii.) centrifugation of cells in round bottom 96 well plates  (Solchaga 
et al. 2011) or in conical tubes. The chondrogenic media has commonly the 
additives TGF-β1 or TGF-β3. StemPro Chondrogenic Differentiation media 
(Gibco, Lifetechnologies) has been used successfully in several equine studies 
(Barberini et al. 2014; Cardoso et al. 2012; Carvalho et al. 2013; Schnabel et al. 
2014). The detection of chondrogenic differentiation is achieved through 
determination of i.) Morphological characteristics, such as the shape and density of 
a tertiary structure, ii.) The use of specific stains and iii.) By evaluation of gene 
expression in differentiated cell pellets. Chondrogenic differentiation is detected by 
a variety of stains including Alcian Blue (Ahern et al., 2011), toluidine blue 
(Bunnell et al., 2008) and Safranin O for glycosaminoglycan (GAG) deposits (Burk 
et al., 2013), hematoxylin and eosin (H&E) for cell structure (Vidal et al., 2008) 
and Massons trichrome (Burk et al., 2013) for collagen fibre formation. 
Chondrogenic-specific lineage gene markers include collagen type 1, collagen type 
2, aggrecan, bone morphogenic proteins, matrix metalloproteinase-1 and -13, sox9 
and cartilage-derived retinoic acid-sensitive protein (Berg et al. 2008; Greco et al. 
2011). 
 Osteogenic differentiation  
Osteogenic differentiation is performed as part of trilineage differentiation and 
evaluates osteoblastic activity. The evaluation of the differentiation potential is to 
i.) Determine the presence of mineralised calcium deposits or ii.)alkaline 
phosphatase activity or iii.) The presence of osteogenic gene markers; 
osteomodulin, osteocalcin, osterix. Alizarin red is a commonly used stain for the 
detection of calcium deposits between days 14-21 of culture (Hoynowski et al. 
2007; Toupadakis et al. 2010) or Von Kossa stain (Burk et al. 2013b; Colleoni et 
al. 2009). The intensity of staining can be used in a semi-quantitative measure to 
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determine osteogenic potential. Staining for alkaline phosphatase activity is also 
performed successfully between days 4-10 in culture (Toupadakis et al. 2010).  
 Tenogenic differentiation 
Tenogenic differentiation of MSC is not part of the set criteria for determining 
stemness, however several groups have evaluated the tenogenic potential of equine 
mesenchymal stromal cells derived from adipose (Youngstrom 2015), bone marrow 
(Lovati et al. 2010; Violini et al. 2009; Youngstrom 2015), peripheral blood 
(Broeckx et al. 2012) and umbilical cord blood (Mohanty et al. 2014). There is no 
universal differentiation protocol and several agents have been used to induce 
tenogenesis in equine MSC; bone morphogenic protein-12 (BMP-12), basic 
fibroblast growth factor, L-ascorbic acid and Tendo-Cell®. The procedure is 
inherently difficult to achieve in vitro as tendon fibrils require a scaffold and tensile 
force applied to form and align correctly. Factors that regulate tenogenic 
differentiation of MSC include; growth factors, mechanical stimulation, support 
from biomaterials or co-culture with tendon fibroblasts (Lui et al. 2011). Tendon 
engineering is an expanding area and relevant to human medicine, so many groups 
are researching this concept. Lovati et al., (2012) and Violini et al., (2009) 
performed tenogenic differentiation in vitro, they evaluated the success with 
morphological exam and gene expression of tendon related markers tenomodulin 
and decorin, as well as tenascin-C and collagen type I. Lovati et al., (2009) used 
low dose (10ng/ml) of basic fibroblast growth factor as well as co-culturing with 
fresh tendon explants in a transwell co-culture system. Violini et al., (2009) and 
Mohanty et al., (2014) used bone morphogenic protein-12 (BMP-12) at (50ng/ml) 
to induce tenogenesis. Youngstrom (2015) created a cyclic strain bioreactor 
designed to simulate gentle exercise and used decellularised tendon scaffolds for 
adipose, bone marrow and tendon derived MSC to attach to in vitro. The cells 
migrated into the scaffold and exhibited an elongated, tenocyte-like morphology as 
evaluated with histology at 10days post seeding. The tensile testing was performed 
after day 10 in culture and all MSC loaded tendon scaffolds showed higher elastic 
modulus and greater failure stress compared with matched controls, which 
consisted of the same scaffolds without added MSC. The bone marrow and tendon 
derived MSC showed greater failure stress (5MPa vs 1MPa) compared to controls. 
A study by Liu et al. (2006) used unwoven polyglycolic acid fibres to form a 
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scaffold, upon which tendon derived tenocytes or dermal fibroblast were cultured 
for 7days in vitro. Then the cellular enriched scaffolds were implanted into lesions 
created in porcine SDFT in vivo. Results showed that fibroblast and tenocyte 
engineered tendons were similar in gross view, histology and tensile strength, 
achieving approximately 75% of natural tendon strength after 26 weeks. They 
proposed that dermal fibroblasts have a promising potential in tendon engineering.  
 
1.4.5 SYNOVIAL FLUID INDUCED DIFFERENTIATION IN 
VITRO 
Several equine studies have investigated autologous and allogenic treatment MSCs 
injected into joints (Broeckx et al. 2014b; Carrade et al. 2011) and tendons (Godwin 
et al. 2012; Ricco et al. 2013; Van Loon et al. 2014)). To our knowledge no equine 
studies have yet evaluated long term survival of MSC injected intra-articular in 
vivo. However, two studies have evaluated equine synovial fluid in MSC culture 
systems in vitro, (Boone 2013; Hegewald et al. 2004). Boone (2013) reported an 
increase in cell proliferation rates correlated with an increased concentration of 
allogenic synovial fluid in the culture media. Hegewald et al (2004) found that 
normal autologous synovial fluid induced chondrogenesis of equine BMSC. The 
synovial fluid induced chondrogenic phenotype showed high levels of expression 
of type-II collagen but less proteoglycan expression compared to cultures 
stimulated with TGF-β1. They found that the size of the formed cartilage pellet 
increased with increased concentration of synovial fluid (up to 50%). Boone (2013) 
found a significant increase in viability and GAG production of BMSC grown in 
50% and 100% allogenic synovial fluid as well as an enhanced chondrogenic 
potential at 50% concentration. 
 
Human studies by Yang et al. (2006) and Leijs et al. (2012) evaluated the effects of 
inflammatory synovial fluid on chondrogenesis in vitro. Chondrocytes were 
isolated from the femoral condyle of a healthy donor (post mortem), the cells were 
passaged and found to de-differentiate into a more fibroblastic phenotype after two 
passages (Yang et al. 2006). Chondrogenesis was induced with TGF-β1 and the 
treatment group was also supplemented with 10% allogenic inflammatory synovial 
fluid, there were no difference noted between treatment and control. However, the 
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synovial fluid treated cells produced significantly less proteoglycans compared with 
the control. Leijs et al. (2012) found that MSC from bone marrow cultured in 20% 
inflammatory synovial fluid upregulated mRNA expression of Interleukin-6 (IL-6) 
and Indolamine (IDO) and suppressed lymphocyte proliferation. Thus, synovial 
fluid-activated human BMSC displayed immuno-modulatory effects in vitro. These 
papers show that in vitro exposure to allogenic inflammatory synovial fluid can 
induce chondrogenesis in both human and equine BMSC cell lines and potentially 
enhance their immuno-modulatory properties. 
 
1.4.6 METHODS OF TRACKING MESENCHYMAL STROMAL 
CELLS IN VIVO 
There are very few equine studies to our knowledge that have followed the fate of 
injected MSC over time. The ways to track stromal cells in the live horse after 
injection are limited. Labelling of cells can be performed with either,  
i.) Fluorescent probes such as green fluorescent protein (GFP). A post-mortem 
histology exam using fluorescent microscopy will enable viewing of remaining 
cells in tissue (Guest et al. 2008). This method is not possible to perform in vivo.  
ii.) Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE; Vybrant CFDA SE 
Cell Tracer Kit [V-12883]; Molecular Probes, Eugene, was used in a porcine model 
to label BMSC (Lee et al. 2007).  
iii.) Radioactive Technetium-99m and scintigraphy have been used successfully in 
the live horse to track MSC (Sole et al. 2013; Spriet et al. 2015).  
iv.) Magnetic nanoparticles attached to MSC have been used in the live horse 
combined with Magnetic Resonance Imaging (MRI) (Bourzac et al. 2014; Lange-
Consiglio et al. 2011). Currently there is no available MRI machine for equine 
clinical applications or research in New Zealand. 
 
Guest et al. (2008) labelled bone marrow stem cells (BMSC) and embryonic derived 
stem cells (EMSC) with green fluorescent protein (GFP) and injected these cells 
into equine SDFTs and subsequently reported on survival rates and distribution 
patterns over time. A porcine study reported successful incorporation of labelled 
MSC into newly formed hyaline cartilage in a surgical osteo-arthritis model as 
assessed post mortem (Lee et al. 2007). The pigs were sacrificed and six and twelve 
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weeks and tissue harvested for both morphological and histological analysis. The 
cell- treated groups showed improved cartilage healing at both time points as 
compared to controls. However, this mechanism of action of incorporation of 
injected MSC into newly formed cartilage have not been studies in the horse. The 
mechanism of MSC becoming incorporated into the architecture of the healing 
tissue is currently challenged due to recent discoveries; three equine studies have 
reported that most MSC do not display long term survival when injected into 
tendons (Becerra et al. 2013; Guest et al. 2008; Sole et al. 2013). Beccera et al. 
(2013) reported only 24% of injected cells persisted in the tendon after 24hours. 
This is in accordance with Sole et al. (2013) that reported a median percentage of 
persistence in the distal limb at 24.1% after regional intra-arterial injection and a 
slightly lower value of 8.5% for regional intra-venous injection. Guest et al (2008) 
reported less than 5% survival of injected MSC at 10days, however EMSC showed 
great survival but also migration in the tissue. The criteria set by Caplan (1991) to 
define a stem cell, states that the cells have to demonstrate long term survival and 
incorporation into tissue. The time frame of survival is not specified by the author. 
However, Caplan (1991) also discuss paracrine effects exerted by MSC on the local 
tissue environment and how these criteria might be challenged in the future as these 
effects are further investigated and immuno-modulation is better defined. 
 
1.5 MESENCHYMAL STROMAL CELLS & FIBROBLASTS 
Fibroblasts are considered mature mesenchymal cells that are particularly abundant 
in the connective of each organ and tissue (Blasi et al. 2010). They are adherent 
proliferating cells which are difficult to remove because they can survive and grow 
even under extremely selective culture conditions. Therefore, these cells are the 
most frequent contaminating cell phenotype present in many cell culture systems. 
Not only is it difficult to apply techniques which successfully eliminate fibroblasts 
from a culture, it is also particularly complex to distinguish MSCs from fibroblasts 
in the same culture. Fibroblasts and MSCs have an extremely similar morphological 
appearance they both proliferate well and have many identical cell surface markers 
 
There is controversy over the relationship between human MSC and fibroblasts 
(Feisst et al. 2013; Hematti 2012) and human studies have failed to identify any 
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differences in the morphology, immunophenotype or trilineage differentiation 
ability between the two cell types (Blasi et al. 2011; Brohem et al. 2013; Covas et 
al. 2008; Lorenz et al. 2008; Strutz et al. 1995; Ulrich et al. 2012). This could have 
large implications for clinical use as the common census is that healing by 
regeneration of tissue is superior to healing by fibrosis. Fibrous tissue has less 
functionality compared with the original tissue and the re-injury rates are increased 
and athletic performance is compromised (Burk et al. 2013a).  
 
Feisst et al. (2013) reported that a number of cell populations with stem cell 
properties have been identiﬁed in cell lines grown from human dermis, including; 
‘‘skin-derived precursors’’ (SKPs), ‘‘ﬁbroblastic mesenchymal stem-cell-like 
cells,’’ ‘‘Dermal mesenchymal stem cells’’ (DMSCs), and ‘‘Muse cells’’. 
However, there is variation in isolation protocols and cell culture methods between 
studies and the phenotypic and functional properties of these cells differ 
substantially. Thus, there is currently no consensus regarding MSC populations in 
human dermis. Cells present within primary dermal ﬁbroblastic cell lines have been 
shown to be capable of differentiation into mesenchymal lineages. 
 
Some studies have successfully achieved differentiation of fibroblasts into 
mesenchymal tissues. For example Lorenz et al. (2008) showed that human skin 
derived fibroblasts could differentiate into adipogenic and osteogenic cells and 
Hanson et al. (2010) showed that vocal fold cells (a fibroblastic cell type) had the 
same differentiation potential and the same cell surface markers present as both 
bone marrow and adipose derived MSC. Tri-lineage differentiation is achieved in 
vitro by the exposure of MSC to supra-physiological concentrations of induction 
agents specific for the adipogenic, osteogenic or chondrogenic pathways. The 
common practice of using the tri-lineage differentiation assays as the gold standard 
for stem cell identification may need to be reviewed as fibroblasts also have been 
shown to have capacity for differentiation.  A study by Blasi et al. 2012 found that 
human adipose derived-MSCs (AD-MSCs) and human dermal fibroblasts (HNDFs) 
cultured in vitro have very similar morphological appearance, growth rate, and 
immuno-phenotypic profile. Both cell types expressed typical mesenchymal 
markers CD29+, CD44+, CD90+ and CD105+ and to a minor extent, the adhesion 
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molecules CD54+, CD56+, CD106+ and CD166+. The same populations were 
negative for the haematopoetic stem cell markers CD34  ̅, CD146  ̅, CD133  ̅, 
CD117  ̅ as determined by flow cytometry. It can thus be argued that flow cytometry 
is of limited use as a method for identifying MSC as the same CD markers are 
present on dermal fibroblasts. Both cell types in this study could be differentiated 
into osteoblast, adipocyte, and also cardiomyocyte-like cells. 
 
To my knowledge only one equine study has compared the immuno-phenotype and 
trilineage differentiation potential between bone marrow derived and dermal 
derived fibroblast. Schnabel et al. (2014) reported an almost identical immuno-
phenotype at passage 2 (P2) of a single dermal fibroblast cell line to that of ten 
BMSC cell lines. The distinguishing feature was that dermal fibroblast cells did not 
express MHC-II, which was in contrast to the BMSC where 11/13 were positive. 
Schnabel et al. (2014) did not achieve positive trilineage differentiation in this cell 
line; however, it appeared to show some chondrogenic differentiation potential, but 
was negative for adipogenic and osteogenic differentiation as determined with oil-
red and Alizarin red staining methods. 
 
Blasi et al. (2012) proposed a method for a functional bio-assay to distinguishing 
between MSC and fibroblasts in humans. The study investigated the cytokine 
profile and the exerted paracrine effects on cells of the immune system. They 
showed that human adipose tissue derived MSCs displayed strong angiogenic and 
anti-inflammatory activity in contrast to human dermally derived fibroblasts. The 
anti-inflammatory effects by adipose MSCs on cells from a human monocyte cell 
line (U937) were seen as a decreased expression of adhesion molecules CD11a and 
CD11b, both involved in inflammatory cell migration. As well as the reduction of 
inflammatory chemokines; Chemokine ligand 5 (CCL5) also known as RANTES 
and Monocyte chemoattractant protein-1 (MCP1), released from the U937 cells. 
The effects were significantly enhanced after activation of the adipose-MSCs with 
TNFα (25ng/ml) for 12hours. In comparison the dermal fibroblasts acquired pro-
inflammatory activity; increased release of CCL5 and MCP1, with the same 
treatment. Activation of equine MSC by exposure to the inflammatory cytokine 
IFN-γ (100ng/ml) for 72hours was reported by Paterson et al. (2014).   
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Recently a paper by Nicolay et al (2016) reported that cisplatin treatment has a 
minimal effect on MSCs stem cell characteristics as compared to dermal fibroblasts. 
Cellular attachment was assessed 24hours after exposure to cisplatin (either 
200ng/ml or 1000ng/ml) for 4hours. MSC morphology and attachment was 
unaffected by treatment and the potential for differentiation was retained. In the 
dermal fibroblast cell line, the cell attachment was significantly delayed at time 
24hours (p<0.05) in a dose related manner compared to control. Viability studies 
also confirmed MSC to have greater resistance to the cytotoxic effects of cisplatin. 
The authors detected cytoskeletal rearrangements and high expression of individual 
heat shock proteins in the two MSC cell lines, which may be responsible for the 
resistance to the cytotoxic effects of cisplatin. 
 
Recent efforts in stem cell research investigate the induction of pluridpotency in 
somatic cell lines, so called induced pluripotent cell (iPS). Nagy et al. (2011) 
reported the generation of iPS cells from equine fibroblasts using a piggyBac 
transposon-based method to deliver transgenes containing the reprogramming 
factors Oct4, Sox-2, Klf4, and c-Myc. The established iPS cell lines express 
pluripotency markers (Oct4, nanog, Sox-2) and can form teratomas containing all 
three of the embryonic germ layer derived tissues, when grafted in vivo into 
immunocompromised mice. Thus, the relationship between stem cells and 
fibroblasts is elusive and more research is needed to categorise these cell lines. 
 
1.6 IMMUNO-MODULATORY EFFECTS OF 
MESENCHYMAL STROMAL CELLS  
1.6.1 DEFINITION  
The term immuno-modulatory describes a stimulating or suppressant effect on the 
cells of the immune system. The ability of a certain cell type (here MSC) to exert 
change on the normal inflammatory cascade by i.) Direct cell to cell contact or ii.) 
By secretion of cytokines and chemokines or iii.) A combination of both 
mechanisms (Kyurkchiev et al. 2014) 
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1.6.2 CYTOKINES 
The aforementioned pro- and anti-inflammatory cytokines have been evaluated in 
several equine studies and reported to be present in diseased joints (Bertone et al. 
2001; Kamm et al. 2010; McIlwraith 2005) and in damaged tendon tissue (Hosaka 
et al. 2002). The progression of osteoarthritis is orchestrated by pro-inflammatory 
cytokines, IL-1β and TNFα and the prostaglandin PGE2 (Boone 2013). Figure 10 
provides a simplified explanation of the actions of TNFα on the immune system. 
 
 
Figure 10 TNFα effect on immune system simplified, adapted from O'Shea et al. 
(2002)  
 
The secretion of these inflammatory mediators by T cells induce further release of 
pro-inflammatory cytokines (IL-6, IL-17, IL-18), chemokines and other 
inflammatory mediators (NO, oncostatin-M, leukaemia inhibitory factor). Both IL-
1β and TNFα upregulate expression of the catabolic enzymes involved in 
extracellular matrix destruction. Kamm et al., (2010) compared the expression of 
cytokines and other metabolic markers in synovium, synovial fluid and cartilage in 
normal and osteoarthritic joints. They found TNFα present in synovial fluid, 
synovium and cartilage, while IL-1β was only present in the cartilage. However, 
Kamm et al. (2010) argued the concentration was below the range of detection of 
the ELISA kit (R&D Monoclonocal antibody, author manufactured ELISA kit 
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developed and used for this trial). Hosaka et al., (2002) demonstrated the presence 
of IL-1α, IL-1β, TNF-α and IFN-γ antibodies in inflamed equine SDFTs with 
immunohistochemical staining. 
 
The TGF-β family consists of TGF-β1-3, bone morphogenic proteins (BMP) 
and activins (Borena et al. 2015). In mammals mainly TGF-β1, -β2 and -β3 
isoforms are found, but TGF-β1 predominates in cutaneous wound healing. 
They are produced by several cell populations; macrophages, fibroblasts, 
keratinocytes, platelets and MSC. TGF-β is a multifunctional growth factor that 
attracts new fibroblasts and macrophages to the wound site, stimulates 
fibroblast proliferation and collagen synthesis, reduces extracellular matrix 
degradation and modulates the immune system. Indeed, MSCs can directly 
attenuate inflammatory responses by decreasing the secretion of the pro-
inflammatory cytokines such as TNF-α and interferon-γ (IFN-γ) while 
enhancing the production of anti-inflammatory cytokines including IL-10. 
 
A review article by McIlwraith (2005) analysed biomarkers of equine joint disease 
and classified them as; i.) Direct biomarkers, which originates from cartilaginous 
or bony structures or are enzymes that are only active in these tissues. ii.) Indirect 
biomarkers, which have the potential to influence the metabolism or integrity of the 
matrix of the various joint tissues. Proteolytic enzymes and their inhibitors, growth 
factors and pro-inflammatory cytokines are indirect biomarkers. Bertone et al. 
(2001) concluded that the presence of Interleukin 6 (IL-6) in synovial fluid was 
both sensitive and specific as a marker of equine joint disease. They found that 
Tumour Necrosis Factor alpha (TNFα) and Interleukin-1beta (IL-1β) are no more 
useful than leucocyte counts in screening for joint disease. TNFα will increase with 
exercise and repeated arthrocentesis (McIlwraith 2005), hence it can’t be 
considered as a specific marker of joint disease 
 
1.6.3 EFFECT OF MESENCHYMAL STEM CELLS ON CELLS OF 
THE IMMUNE SYSTEM 
MSCs have the unique combination of self-renewal and multi-lineage 
differentiation capacity as well as immuno-modulatory properties (Kyurkchiev et 
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al. 2014). MSCs can exert profound immuno-modulatory effects on cells of the 
innate and adaptive immune systems via a variety of mechanisms, especially 
cytokine and chemokine secretion (Hoogduijn et al. 2010). Mesenchymal stromal 
cells have multipotent capacity, which allows them to differentiate from a 
fibroblastic morphology into osteoblasts, chondrocytes, adipocytes, tenocytes and 
other cell types in vitro (Eggenhofer et al. 2014). MSC were initially thought to 
migrate to the injured tissue and then undergo differentiation into the type of tissue 
they were administered to. For example; tendon or cartilage to then form part of the 
new architecture of that tissue. However, more recent studies (Guest et al. 2010a; 
Paterson et al. 2014) showed that MSCs do not display long term survival in tendon 
tissue after implantation. Less than five percent (<5%) of MSC injected into equine 
superficial digital flexor tendons survived at 10 days (Guest et al. 2010a). The 
results seen on tissues after MSC therapy are now thought to be achieved through 
paracrine effects rather than through directed differentiation. The MSC have been 
shown to have immuno-modulatory effects on T-cells (Bouffi et al. 2010) as well 
as trophic effects on endogenous stem cells (Guest et al. 2010a; Hoogduijn et al. 
2010). The cells communicate by secreted proteins, so called cytokines and these 
provide the signals to coordinate the inflammatory response. Some cytokines act to 
broadly provoke the inflammatory response; such as IL-1, IL-6 and TNFα. 
Zafranskaya et al. (2013) showed that PGE2 production depends on cell-to-cell 
contact of MSC and lymphocytes. TGF-β is a negative regulator of proliferation in 
many cells and has anti-inflammatory actions in some settings. T helper cells are 
required to stimulate B cell responses as well, with the cytokines IL-10, IL-4 and 
other cytokines regulating the clonal selection and differentiation of antigen-
specific B cells to form antibody-secreting plasma B cells and memory cells. 
Eggenhofer and colleagues (2014) discuss that in vitro culture alters the 
immunological phenotype of MSCs. They propose that the MCSs can induce a more 
substantial recruitment of tissue specific repair cells after in vitro culture and 
purification. 
 
Equine mesenchymal stromal cells can produce a range of bioactive trophic factors, 
inﬂammatory mediators and adhesion molecules that function to decrease 
inﬂammation, inhibit scar formation, inhibit apoptosis and increase angiogenesis 
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(Kol et al. 2013). Mesenchymal stromal cells need to be activated to perform these 
functions (Paterson et al., 2013 (Blasi et al. 2011; Carrade et al. 2012)a). MSC 
growing in normal culture conditions, derived from either adipose, bone marrow, 
umbilical cord blood and matrix, neither stimulated nor inhibited lymphocyte 
proliferation (Carrade et al. 2012). The MSC did show continuous expression of 
TGF-β1. However, when grown in the presence of activated T-cells all the MSC 
cell lines secreted IL-6 and PGE2. PGE2, IL-6, NO, and IDO have been implicated 
as factors that decrease T-cell proliferation. Activation of MSC has been achieved 
by; 
i.) Presence of TNFα in culture media, 25ng/ml for 12hours (Blasi et al. 2011; 
Kol et al. 2013; Paterson et al. 2014); 
ii.) Presence of IFN-γ in culture media, 100ng/ml for 72hours (Paterson et al. 
2014); 
iii.) Co-culture of the MSC with activated T-cells (column separation 0.5g nylon 
wool) (Carrade et al. 2012; Carrade Holt et al. 2014); 
iv.) Presence of allogenic mononuclear cells (MNC) (Carrade et al. 2012; 
Paterson et al. 2014; Tessier et al. 2015); or 
v.) Presence of autologous MNC as the stimulator cell. (Tessier et al. 2015). 
 
When activated in vitro, equine MSCs exhibit several immunosuppressive effects 
(Boone 2013). MSC have been shown to decrease lymphocyte proliferation, 
decrease T-cell production of certain pro-inflammatory cytokines (TNFα and IFN-
γ), and increase their production of certain anti-inflammatory cytokines TGF-β1, 
PGE2, IL-6 and IL-10, (Boone 2013 (Carrade et al. 2012), Nitric oxide (NO), 
hepatocyte growth factor and Indoleamine 2,3-dioxygenase (IDO) (De Schauwer et 
al. 2014; Tessier et al. 2015). Carrade et al. (2012) isolated five MSC lines from 
each tissue source, adipose tissue, bone marrow, umbilical cord blood and cord 
matrix. Lymphocyte proliferation was assessed in a mixed leukocyte reaction, and 
mediator secretion was determined by ELISA. Unstimulated MSCs did not alter 
lymphocyte proliferation or secrete mediators, except for TGF-β1, which was 
continuously secreted by MSC of all origins. When activated, MSCs of all tissue 
types showed anti-inflammatory effects; decreased lymphocyte proliferation, 
decreased production of TNFα and IFN-γ and increased IL-6 and prostaglandin 
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PGE2 secretion. Bone marrow MSCs and umbilical cord blood MSCs also produced 
nitric oxide (NO), while adipose MSCs and umbilical cord matrix MSCs did not. 
In contrast to De Schauwer et al. (2014) and Tessier et al. (2015) equine MSCs did 
not produce IDO in this study. In humans, NO is an upstream regulator of IL-10 
and TGF-β1, and a direct regulator of IDO (Carrade et al. 2012). Variable results 
regarding the production of equine IDO indicates that NO may also participate in 
upstream regulation of IL-10 or TGF-β1 as well as in its other functions, including 
vasodilation and the immune response to pathogens.  MSCs from multiple tissue 
sources and species have been shown to produce PGE2 as part of their 
immunomodulatory response. Equine MSCs modulate T cell proliferation through 
a PGE2 dependent mechanism. T cell proliferation is one indicator that lymphocytes 
have become activated and the secretion of pro-inflammatory molecules is a critical 
part of this response, especially TNFα and IFN-γ production. Carrade et al. (2012) 
suggest that both animal species and tissue source affect the mechanism through 
which MSCs modulate immune cell function. MSCs from solid-tissue-derived 
sources inhibited T-cell proliferation through apoptosis in contrast to blood-derived 
MSCs that inhibited T cell proliferation by cycle arrest.  
 
Paterson et al. (2012) examined the gene expression of embryonic stem cells (EMS) 
and bone marrow derived stromal cells and also the presence of cytokines; INF-γ, 
TNFα, IL-6 and IL-10, in the MSC culture media (conditioned media) by ELISA. 
The stem cells were co-cultured with peripheral blood mononuclear cells (PBMC) 
to determine their effect on proliferation. They found that embryonic stem cells did 
not affect baseline proliferation of PBMCs. While bone marrow stromal cells 
significantly suppressed PBMC baseline proliferation, thus having an anti-
inflammatory effect. A greater suppressive effect was noted when the cells types 
were in direct contact in the dish (P=0.00001) than when PBMC were exposed to 
the conditioned media. However, the conditioned media still had a significant effect 
on PBMC and mRNA expression of IL-6 and INF-γ were reduced (P=0.01). Thus, 
soluble factors also play a role in MSC-mediated immune suppression. Paterson et 
al. (2012) also found that MSCs secreted IL-6 despite no exposure to PBMCs. 
Immunomodulation and functionality of activated MSC and DFs is an interesting 
key concept. I. and Sorrell (2015) suggest that in the event of trauma or infection 
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tissue specific MSCs are activated and will exert immuno-modulation, which 
ultimately over time (weeks to months) is seen as specific tissue regeneration. 
MSCs appear to be local managers of the tissues’ innate regenerative potential. If 
MSC can be activated during controlled conditions in vitro and their function 
recorded and evaluated, it may provide some insight on how their effects could be 
managed in vivo to reach desired outcomes. 
 
1.7 AIMS AND OBJECTIVES OF STUDY 
The ultimate aim of stem cell research in horses in New Zealand is to provide an 
effective, proven and readily accessible treatment option for equine athletes 
suffering from musculoskeletal injury. This study will aim to perform a 
comparative analysis of stromal cells isolated from various tissues; bone marrow, 
adipose tissue, peripheral blood and umbilical perivascular tissue (Wharton’s jelly) 
as well as skin derived fibroblast cells, using conventional methods. It also aims to 
test the immunomodulatory potential of stromal cells of mesenchymal origin in 
vitro.   
 
More specifically these objectives will be carried out: 
• To document and assess cell culture characteristics and morphology of MSC 
derived from adipose, bone marrow, peripheral blood, umbilical cord matrix 
and dermal tissue. To evaluate cellular morphology and population doubling 
time for each individual cell line. 
 
• To assess cellular morphology and growth characteristics after 
incorporation of equine synovial fluid into the culture system. 
 
• To assess the trilineage differentiation potentials for selected cell lines by 
performing adipogenic, chondrogenic and osteogenic differentiation using 
commercial differentiation media. 
 
• To compare the immunophenotype of said cell populations by 
immunocytochemistry and flow cytometry as well as a biological assay.  
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• To activate stromal cells from bone marrow, umbilical tissue and dermal 
fibroblasts with either TNFα or allogenic inflammatory synovial fluid and 
perform an analysis of the cell culture supernatants with equine specific 
ELISA to determine the production of certain cytokines by activated cells 
compared to controls. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 EXPERIMENTAL DESIGN SUMMARY 
Ethics approval was gained from the University of Waikato School of Science and 
Engineering Animal ethics committee (Protocol 952) prior to the commencement 
of this study. Live animal procedures were minimised by the inclusion of 
cryopreserved mesenchymal stromal cell samples obtained commercially or via 
collaborators (Redmond Hubbard 2014). Post mortem dermal and adipose tissue 
and synovial fluid samples were obtained from horses that were culled for reasons 
unrelated to this study. Donors are described further in section 2.2.1  
 
2.1.1 EXPERIMENT 1: MORPHOLOGICAL STUDY 
The aim was to isolate and culture MSC from various equine sources and DFs at 
standardised in vitro cell culture conditions and to determine the morphology and 
culture characteristics for these cell populations. The two null hypotheses were 
tested (see below). The observations of morphology and confluency were 
performed at set time points and photos were taken to illustrate the similarities 
between equine MSC and DFs in vitro. 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have equivalent morphological characteristics as 
dermally derived fibroblasts 
 
Population doubling times at passage 4 (P4) were calculated for each source of 
MSC and DFs. 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have equivalent population dynamics as measured 
by population doubling times, as dermally derived fibroblasts  
 
Detection of mycoplasma species was performed with PCR and agarose gel 
electrophoresis on all cell lines to ensure no contamination.  
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2.1.2 EXPERIMENT 2: IMMUNOPHENOTYPING  
The methods of immunocytochemistry and flow cytometry were used to determine 
the presence of a selected panel of cell surface markers identified in the literature, 
that currently form part of the laboratory assessment to positively identify a stem 
cell. To optimise the use of primary and secondary monoclonal antibodies an initial 
dilution series for markers CD29 and MHC-II was performed. The following 
hypothesis was investigated; 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have the same qualitative expression of cell surface 
markers, CD29, CD44, CD90 positive and CD45, MHC-II negative as dermally 
derived fibroblasts  
 
Flow cytometry was performed under the guidance of Dr Anna Brooks at The 
Dunbar Laboratory, University of Auckland, NZ. Polychromatic flow cytometry 
was used to characterise and compare the mesenchymal cell populations from 
equine adipose tissue, bone marrow, peripheral blood and umbilical cord matrix as 
well as equine dermis. A panel of five (5) CD markers including; CD29, CD44, 
CD45, CD90, MHC-II as well as DAPI, was used to label the cells for sorting. 
Samples for flow cytometry were analysed at the fourth passage (P4), except the 
commercial DF cell line (P16) and the peripheral blood mononuclear cells (pMNC) 
(P-1). The pMNC (P-1) were used as a positive control for the negative MSC 
markers CD45 and MHC-II.  
 
2.1.3 EXPERIMENT 3: TRILINEAGE DIFFERENTIATION 
The trilineage differentiation potential where cells are induced to form bone, 
cartilage and fat is a standard method and accepted determination criteria to identify 
human stem cells. Trilineage differentiation with commercial induction media 
(StemPro) was performed for three elected cell populations (BMSC, UMBT and 
DF). A semi-quantative scoring method was adapted from Redmond Hubbard 
(2014) which involved a morphological evaluation as well as qualitative staining 
assays. A new concept that included cluster scoring as a measure of differentiation 
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of cells grown in culture system incorporating synovial fluid was used to assess 
change quantitively. The following hypothesis was investigated; 
H0: The hypothesis is that stromal cells from bone marrow and umbilical cord tissue 
have an equal potential for trilineage differentiation as dermally derived fibroblasts  
 
2.1.4 EXPERIMENT 4: SYNOVIAL FLUID MODEL 
-Incorporation of allogenic synovial fluid in MSC culture system 
 
The aim was to simulate intra-synovial conditions in vitro to understand the effects 
of this environment on MSC and DFs. It was hypothesised that equine allogenic 
synovial fluid incorporated into the culture media would have an effect on 
morphology, confluence and differentiation potential for MSC and DFs in vitro. 
Normal synovial fluid (SF) was obtained from supposedly healthy joints and 
inflammatory synovial fluid (I-SF) was obtained from diseased joints as defined in 
section 2.2.1. 
The culture characteristics of DF, BMSC and UMBT cell populations grown in 50% 
normal SF and in 50% I-SF were investigated with the null hypothesis stating;  
H0= The hypothesis is that stromal cells from bone marrow, umbilical cord tissue 
and dermally derived fibroblasts have the equivalent morphological characteristics 
when grown in standard culture conditions or culture containing 50% normal 
synovial fluid or culture containing 50% inflammatory synovial fluid 
 
The following outcome variables were measured;  
1. Percentage confluence, of cells populations at three different time points; 
T=24h, T=48h and T=168h 
2. Phenotypic change, defined as;  
i.) Number of clusters at T=24, 48 and 168h  
ii.) Number of pellets at T=24, 48 and 168h 
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2.1.5 EXPERIMENT 5: BIO ACTIVATION ASSAY 
-Measuring cytokine production of BMSC, UMBT and DF populations after  
activation 
A comparison of the in vitro production of cytokines from mesenchymal stem cells 
and dermal fibroblasts after activation with tumour necrosis factor alpha (TNFα) or 
inflammatory synovial fluid (I-SF). 
H0: The hypothesis is that activated stromal cells from bone marrow and umbilical 
cord tissue have equivalent cytokine production as activated dermally derived 
fibroblasts. 
 
H0: The hypothesis is that activation with TNF alpha of stromal cells from bone 
marrow or umbilical tissue or dermal tissue derived fibroblasts equals the effect of 
activation of the same cell populations activated with inflammatory synovial fluid. 
 
An initial temporal assay (ELISA1) of samples collected at four different time 
points (T= 24, 48, 72 or 168hours) was performed from one selected cell line, from 
each of bone marrow and dermal fibroblast origin; (BMSC N=1 and DF N=1). This 
was done to determine an optimal time point for future sample analysis as a full 
temporal analysis was not possible due to limited funds. The time point T=24hours 
was selected based on concentrations measured in this experiment, there appeared 
to be no greater concentration effect measured after this time point, see Appendix 
2 for graphs from temporal assay. The following experiment evaluated the cytokine 
production of each cell population as measured by cytokine concentration in the 
cell supernatant using equine specific sandwich ELISAs. Cytokine production was 
measured:  1. After TNF-α activation vs control (CM) 
  2. After I-SF activation vs control (CM) 
  3. Per 104 cells using population doubling data at P4 
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2.2 MATERIALS AND METHODS 
2.2.1 ANIMALS AND TISSUES COLLECTED 
The selection of donors depended on horses available at the facility and horses that 
were being culled for reasons unrelated to this study, during a certain time frame 
(April 2015- October 2015), when tissues were collected for the purpose of this 
study. The horses were examined prior to euthanasia to assess their breed, sex, 
approximate age, overall health status and lameness score at walk as well as 
palpation of the carpal, tarsal and stifle joints to detect any heat or effusion. Adipose 
tissue, dermal tissue and synovial fluid from normal joints were collected within 
15minutes ex vivo at a local abattoir. The horses were euthanised for reasons 
unrelated to this study. 
 
Four dermal fibroblast cell lines were acquired, including one commercial cell line; 
“USA” (Equus caballus E.Derm (NBL6, CCL-57™ATCC, USA) and one kindly 
donated, “Otago” from The University of Otago, New Zealand (Courtesy Dr L. 
Wise). The remaining adipose and bone marrow derived cell lines were obtained 
from cryopreserved stock from The University of Waikato cell line inventory 
(Redmond-Hubbard 2014) or from clinical cases seen at EquiBreed NZ Ltd. For the 
cryopreserved ADSC and BMSC samples there were no record of age of the donors. 
However, the sex of these donors was known, all samples were obtained from 
mares, which were resident at Equibreed NZ.   
 
Peripheral blood samples were collected in vivo by jugular veni-puncture by a 
veterinarian at an equine breeding facility in the Waikato region. Umbilical cords 
were collected on one Standardbred stud farm and one Thoroughbred stud farm in 
the Waikato region. The cords were allowed to break off naturally from the foal 
before the ex vivo tissue samples were collected as outlined in Section 2.2.4.1 
Table 2 specifies the animal identification and origin of all samples (N=31) used in 
this study. 
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Animal 
ID 
 
Sex 
 
Breed/A
ge Tissue 
In 
vivo 
Ex 
vivo 
Cryopreserve 
samples 
Commercial  
cell line 
W1 C foal TB/NA UMBT  x 
  
W2 C foal TB/NA UMBT  x 
  
W3 F foal TB/NA UMBT  x 
  
W4 C foal TB/NA UMBT  x 
  
H F foal SB/NA UMBT  x 
  
Y F foal SB/NA UMBT  x 
  
T C foal SB/NA UMBT  x 
  
Q F foal SB/NA UMBT  x 
  
LH2 M  TB/NR BMSC 
  
X 
 
LH3 M SB/NR BMSC 
  
X 
 
LH4 M SB/NR BMSC 
  
X 
 
LH5 M SB/NR BMSC 
  
X 
 
LH6 M SB/NR BMSC 
  
X 
 
Tanga G TB/11y BMSC 
  
X 
 
USA F QH/4y DF 
   
X 
Otago NR NR/NR DF 
  
X 
 
Copper M TB/7y DF 
 
x 
  
Becky M SB/10y DF 
  
X 
 
Eye4F M TB/8y pBSC X 
   
PA NR SB/NR pBSC X 
   
PM8 M TB/NR pBSC 
  
X 
 
PM13 M NR/NR pBSC 
  
X 
 
LA G SB/15y pBSC 
 
x 
  
LH4 M SB/NR ADSC 
  
X 
 
LH6 M SB/NR ADSC 
  
X 
 
Copper M TB/10y ADSC 
 
x 
  
PM13 M NR/NR ADSC 
  
X 
 
Bird M SB/10y pBMNC X 
   
Emmy M SB/15y pBMNC X 
   
Famietta M WB/10y pBMNC X 
   
Guy M SB/6y pBMNC X 
   
Table 2 Animal ID and origin of samples. C= Colt F= Filly G= Gelding M= Mare 
NR= No record.  SB= Standardbred TB= Thoroughbred QH= Quarter Horse WB= 
Warmblood. Adipose Derived stromal cells (ADSC), Bone marrow stromal cells 
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(BMSC) Dermal fibroblasts (DF), Peripheral blood stromal cells (pBSC),peripheral 
blood mononuclear cells (pBMNC), Umbilical tissue stromal cells (UMBT). 
 
Apparently normal synovial fluid samples were collected by arthrocentesis ex vivo. 
The joints selected for inclusion were carpal, tarsal and stifle joints, due to the large 
volume and ease of collection of synovial fluid from these joints. The joints were 
clipped and prepared aseptically by scrubbing with chlorhexidine for five minutes 
and wiping with methanol prior to arthrocentesis. 10ml syringes and 19G needles 
were used and the fluid from each joint was injected into separate 10ml plain tubes 
and placed in a chilly bag on ice. The inflammatory synovial fluid samples were 
collected in vivo from horses undergoing arthroscopic surgery at an equine hospital, 
for reasons unrelated to this study (Courtesy Dr G Quinn, Hamilton Veterinary 
Services, New Zealand). Table 3 defines the origin of the normal and inflammatory 
synovial fluid used in the experiments, and Table 4 shows the attempt to 
characterise the fluid with respect to nucleated cell count, total protein and serum 
amyloid-A content. 
Horse ID Date 
Age 
(approx  Diagnosis 
Carpal 
vol ml 
Tarsal 
vol ml 
Stifle 
vol ml 
Total 
vol ml  
ACP1 15.07.24 10 Normal 6 6 6 18 
ACP2 15.08.04 15 Normal 5 4 7 16 
ACP3 15.09.24 8 Normal 4 4 6 14 
Pooled 
Normal       48 
SX1 15.09.02 1 R OCD 0 5 0 5 
SX2 15.09.02 1 
Bilat 
OCD 0 10 0 10 
SX3 15.09.03 1 
Bilat 
OCD 0 8 0 8 
SX4 15.09.07 3 
Carpal 
chip 3 0 0 3 
SX5 15.09.08 1 
Bilat 
OCD 0 10 0 10 
SX6 15.09.14 1 
L OCD 
LOCD 0 6 8 14 
Pooled 
I-SF       50 
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Table 3 Origin and definition of synovial fluid samples. Two pooled samples were 
created one for normal synovial fluid (Pooled Normal) and one for inflammatory 
synovial fluid (Pooled I-SF). 
 
Horse ID 
Culture 
24h 
Culture 
48h Total Protein Serum Amyloid A Smear 
ACP1 neg neg    
ACP2 neg neg    
Pooled 
Normal neg neg 10g/L 2mg/L 
no cells 
seen 
SX1 neg neg    
SX2 neg neg    
SX3 neg neg    
SX4 neg neg    
SX5 neg Neg    
SX6 neg Neg    
Pooled  
I-SF neg Neg 12g/L 3mg/L 
no cells 
seen 
Table 4 Further description of synovial fluid used in experiments. 
 
2.2.2 PLASTIC CONSUMABLES 
The culture flasks used were made from clear polystyrene with good optical 
properties and treated with Nunclon™ delta surface (ThermoFisher). Nunclon delta 
is a proprietary cell culture surface treatment used to improve the adhesion ability 
of a range of cell types. Two flask sizes were used (T25 and T75) and the flasks had 
angled necks and filter caps to allow airflow and minimise chance of contamination. 
Falcon™ 15mland 50ml conical centrifuge tubes, as well as 3ml sterile plastic 
Pasteur pipettes were used in all culture preparation work. 
2.2.3 CULTURE MEDIA 
The basal culture media consisted of Dulbeccos’ minimal essential medium 
(DMEM) low glucose (ThermoFisher) 10% FBS (ThermoFisher), 1% Antibiotic-
antimycotic (Sigma), 0.1% fungizone (Sigma), and 0.05mg/ml gentamicin 
(ProPharma). All culture media and phosphate buffered saline (PBS) 
(ThermoFisher) were prepared in the sterile fume hood and filter sterilised with a 
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0.22µm syringe filter (Minisart, Sartorious stedim) then kept refrigerated at 4°C. 
When media was used the bottle was wiped down with ethanol before placed in 
sterile fume hood. The amount of media required for culture work was poured off 
from the stock bottle, either into sterile culture flasks or 50ml tubes before placed 
in the incubator to warm to 37°C before adding cells. 
 
2.2.4 PROTOCOLS FOR TISSUE HARVEST AND PREPARATION 
OF MESENCHYMAL STROMAL CELL LINES FOR CELL 
CULTURE 
An extensive analysis of equine specific peripheral blood protocols as well as 
umbilical cord tissue protocols were performed before commencement of the 
experimental phase of this thesis. Appendix 3. details a step by step analysis of the 
available protocols found in the literature on the harvest and tissue processing 
methods. For adipose and bone marrow the samples were obtained cryopreserved 
from a previous study (Redmond Hubbard 2014). 
 
Briefly, all tissue samples were processed to yield a mononucleated (MNC) cell 
fraction, which is a heterogeneous mixture that contain mesenchymal stromal cells 
(MSCs), additional mononuclear cells (MNCs) and red blood cells (RBCs). The 
mononuclear cells were sub-cultured using a sterile cell culture protocol as 
described below in Section 2.2.5 
 Umbilical cords (UMBT) 
At the time of foaling, within minutes of the umbilical cord breaking off naturally 
between the foal and the placenta, a 10-15cm segment of the cord was cut at the 
distal end previously closest to the foal. The segment was rinsed in 10% iodine then 
placed in a one litre container containing 300ml of 70% ethanol for 10 minutes to 
remove environmental contamination. The cord segment was then placed in a sterile 
250ml jar with screw top with 100ml of Vigro® embryo flush media (Minitub, 
Australia) supplemented with 2% Antibiotic-antimycotic (Sigma, USA) and 0.05% 
gentamicin (ProPharma). The jar was placed into a chilly bin and stored on the farm 
in the fridge at 4°C before transported to the laboratory. Samples were processed 
within 12 hours. 
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In a sterile fume hood the umbilical cord was dissected to obtain the perivascular 
(Whartons’ jelly) tissue, see Figure 11 for gross anatomy of the equine umbilical 
cord before and after processing.  
 
Figure 11 Gross anatomical views of a segment of an equine umbilical cord A.) 
Unprocessed cord segment B.) Cross section of cord C.) Cord opened up to expose 
perivascular tissue and Wharton’s jelly D.) After removal of perivascular tissue and 
Wharton’s jelly, showing the two umbilical arteries (top and bottom) and umbilical 
vein (middle) 
 
The protocols of A. B. Lovati et al. (2011) and Cardoso et al. (2012) were modified 
as described. The perivascular tissue and Wharton’s jelly were mechanically 
minced with fine scissors and the material was weighed and placed into a sterile 
50ml tube. The tissue sample was enzymatically digested with 0.75mg/ml 
collagenase 1, in the shaking incubator for 8hours at 37°C. The enzyme was 
removed with duplicate washes of 5minutes each in PBS buffer supplemented with 
10% FBS. The samples were then centrifuged at 250g for 10 minutes at room 
temperature (RT) and the supernatant was removed. After the second wash the cell 
A B 
C D 
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pellet was re-suspended in 2ml of warm (37°C) basal culture media and cells were 
counted manually with a haemocytometer and assessed for viability with trypan 
blue stain. Cells were plated at 1x106 cells/cm2 in T25 flasks with 10ml of basal 
culture media. The flasks were placed in the Heal Force, (HF 151, Acorn Scientific) 
incubator at 37°C with 5% CO2 and 90% humidity. These are the standard cell 
culture growth conditions used for the purposes of this thesis. The flasks were 
observed daily and after an initial 48h period of allowing for cell attachment, the 
all of the spent media was replaced and then medium was changed every 3-4 days 
until 60-80% confluence.  
 
When confluence was estimated to be 60-80%, the cells were trypsinised using 5ml 
of warm (37°C) trypsin (0.05% trypsin EDTA, Sigma). The cells were gently 
swirled in the flask for 30 seconds then excess liquid was poured off and the flask 
allowed to stand for 2-4minutes in the 37°C incubator. When cells were observed 
to detach from the plastic, the flask was removed from the incubator and 5ml warm 
culture media containing 10% FBS was added to neutralise the enzyme. The cellular 
suspension was removed with a 3mm sterile transfer pipette and added to a 15ml 
conical falcon tube. The tube was centrifuged at 250g for 5minutes at RT to pellet 
the cells. The supernatant was removed and cells re-suspended in 1ml of warm 
culture media. After counting (refer to section 2.2.5.1), the cells were either 
passaged or cryopreserved (section 2.2.6). Cells were passaged and re-seeded at 
5.0x103 cells per cm2 or frozen in aliquots of 1.0x106 cells in one millilitre vials in 
1ml of cryogenic media (75% DMEM (low glucose) with 25% FBS and 5% 
DMSO). 
 Peripheral Blood (pBSC) 
Peripheral blood (20ml) was collected in EDTA tubes. The tubes were kept at 4°C 
and blood samples processed within 4hours of collection. Briefly, the tubes were 
centrifuged at 1000g for 20minutes at RT. The buffy coat was gently removed by a 
sterile 3ml pipette and transferred to a 15ml sterile tube. Sterile PBS was added 1:1 
(v/v) and mixed. The sample mixture was layered gently onto an equal volume of 
Lymphoprep® (MediRay, NZ). Then the tubes were centrifuged at 600g for 
15minutes at RT. The interphase was collected and washed with 1X PBS buffer at 
200g for 10minutes at RT. The resulting fractional layers are seen in Figure 12. 
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Figure 12 Peripheral blood separation using Lymphoprep. A.) PBS fraction, B.) 
MSC Interface, C.) Lymphoprep fraction, D.) Red blood cell fraction. From 
Redmond Hubbard (2014) with permission. 
 
The wash steps were repeated three times with the supernatant discarded after each 
wash. After the final wash the cells were re-suspended in 2ml of warm culture 
media (DMEM (low glucose), 20% FBS, 10-11M dexamethasone, 50ug/ml 
gentamicin, 250ng/ml fungizone, 10µl/ml antibiotic-antimycotic). A 10µl sample 
of the cellular suspension was added to 20µl of trypan blue stain and vortexed. Then 
10µl of this mixture was added to each of two chambers on the haemocytometer 
and both chambers counted (five squares each) then averaged. The mononuclear 
cell counts were recorded and cells plated at 5x105 cells/cm2 in 10ml media in T25 
flasks (Nunc Delta, 25cm2, Thermo Fisher Scientific). The flasks were incubated at 
37°C at 5% CO2 and 90% humidity. The flasks were observed daily and after 
allowing 96hours for initial cell attachment the media was replaced, then every 3-4 
days. At estimated 60-80% confluence the cells were trypsinsed as described in 
section 2.2.6. The cells were either passaged; re-seeded in new flasks at 5.0x103 
cells/cm2 or cryopreserved. 
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 Skin derived Dermal Fibroblasts  
A skin biopsy (2x2cm2) was harvested using sterile technique. The hair was clipped 
and then further shaved with a disposable shaver, then scrubbed with chlorhexidine 
surgical scrub for 5minutes before wiped with methylated spirit. A number 20 
scalpel blade was used to cut the skin layers and forceps were used to hold and 
remove the sample. The skin biopsy was placed in Vigro® embryo flush media and 
placed in a chilly bin on ice for transportation to the laboratory. At the laboratory 
the skin biopsy was further dissected in a sterile fume hood and the hair and 
epidermis were removed with a number 10 scalpel blade and discarded. The dermal 
layer was cut into fine pieces and minced with scissors. The tissue was weighed and 
placed in a 50ml sterile tube and covered with DMEM (low glucose), 0.05mg/ml 
gentamicin and 1mg/ml collagenase type 1. The tube was incubated in a shaking 
incubator for 1hour at 37°C. The whole content; the dermal digest, was poured into 
a T25 flask with 20ml of basal culture media (DMEM (low glucose) 10% FBS, 1% 
Antibiotic-antimycotic, 0.1% fungizone, 0.05mg/ml gentamicin). The flasks were 
placed in the incubator under standard cell culture conditions; 37°C at 5% CO2 and 
90% humidity. The flasks were observed daily and after 48hours of initial cell 
attachment the media was replaced, then again every 3-4 days. At an estimated 
percentage of confluence at 60-80%, the cells were trypsinised and passaged and/or 
cryopreserved (section 2.2.6). 
2.2.5 STANDARD CELL CULTURE PROTOCOLS 
Cell culture work was performed under sterile conditions at the University of 
Waikato (PC2 laboratory, Room C2:03). An aseptic cell culture technique was 
strictly followed and performed in a laminar flow hood to avoid environmental 
contamination of cultures. All cell lines used in this study were screened by PCR to 
eliminate mycoplasma as outlined in section 2.2.7.  
 Cell counting protocol 
A 0.100mm (0.0025mm2) Neubauer improved bright-line haemocytometer 
(Fortuna, Germany) was used to manually perform cell counts Figure 13.  
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Figure 13 Neubauer improved counting chamber with gridlines shown 
 
A 1:2 (v/v) dilution of 10µl sample of the cellular suspension was added to 20µl of 
trypan blue stain in a 0.5ml Eppendorf tube and vortexed for 10seconds. Then 10µl 
of this mixture was added to each of two chambers on the haemocytometer and five 
large squares counted on each. The total number from the ten squares was divided 
by 2 to get the average number of cells in five squares. Then the cell count was 
calculated with the formula outlined in Equation 1  
Equation 1 
 
 
Equation 2 Haemocytometer count 
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Equation 3 Population/Cell Doubling time (DT) 
 
End cell = number of harvested cells 
Start cell = number of seeded cells 
End cell / start cell can also be referred to as the fold change in growth 
 
For most of the experiments cells from passage four (P4) were used, thus the 
characterisation of the population doubling times at this passage was necessary for 
calculating number of cells present at certain time points during the experiments. 
Number of P4 cells present after T= hours of incubation. Number of P4 cells present 
after T= hours of incubation. 
    
Equation 4 Cell numbers at T=X hours 
 
 
2.2.6 CRYOGENIC PREPARATION AND PROTOCOL. 
 Trypsinisation 
To trypsinise the cells an aliquot of 0.05% trypsin EDTA in PBS free off 
magnesium and calcium was placed in the incubator to warm to 37°C. The flasks 
containing cellular monolayers at 60-80% confluence, were taken into the sterile 
fumehood. The cell supernatants were poured off into a beaker then 10ml of sterile 
PBS was used to wash the flask before pouring off, this step was repeated twice. 
5ml of trypsin was added to each flask and it was swirled for 30seconds to contact 
the whole surface. Then the excess trypsin was poured off and flasks placed in the 
incubator for 2minutes. After 2minutes the flasks were placed on the microscope to 
view the cells, the flasks were gently swirled to detach the cells. If cells were still 
adhered another the flasks were placed back into the incubator for another minute. 
To stop the enzymatic process, 5ml of culture media containing 10% FBS was 
added to the flask and the whole content from the flask was retrieved with a Pasteur 
 67 
 
pipette and put into a15ml conical tube. This tube was then gently centrifuged at 
250g for 5minutes. The cell supernatant was pipetted off and 1ml of warm basal 
culture media was added and the cell pellet was gently re-suspended, and cells could 
be counted as per section 2.2.5.1. 
 
 Cryopreservation 
After the cell count had been established and the desired number of cells passaged, 
the cellular suspension was again centrifuged at 250g for 5minutes at RT. The 
supernatant was removed, and the cell pellet re-suspended in 1ml of cryogenic 
media at 4°C. Standard cryogenic media consisted of; 75% DMEM (low glucose) 
with 25% FBS and 5% DMSO. 
 
The dilution factor was calculated for each sample and cryogenic media added to 
achieve a final concentration of 1x106 cell/ml. A 1ml aliquot was added to each 1ml 
cryogenic vial (Greiner, Mediray). Vials were then placed in a Mr Frosty controlled 
freezing container (ThermoFisher Scientific) to freeze at the rate of -1°C per minute 
in the -70°C Freezer. 
 Thawing procedure of cryogenic samples for cell culture 
Mesenchymal stromal cell samples were stored in cryogenic vials in -70°C freezer. 
They were removed from the freezer and held with forceps in a warm (37°C) water 
bath until just melted during 30-60s. The vials were then wiped with paper towels 
to dry and with ethanol to disinfect the vials. The cellular suspension containing 
1x106 cells in 1ml of cryogenic media (75% DMEM (low glucose) (12320-032, 
Gibco, Lifetechnologies), 20% FBS (1009-148, Gibco, Lifetechnologies) and 5% 
DMSO (Sigma) was removed from the vial with a 3ml sterile transfer pipette and 
put in a 15ml conical tube. Warm (37°C) DMEM (lg) wash media was dripped in 
slowly for the first 3ml then rapidly up to 10ml. The samples were mixed and 
centrifuged at 250g in an Eppendorf table centrifuge (5810 R, ThermoScientific), 
for 5minutes at RT. The supernatant was tipped off in a waste beaker and the cell 
pellet was gently re-suspended in 1ml of warm culture media (DMEM (low glucose 
(1g/L)) (ThermoFisher), 10% FBS (ThermoFisher), 1% Antibiotic-antimycotic 
solution (Sigma), gentamicin 0.05mg/ml (ProPharma) and Fungizone 0.01% 
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(Sigma). A 10µl sample of the cellular suspension was removed with a 10µl pipette 
and added to 20µl of trypan blue stain in a 0.5ml Eppendorf tube and vortexed for 
10seconds. Then 10µl of this mixture was added to each of two chambers on the 
haemocytometer and viewed on an inverted Leica DMRD microscope at 10x and 
cell number counted. The cells at a seeding density of 5x103 live cells/cm2 were 
then added to either a T25 (in 10ml media) or T75 (20ml of media) flask and 
cultured for 36-72hours before an active growth phase/log phase was established. 
At an estimated confluency of 60-80% the flasks were then trypsinised to passage 
the cells or to cryopreserve the cells for later use in the experiments.  
 
2.2.7 MYCOPLASMA DETECTION  
 DNA extraction 
Cryogenically preserved cells were thawed at RT and centrifuged at 200g for 5 
minutes 4°C in a benchtop centrifuge (Eppendorf). The supernatant was removed, 
and the cell pellet was re-suspended in a 200µl volume Digestion buffer containing 
10µl of 10mg/ml Proteinase-K. The samples were then digested overnight in a 
600rpm shaking thermomixer at 65°C. The following day the samples were cooled 
to RT and vortexed vigorously for 20 seconds. In the fume hood, 200µl of 
chloroform was added in order to remove protein from the sample. The tubes were 
mixed by vortexing vigorously for 20 seconds and finally incubated on a rotating 
mixing wheel for 5minutes at RT. The sample was centrifuged at 10,000g for 
5minutes at 4°C. The top aqueous layer was transferred to a new sterile 1.5ml 
Eppendorf tube. Two volumes of ice-cold ethanol (100%) and one volume 2:1v/v 
of 3M Sodium Acetate (NaOAc) was added to precipitate the DNA. The tube was 
placed at -20°C for a minimum of one hour. The tubes were removed then 
centrifuged at 16,000g for 20 minutes at 4°C. The supernatant was removed 
carefully and the pellet was washed by the addition of 1ml ethanol (70%). The 
samples were centrifuged at 16,000g for 15min at 4°C. The supernatant was 
removed by pipetting and discarded, the tube was left to airdry to ensure no 
remaining ethanol present. The DNA was re-suspended in 100µl 10mM TE-buffer 
(pH 8) and stored on ice. The DNA concentration and quality was measured using 
the Nanodrop spectrophotometer. 
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 Determination of sample DNA concentration using NanoDrop™ 
spectrophotometry 
The NanoDrop spectrophotometer (NanoDrop 2000, ThermoScientific) was used 
as outlined by the manufacturer. Briefly, the Nanodropwas cleaned using 5µl 
milliQ water and tissue paper. A blank was determined by placing 1µl of TE-buffer 
on the detector. Each sample was then added in a 1µl drop onto the detector and 
analysed. The detector was wiped carefully between each sample. A graph was 
obtained with the concentration and purity data displayed following the recording 
of the absorbance (A) readings at A260, A280 and A280, respectively. A minimum 
value of 50ng/µl is desired for the PCR analysis and if the values were higher than 
50ng/µl a dilution was performed accordingly. 
 Polymerase Chain Reaction (PCR) 
The PCR method used was developed by Uphoff and Drexler (2004). Primers were 
sourced from the University of Waikato University Inventory as described by 
Mayall (2015).  Briefly, a 5µm primer mix of degenerate primers (Table 5) that 
target the Mycoplasma DNA was prepared and then a PCR mastermix with i-Taq 
(iNtRON Biotechnology, Ngaio Diagnostics Ltd, New Zealand) was prepared 
Table 5. Positive (POS) and negative (NEG) controls were included;  
 
Primer  Nucleotide sequence (5’ to 3’)  Orientation 
LMP13 CGCCTGAGTAGTACGTwCGC FORWARD PRIMER* 
LMP14 TGCCTGrGTAGTATGCTCGC FORWARD PRIMER* 
LMP15 CrCCTGAGTAGTATGCTCGC FORWARD PRIMER* 
LMP16 CGCCTGGGTAGTACATTCGC FORWARD PRIMER 
LMP17 GCGGTGTGTACAArACCCGA REVERSE PRIMER* 
LMP18 GCGGTGTGTACAAACCCCGA REVERSE PRIMER 
Table 5 Primers Mycoplasma PCR. The molarities of primers containing accessory 
symbols (w or r)* are reduced by 50%, therefore is adjusted for accordingly in Table 
6) 
 
Table 6 depicts the primer concentration and volume used to prepare a 5µm Primer 
and the PCR reaction was planned and set up as follows in Table 7. 
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Primer Concentration Volume  
LMP13 100µm  20µl 
LMP14 100µm  20µl 
LMP15 100µm  20µl 
LMP16 100µm  10µl 
LMP17 100µm  20µl 
LMP18 100µm  10µl 
Sterile MQ H2O   100µl 
Table 6 Primers Mastermix for Mycoplasma detection 
 
SAMPLE 
ID (lane 1-8) 
2x PCR 
Mix (i-
Taq) 
(µl) 
5µM 
Primer 
Mix 
(µl) 
POS 
Control 
(µl) 
NEG 
Control 
(µl) 
Internal 
DNA 
(µl) 
Test 
Cell  
DNA  
(µl) 
H2O 
(µl) 
NEGATIVE 
Control 
12.5 1   1     11.5 
NEGATIVE 
Control plus 
Internal 
DNA 
12.5 1   1 1   10.5 
POSITIVE 
Control 
12.5 1 1       10.5 
POSITIVE 
Control plus 
Internal 
DNA 
12.5 1 1   1   9.5 
Sample 1 
12.5 1       1 10.5 
Sample 1 
plus Internal 
DNA 
12.5 1     1 1 9.5 
Sample 2 
12.5 1       1 10.5 
Sample 2 
plus Internal 
DNA 
12.5 1     1 1 9.5 
Table 7 PCR Reaction for Mycoplasma detection 
 
Eight PCR tubes were labelled with numbers 1-8 and a 10µl volume was pipetted 
into the tubes in the sterile fume hood. The PCR tubes were placed in the 
thermocycler (BioRad) using the conditions outlined in Table 8.  
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Table 8 PCR thermocycler conditions. 
After completion of the thermocycle protocol the samples were allowed to cool at 
RT before agarose gel electrophoresis. 
 Agarose gel preparation 
A 1.3% TAE agarose gel was prepared in a 250 ml Erlenmeyer flask using 40ml of 
TAE buffer and 0.52grams of agarose (HyAgarose 9012-36-6), Hydragene). The 
flask with its content was weighed and the weight recorded, then placed in a 
microwave oven on medium high for two minutes. If crystals of agarose could be 
seen, the mixture was then heated in one minute intervals until the crystals fully 
dissolved and the mixture was clear. The flask was re-weighed and de-ionised water 
was added to compensate for evaporative loss during heating. The agarose was 
cooled to 55-60ºC and then 2ul of Redsafe (21141, iNtRON) stain was added to 
allow visualisation of the DNA under UV light. The mixture was poured into a level 
gel tray and allowed to set at RT. 
 Agarose Gel Electrophoresis 
The agarose gel was lifted from the mould and placed in TAE buffer in the 
electrophoresis tank (Owl Separation Systems). TAE buffer was added to 
completely immerse the gel. Two microliters of a 100 base pair (bp) ladder (PCR 
DNA ladder, M106R, Genescript, USA) was loaded in well 0 and after this 10µl of 
each sample (1-8) was loaded into corresponding well. The i-Taq has loading dye 
already added. The agarose gel was run at 90V, 500mA for 30minutes at RT. 
Following electrophoresis, the gel was lifted from the tank and placed in the trans-
illuminator (Aplgen Omega Lum G Gel Documentation System, GMI) and viewed 
and photographed under UV light. Mycoplasma positive samples are expected to 
show a band at 502-520bp. All samples containing the internal control DNA should 
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show a band at 986bp. The internal control demonstrates that the PCR conditions 
are working.  
2.2.8 TRILINEAGE DIFFERENTIATION 
The trilineage differentiation potential was assessed for dermal fibroblasts, bone 
marrow and umbilical matrix derived cell lines. We assessed the differentiation 
potential of all cell populations at P4, as this was the passage where we had obtained 
sufficient number of cells and previous studies had used passages between P2 and 
P5, the decision was made to use cells all at the same passage to eliminate 
variability. This was achievable except for the commercial DF cell line, which was 
purchased at P13 and in order to multiply numbers the passage we worked with was 
at P16. The differentiation potential was assessed using a semi-quantitative 
measuring scoring system, scale 0-9.  
 
Adipogenesis was confirmed at 14 days by using Oil Red staining of lipid droplets 
within the cytoplasm and a nuclear counterstain of haematoxylin eosin (H&E, 
Sigma). Chondrogenic differentiation was confirmed either by i.) fixation of 
monolayers grown in various culture conditions at different time points and staining 
with Alcian Blue, which highlights deposits of glycosaminoglycan’s (GAGs) or ii.) 
by the harvest of cartilage pellets at Day 21 in chondrogenic induced cultures and 
subsequent fixation and cryostat preparation of pellets for histology and Alcian blue 
staining to visualize GAGs, lacunae formation and chondrocytes within the pellet 
matrix, counter staining with H&E. Osteogenic differentiation was confirmed 
between day 14-21 by staining of the monolayer with Alizarin Red to visualise 
calcium deposits. 
 Adipogenic differentiation 
A commercial kit (Stempro® Adipogenic Differentiation Kit, A10410-01 Gibco) 
was used according to manufactures instruction and as per Barberini et al.(2014) 
and Carvalho et al. (2013). Actively growing cells were trypsinised as per standard 
protocol, centrifuged with the supernatant discarded by decanting. The cells were 
re-suspended in 1ml basal culture media and counted manually with a live/dead 
stain (trypan blue) and a Neubauer haemocytometer. Cells were plated 1x104 cells 
per cm in 24-well plates (Nunc Delta, ThermoFisher) in 1ml basal culture media. 
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The cells were allowed to attach and multiply for 48hours until 60-70% confluent. 
Spent media was removed with a 3ml transfer pipette and discarded and 1ml of new 
basal culture media was applied to the control wells and also 1ml of the StemPro 
Adipogenic differentiation media was added to duplicate wells on the same plate,  
The plates were observed every 24hours for confluence and morphology and photos 
were taken at 2, 7 or 14days. Media was changed every three days. After 7, 14 or 
21days the plates were removed from the incubator and media removed by a 3ml 
pipette. Each well was washed with PBS three times, then 1ml of 
4% paraformaldehyde (PFA) was applied for 20minutes at RT to fixate the cells. 
The PFA was removed and the wells were rinsed with 1ml PBS twice followed by 
1ml of 60% isopropanol for 5minutes. The plate was then inverted to pour the 
excess off prior to Oil Red-O staining. 
 
Oil Red-O stain was freshly prepared according to a protocol derived from Lonza, 
2011.  Briefly, in the fume hood, 150mg Oil-Red-O powder added to 50ml 99% 
isopropanol. Thirty millilitres of this solution was mixed with 20ml deionized water 
and allowed to stand for 10minutes at RT, before filtered through filter paper into a 
clean beaker. One millilitre of the Oil-Red-O stain was added to each well and 
incubated for 5minutes at RT. Tap water was slowly rinsed down the centre of the 
plate to allow each well to be washed without direct pressure, ensuring the 
monolayer was kept intact. The wells were counterstained with 1ml of 
Haematoxylin for one minute at RT and then the tap water rinse step was repeated. 
Plates were viewed in a brightfield microscope (Olympus IX71) and photos were 
taken at 10x and 40x magnification. Each cell line was assessed for number and 
size of lipid vesicles and given a semi- quantitative adipogenic score,  ranging from 
zero to nine (Table 9). 
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Percentage of 
differentiated cells 
Number of lipid vesicles  
Within cytoplasm 
Size of lipid vesicles  
0  0-25 0  0 0  0 
1  25-50 1  0-5 1  Small 
<1/3 of nucleus 
2  50-75 2  5-10 2  Medium 
=1/3 of nucleus 
3  75-100 3  >10 3  Large 
>1/3of nucleus 
Table 9 Semi-quantitative Adipogenic scoring system (0-9). Adapted from 
Redmond-Hubbard (2014).  
 Chondrogenic differentiation  
The protocol used for chondrogenic differentiation was based on three different 
methodologies. Firstly, a commercially available Stempro® Chondrogenic 
Differentiation Kit (A10069-01, Gibco) was used as per manufactures instruction. 
A highly concentrated cell suspension was made containing 1.6x107 cells per ml. 
For the micromass culture system; a 5µl drop of this solution (8.5x104 cells) was 
placed in the centre of the well in a 24well plate and incubated in a high humidity 
chamber inside the incubator (37°C 5% CO2) for two hours, then basal culture 
media was added to the control wells and chondrogenic differentiation media in 
duplicate wells. Then incubated at 37°C in 5% CO2 and grown for 14-21 days with 
regular media change every 3-4days. The cells were observed every 24hours for 
confluence and morphology and photos were taken at 48hours, 7, 14 and 21days. 
 
Secondly, the micromass culture system published by Pilz et al. (2010) was adapted 
as follows. The differentiation was carried out in 96 well round-bottomed plates 
(Nunc, ThermoFisher). The wells were seeded with 8.5 x 105 cells in 5μl drops of 
basal culture medium placed in the centre of the well. The micromass droplets were 
incubated at two hours at 37˚C in 5% CO2; 180μl of StemPro® chondrogenic 
medium was pipetted into the wells and culture continued for 21days with regular 
media change every 3-4days. 
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Finally, a pellet culture system described by Redmond Hubbard (2014) was carried 
out in parallel. A cell suspension containing 2.0x105 cells were transferred to a 15ml 
tube and washed twice in PBS by centrifuging at 150g for 3minutes, after the second 
wash the supernatant was completely removed and 500µl of the StemPro 
chondrogenic media was applied to completely cover the cell pellet. The tubes were 
placed in a rack in the incubator (37°C 5% CO2) and grown for 21 days with regular 
media change every 3-4days. 
 
Using the micromass and pellet culture protocol it was not possible to view the cells 
on the microscope during the differentiation process. However, the media was 
inspected regularly for colour and cloudiness that would indicate contamination. 
 
To confirm chondrogenic differentiation two staining methods were used;  
 
1.) Staining of cells in a 24 well plate 
After 7, 14 and 21 days respectively one third of the samples were fixed and 
evaluated. Each well of the 24-well plate were washed three times with PBS, then 
4% PFA was applied for 20minutes at RT to fix the cells. One millilitre of Alcian 
Blue was applied overnight in the dark at RT to stain the monolayer in the wells. 
The wells underwent multiple washes with PBS until no dye residue was remaining. 
The monolayer was viewed on an inverted microscope (Olympus IX71)) at 10x and 
40x magnification and photos were taken.  
 
2.) Staining of cryopreserved sections 
After 21 days the resulting cartilage pellets were harvested from the 96-well plate 
or 15ml tube and evaluated by histology. Briefly; pellets were detached and lifted 
from the wells or the 15ml tubes by use of a 21g needle and a fine tipped disposable 
pipette. The pellets were fixed in 1ml of 4% PFA for 1hour, then dehydrated three 
times in 400µl 30% sucrose solution before being incubated in 400μl of 30% 
sucrose overnight at 4°C. The following day 2/3 of the sucrose solution was 
removed and two drops of OCT (Jung tissue freezing medium, ThermoFisher) was 
added. The tube was incubated over night at 4°C to ensure penetration of OCT into 
the pellet. Half a millilitre of Alcian blue stain was applied to each pellet for 
30minutes to stain the surface layer to make visualisation easier during the cryostat 
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sectioning step. Each cryomould was half filled with OCT and a pellet was placed 
in the centre of the mould and covered with more OCT. The moulds were snap 
frozen with freezing spray (Surgipath, Frostbite freezing spray) and sectioned at 
4μm on a cryostat (Leica, CM1850). The sections were placed onto Surgipath Apex 
microscope slides and air-dried overnight. The slides were placed in a 3% Acetic 
acid wash for 3min, then placed in 1% Alcian Blue stain overnight and rinsed in 
distilled water for 1min or until clear. A nucleic acid counterstain (H&E, Sigma 
Aldrich) was applied for 1 minute then rinsed with tapwater. After being dipped 
briefly in alcohol to dehydrate then dipped in xylene, the slides were allowed to air 
dry. Using xylene mounting medium (Organo/Limonene Mount, #O8015 Sigma 
Aldrich) and glass coverslips the slides were viewed at 10x and 40x magnification 
on the microscope (Zeiss, Axiovert 40 CFL) to evaluate staining of 
glycosaminoglycans (GAGs) and the formation of lacunae. An adapted version of 
a semi-quantitative scoring system developed by Redmond-Hubbard (2014) was 
used to assess structural changes to the pelleted cells and the intensity of Alcian 
Blue staining Table 10. 
Pellet shape and structure  Lacunae formation  Staining intensity of pellet  
0  No tertiary structure  0  No gaps  0  No colour change  
1  Soft, irregular 1  < 10% 
gaps  
1  Light blue  
2  Round, Medium 
hardness  
2  10-50% 
gaps  
2  Medium blue  
3  Round, Hard pellet  3  >50 % 
gaps  
3  Intense blue  
Table 10 Semi-quantitative Chondrogenic scoring system (0-9). Adapted from 
Redmond-Hubbard (2014) 
 Osteogenic differentiation 
A commercial kit (Stempro Osteogenic Differentiation Kit, A10069-01, Gibco) was 
used according to manufacturer’s instruction and as per Spaas 2012. Cells were 
plated at 5x103 cells per cm in 24-well plates (Nunc, ThermoFisher) in 1.0ml basal 
culture media and allowed to attach and multiply for 48hours until 60-70% 
confluent. Spent media was removed and discarded. One millilitre of new basal 
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culture media was applied to the control wells and 1.0ml osteogenic differentiation 
media to triplicate wells on the same plate. The cells were observed and scored 
every 24hours for confluence and morphology; number of clusters and pellets, and 
photos were taken at 2, 7, 14 and 21 days. The media was changed every 3days. 
After 7, 14 and 21 days the plates were removed from the incubator and media was 
removed and discarded. Each well was washed with 1ml of PBS three times. Then 
4% PFA was applied for 20minutes at RT to fixate the cells. Alizarin red (pH 4.2) 
was applied for 45minutes in the dark at RT to stain the monolayer. The wells were 
given a thorough wash with tap water until no stain residue was remaining. The 
monolayer was viewed on an inverted Olympus IX71 microscope at 10-40X 
magnification and photos were taken. An adapted version of a semi-quantitative 
scoring system devised by Redmond-Hubbard (2014) was used to assess structural 
changes to the pelleted cells and the intensity of Alizarin red staining (Table 11). 
 
Percentage of 
differentiated cells 
Area of staining Stain intensity 
0 <5% 0 Small                0-25µm 0 No stained cells 
1 10-25% 1 Small/medium  25-50µm 1 Light red 
2 25-50% 2 Medium            50-75µm 2 Red 
3 >50% 3 Large               75-100µm 3 Bright red 
Table 11 Semi-quantitative Osteogenic scoring system (0-9) adapted from 
Redmond-Hubbard (2014) 
 
2.2.9 IMMUNOCYTOCHEMISTRY 
-Use of fluorescent antibodies to determine CD marker expression 
 
Equine mesenchymal stromal cells for the immunocytochemistry experiment were 
grown in sterile conditions with standard basal culture media (Chapter 2.2.3) on 
13mm glass coverslips inserted into 24well plates (Nunc Delta, ThermoFisher) until 
estimated confluence of 80%. Fixation of cells was performed as described by 
Leica-Microsystems (http://www.leica-microsystems.com/science-lab/how-to-
prepare-your-specimen-for-immunofluorescence-microscopy). Chilled, (-20°C) 
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100% Methanol (MeOH) was gently added to the wells and incubated at -20°C for 
20minute to fix the cells. The fixation solution was aspirated and discarded and then 
pre-chilled (-20°C) then 80% Acetone was added for one minute to permeabilise 
the cells. The wells were then washed twice with PBS before adding 1ml of PHEM 
buffer (60mM PIPES, 25mM HEPES, 10mM EGTA and 2mM MgCl2) to each well, 
for storage. Before the next step the PHEM buffer was removed and the coverslips 
with the fixed cellular monolayer were removed manually with forceps from the 
wells. The coverslips were placed on a glass microscope slide with the monolayer 
facing up. An aliquot of 20µl of the primary monoclonal antibody diluted (1:40) in 
Sodium azide (PBSNaAz) solution, (see Table 12 for antibodies used), was applied 
to the coverslips and incubated at 4°C overnight. No primary antibody was applied 
to the negative control, just the PBSNaAz solution. After overnight incubation the 
coverslips were washed three times with PBS. Then 20µl of the secondary antibody 
conjugated (1:200) to a fluorophore (rat anti-mouse FITC) was applied to the 
coverslips and incubated for 30minutes at 37°C in the dark. After this the coverslips 
were washed with PBS three times and allowed to air dry. Before mounting them 
on glass slides in glycerol mounting media. The slides were kept covered or in the 
dark during this procedure to avoid bleaching of the fluorescence. They were 
viewed immediately on a Zeiss Axiostar phase contrast microscope fitted with a 
fluorescence power pack. If fluorescence was observed, photos were taken within 
1hour of completion of staining on an Olympus microscope fitted with a 
fluorescence pack/blue light laser (488nm) at 40x magnification. The cells were 
observed in bright field and blue light fluorescence and photos of each view were 
taken. The staining intensity was given a subjective score of 0-4 with 0 being no 
fluorescence observed and 3 being very intense fluorescence.  
Primary Antibody Supplier Code  Clone 
CD105 reactive against horse Abacus SEMCA1557  clone SN6 
CD29 mouse anti-human Norrie 303001  clone TS2/16 
CD44 rat anti-mouse/human Norrie 103001  clone IM7 
CD45 mouse anti-human Abacus SEMCA87A  clone F10-89-4 
MHC-II mouse anti-human Abacus SEMCA1085GA clone CVS20 
Table 12 Primary non-conjugated antibodies used for Immunocytochemistry 
 79 
 
The reported immunophenotype for equine MSC is: CD29+, CD44+ and CD90+ and 
CD45  ̅ and MHC-II  ̅, respectively. Equine peripheral blood mononuclear cells at 
P-1, were used as positive control for CD45 and MHC-II monoclonal antibodies. 
  
2.2.10 FLOW CYTOMETRY 
-Method for determining presence of CD-markers on cell surface. 
 
Mesenchymal stromal cell and dermal fibroblast samples stored in cryogenic vials 
(Greiner, MediRay) in liquid nitrogen vapour, were thawed in a 37°C water bath 
until the cellular suspension had just melted over 30-60s. Then the vials were dried 
with a paper towel and wiped with ethanol for disinfection. The cellular suspension 
containing 1x106 cells in cryogenic media was removed from the vial with a 3ml 
sterile transfer pipette and added to a 15ml conical tube. Warm (37°C) DMEM (low 
glucose (1g/L)) wash media was dripped in slowly for the first 3ml then added 
rapidly up to 12ml. The samples were mixed by inversion and centrifuged at 250g 
for five minutes at 20°C. The supernatant was tipped off in a waste beaker and the 
cell pellet was gently re-suspended in 1ml of warm culture media (DMEM (low 
glucose (1g/L), Thermo Fisher), 10% FBS (Thermo Fisher), 1% Antibiotic-
antimycotic solution (Sigma), gentamicin 0.05mg/ml (ProPharma) and Fungizone 
0.01% (Sigma). The cells were set to equilibrate in a humidified incubator 37°C 5% 
CO2. After one hour of incubation the cells were stained with trypan blue and 
counted manually using a haemocytometer. The live cell counts were recorded and 
dilution factors were applied to have the same concentration of cells per millilitre 
for analysis. The cells were centrifuged at 250g for 5minutes at 4°C to rapidly cool. 
Then the supernatant was tipped off and the cells re-suspended in FACS Buffer 
(PBS 1x and 1% FBS) to a concentration of 5 x104 cells per 10µl. An aliquot of 
40µl (2x105cells) was used in the experiment. For each sample, 40µl was placed in 
two FACS tubes (round bottom 5ml glass tube); one unstained (negative control) 
and one sample, stained with 10µl of fluorescent antibody mastermix (Table 11.). 
The samples were incubated on ice in the dark for 30minutes, then washed twice in 
1ml FACS Buffer and centrifuged 250g, 5min, 4°C. Two and a half microlitre of 
4',6-diamidino-2-phenylindole (DAPI) nuclear stain (AbD Serotec, BUF061) was 
added and the cells were re-suspended in the residual volume of Fluorescence-
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activated cell sorting (FACS) buffer (approx. 50µl) before vortexed and analysed 
on the BD SORP FACS Aria II cell sorter. The machine had initially been calibrated 
to determine a set voltage for each fluorophore. For each sample 100,000 events 
were recorded, and the dot plots were analysed for mean fluorescent intensity using 
FlowJo V7.6.5 analytical software (TreeStar, Ashland, USA). 
 
An initial titration of antibodies was performed to determine the optimal 
concentration of each fluorophore. A mixture of mesenchymal stromal cells 
(ADSC, BMSC, UMBT and pBSC) was prepared and a 2-fold dilution series 
performed for each fluorophore. The optimal concentrations were determined and 
subsequently used in the main experiment. For the main experiment, a preparation 
of a fluorescent antibody mastermix was made (Table 13) to increase the speed of 
running the samples. An aliquot of 10µl of the mastermix was used per sample. 
CD 
marker Code Company Clone Fluorophore Dilution Mastermix  
CD29 303004 Mediray TS2/16 PE 1/20 2.5µl 
CD44 103030 Mediray IM7 PE/CY7 1/80 0.625µl 
CD90 202528 Mediray OX-7 ALEXA700 1/80 0.25µl 
CD45 
SEMCA 
87APCT Abacus 
F10-89-
40 APC 1/20 5µl 
MHC-II 
SEMCA 
1085F Abacus CVS20 FITC 1/80 1.25µl 
Table 13 List of conjugated antibodies and dilutions used for the Mastermix for 
Flow cytometry 
 
2.2.11 SYNOVIAL FLUID MODEL 
 Set up of plates 
MSC from bone marrow, umbilical tissue and skin derived fibroblasts were utilised 
in this experiment. The MSCs were plated on 24-well plates (NuncDelta, 
ThermoFisher) at a seeding density of 20,000 cells per well = 11,300 cells per cm2 
(Area per well = 1.76715 cm2) in one millilitre of media. In the pilot experiment the 
cells were grown directly on the bottom of the plate, for the replications we used 
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sterilised (soaked in ethanol then flamed through Bunsen burner) 13mm glass 
coverslips inserted into the wells to allow removal for staining procedure.  
 
The cells were assessed daily for attachment, morphology, growth pattern and 
degree of confluence. Photos of the cells were taken at 1, 2, 3 and 7days. The culture 
media was left unchanged for the duration of the experiment (Total 7days). This 
was done to assess cellular activity and how quickly they would metabolise the 
nutrients and to see if any resulting pH changes were caused by the cells themselves 
or the various concentrations of synovial fluid incorporated into the culture system. 
The cultures were assessed and the colour of the phenol red indicator in media was 
noted. On Day 0 and Day 7, the pH of the cell supernatant from each well was 
measured with pH indicator paper (Whatman, ThermoFisher).  
 
For replication one and two; antibiotics and HEPES were added to the synovial 
fluid at identical concentration as the culture media, HEPES is a 
zwitterionic organic chemical buffering agent that helps minimise effects of change 
in carbon dioxide concentration produced by cellular respiration. Its’ useful pH 
range is 2.5 to 3.5 or physiological pH 6.8 to 8.2.  
 
To each ml of synovial fluid the following additives were included -: Antibiotic-
antimycotic 0.001ml, Gentamicin 0.00125ml, Fungizone 0.0005ml, HEPES 
5.96mg, the mixture was then vortexed for 20seconds. No signs of bacterial or 
fungal contamination was noted in the cultures. 
 
A subjective estimation of confluence was performed by the same person in all 
experiments. A semi quantitative scoring system was devised by the author, where 
the number of cell clusters and their density (cluster or pellet) were recorded per 
well, was used to describe the change in morphology and growth pattern that was 
observed. 
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Trial  
Treatment group: 
Cell source and  
sample number Culture media composition 
Pilot study UMBT N=4       
0% (control), 10%; 50% and 100% (no 
additives to the SF)  
Rep 1 UMBT N=4      
0% (control), 50% and 90% (added 
antibiotics, antifungal and HEPES to SF    
Rep 2 UMBT N=4 
0% (control), 50% and 90% (added 
antibiotics, antifungal and HEPES to SF 
Mixed Various N=4     
0% (control), 6.25%, 12.5%, 25% and 
50% (added antibiotics, antifungal and 
HEPES to SF 
BMSC BMSC N=4 
0% (control), 50% (added antibiotics, 
antifungal and HEPES to SF 
DF DFs   N=4 
0% (control), 50% (added antibiotics, 
antifungal and HEPES to SF 
UMBT UMBT N=4 
0% (control), 50% (added antibiotics, 
antifungal and HEPES to SF 
Table 14 Different concentrations of allogenic synovial fluid evaluated  
 Normal Synovial fluid experiment 
Various volumes of allogenic synovial fluid (SF) were obtained ex vivo from 
clinically normal joints by arthrocentesis. The joint was considered normal if the 
horse was free from lameness at the walk prior to euthanasia, and there were no 
clinical signs such as heat, pain or joint effusion present, that are commonly 
associated with joint disease (osteo-arthritis OA or degenerative joint disease DJD 
or septic joint disease SJD). The SF was collected ex vivo in a sterile manner at a 
local abattoir or on farm immediately after euthanasia. The hair was clipped over 
the carpal and stifle joints. Chlorhexidine surgical scrub was applied for a minimum 
of five minutes before the skin was wiped with methylated spirit. A sterile 10ml 
syringe and 21gg needle were used for arthrocentesis. Immediately after aspiration 
the SF was injected into sterile blood sample tubes containing no additives or 
anticoagulants (red top). Samples from different joints were mixed together to 
create one pooled synovial fluid sample per donor. The samples were kept at 4°C 
and processed within 4hours. At the laboratory the synovial fluid samples were 
centrifuged at 1000g for 10minutes to pellet any cellular content. The pellet was 
discarded, and the supernatant was removed and filtered (0.45µm Minisart, 
Sartorious stedim syringe filters) and frozen in 10ml aliquots in 15ml tubes at -
70°C. An aliquot of each sample of synovial fluid was plated on 5% sheep blood 
 83 
 
agar plates and placed in a 37°C incubator and visualised for any bacterial growth 
at 24hours and 48hours, if any growth was detected the sample would be discarded. 
An aliquot of each SF sample was also sent to an independent laboratory; New 
Zealand Veterinary Pathology, Hamilton and tested for Serum Amyloid A (SAA) 
and Total protein (TP) content.  
 Normal Synovial fluid pilot trial 
The growth potentials of equine mesenchymal stromal cells from skin derived 
fibroblasts, bone marrow, umbilical cord perivascular tissue were determined in 
varying concentrations of equine allogenic synovial fluid (SF) obtained from 
apparently normal joints. 
 
Normal synovial fluid samples were obtained ex vivo from aseptically prepared 
carpi or stifle joints as previously described in section 2.2.1. The synovial fluid 
samples were cryopreserved and kept at -70°C and thawed in RT before used in the 
experiments. Mesenchymal stromal cells for the synovial fluid pilot trial were 
grown in sterile conditions in duplicates on 24-well plates. Replications one and 
two were done with the cells grown on sterile 13mm glass coverslips inserted into 
the 24well plates. The basal culture medium was used in all experiments as 
described in Section 2.2.3 except that 5.96mg/ml of HEPES buffer 25mM, was 
added to the 50/50 SF media to help maintain physiological pH in the culture 
media.    
 Inflammatory Synovial fluid  
The collected inflammatory synovial fluid (I-SF) samples were kept at 4°C and 
processed within 6 hours of collection. The samples were centrifuged at 1000g for 
10min at 4°C, the cell pellet was discarded while the supernatant was retained, 
filtered through a 0.45µm syringe filter (16555, Minisart, Sartorious stedim), 
frozen, and stored at -70°C. An aliquot of each sample of I-SF was plated on sheep 
blood agar plates and placed in a 37°C incubator and visualised for any bacterial 
growth at 24hours and 48hours. If any growth was detected the sample was 
discarded.  
 
 84 
 
The I-SF samples (N=12) were thawed at RT. Duplicate 0.5ml aliquots from each 
donor were placed in 1ml sterile Eppendorf tubes and again cryopreserved and kept 
at -70°C. The remainder I-SF samples were then pooled to make up a total volume 
of 50ml. An aliquot was taken from this pooled sample and tested for bacterial 
contamination on 5% sheep blood agar plates, the plates were visualised for any 
bacterial growth at 24hours and 48hours. Samples negative for any bacterial growth 
were sent to The New Zealand Veterinary Pathology (NZVP) laboratory for 
analysis of SAA and TP.  
 Inflammatory Synovial Fluid Experiment  
The growth potentials of equine mesenchymal stromal cells and dermally derived 
fibroblasts were determined in 50% inflammatory allogenic synovial fluid mixed 
with 50% basal culture media (v/v). 
 
Stromal cells from bone marrow, umbilical cord perivascular tissue and dermally 
derived fibroblasts were grown in sterile conditions in 24-well plates using basal 
culture medium (Section 2.2.3). The plates were kept at 37°C with 5% CO2 in a 
humidified incubator (HealForce). The cells were assessed daily for attachment, 
growth pattern and degree of confluence as well as morphology. An estimation of 
confluence was performed by the same person in all experiments. The term 
confluence in cell culture is commonly used to describe the density of adherent cells 
and it is used as a measure of proliferation (Freshney 2010). It is combined with an 
estimated percentage, as an example 10% confluency means that 10% of the surface 
of the flask is covered with cells, 100% means that it is entirely covered. A record 
was also kept of the observed morphological change and the number of clusters as 
well as the number of pellets formed.  
 
2.2.12 BIO ACTIVATION ASSAY 
 Cytokine analysis by enzyme linked immunoassay (ELISA) 
A bio assay was set up to activate equine MSC and DFs with either TNFα or I-SF 
and compare with control cell populations grown in normal basal culture media. 
The outcome was to sample the cell supernatant and analyse for a panel of 
inflammatory and anti-inflammatory cytokines as listed in Table 15. 
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The plates were set up as Table 15 and cells were plated at a density of 20,000 cells 
per well in 1ml of media, allowed 36hours to attach and equilibrate to reach a state 
of active growth/log phase. The culture media was removed together with any 
unattached cells and cellular debris. The cells were exposed to one of three 
conditions;   
1.  Basal Culture Media (CM) control 
2.  Tumour Necrosis Factor alpha 25ng/ml (TNFα) in basal culture media 
3.  Inflammatory Synovial fluid 50% (I-SF) with 50% basal culture media (v/v) 
with 2X antibiotics/antifungals (1% Antibiotic-Antimycotic 1X, 0.05mg/ml 
Gentamicin and 0.01% Fungizone) and 25mM/L HEPES) to give the same 
final concentration as the basal culture media. 
Time 
(hr) 
Control 
CM 
Treatment
1 - TNFα  
Treatment 
2  - I-SF  
Control 
CM 
Treatment 
1  -TNFα  
Treatment 
2 - I-SF  
24             
48             
72             
168             
Table 15 Layout of 24-well plate for activation experiment, one horse per plate, 
duplicate samples for each time point 
 
The cell cultures were exposed to the activation conditions for 12hours, after this 
the activation agent and all supernatants were removed and discarded and the 
monolayers were washed three times with 1ml PBS. One millilitre of basal culture 
media was subsequently added to the wells and the plates were incubated as per 
normal cell culture protocol. The cell cultures were observed every 24hours and 
estimations of confluence and change in morphology were recorded and 
photographed. At each time point (24, 48, 72 and 168h) duplicate 1ml sample 
aliquots of the cell supernatant were collected into 2ml Eppendorf tubes and frozen 
at -70°C. These samples were later run on equine specific sandwich ELISAs 
(Genorise, USA) for testing of six selected cytokines, see Table 16. 
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After the initial sample aliquot was taken, new basal media was added to the well 
and cells were left growing for 21days, with medium changes every 3-4days, then 
cultures were terminated. Some plates had chondrogenic pellets and alcian blue 
stain was applied in situ and photographs were taken, other pellets were harvested 
at 21 days and processed for cryostat sectioning and staining as per the 
chondrogenic differentiation protocol, Chapter 2.2.8.2. 
 Cytokine analysis - ELISA  
Equine specific ELISA kits for the following cytokines; IL-1b; IL-6; IL-10; TGF-
β1, TNFα and PGE2, were obtained from Genorise Scientific, USA.  
 
Pro-inflammatory cytokines Anti-inflammatory cytokines 
Tumour necrosis factor alpha (TNFα) Transforming growth factor beta 1 (TGF-β1) 
Interleukin-1 beta (IL-1β) Interleukin-10 (IL-10) 
Interleukin-6 (IL-6) Interleukin-6 (IL-6) 
Prostaglandin E2 (PGE2)  
 
Table 16 Selected cytokine panel 
 
 
The reagents were prepared as per manufacturers’ instructions and the assay 
procedure was followed exactly. The set up of plates and washer were set up as per 
Figure 14 Overview of cytokine experiment setup. A). Microplate washer and 
reader set up, B) developed ELISA plates and C). Sterile preparation of samples 
for bio assay experiment 
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Figure 14. An automated plate washer (Wellwash Versa, Thermo Scientific) was 
used to wash plates between each step and the plates were read on a microplate 
reader at 450nm. The resulting data was saved as a Microsoft excel file. 
Cryogenically preserved 1ml aliquots of cell culture supernatant were thawed in 
tube racks at RT until just melted, then placed on ice to remain cool at 4°C. The 
ELISA strip plates were removed from 4°C and allowed to come to RT. A two-fold 
serial dilution of the standard of each cytokine was performed and 100µl of each 
known concentration was added to duplicate wells on the ELISA plate. The cell 
culture supernatant samples were vortexed (5sec) and 100µl was added to duplicate 
wells. The plate was covered and incubated at RT for two hours. Three washes were 
done through the automated plate washer and excess liquid was blotted away to 
ensure complete removal of the wash buffer. Then 100µl of detection antibody was 
added to each well and incubated for two hours at RT. The wash procedure was 
repeated. Then 100µl of working dilution of Conjugate was added and the plate was 
incubated in the dark for 20minutes. The wash procedure was repeated. Then 100µl 
of Substrate solution was added to all wells and incubated for 20minutes in the dark, 
after which 50µl of Stop solution was added and the absorbance was read 
immediately on the microplate reader and data recorded.  
 Pilot trial; Temporal Study of one selected bone marrow and one 
dermal fibroblast cell line 
An initial validation experiment was performed using stromal cells from two 
different mesenchymal sources; BMSC (N=1 r=2) and DF (N=1 r=2). A temporal 
analysis of absorbance of all set time points (1, 2, 3 and 7days) was performed for 
each of those two donors. Plain culture media and media containing various 
concentrations of synovial fluid were also tested for confirmation of blank and 
background readings. This temporal analysis was done with the aim to identify an 
optimal time point where the remainder samples could be compared. The 24hour 
time point was selected for the continuing experiment. 
 
The second part of the experiment (ELISA2 and 3) was performed with three cell 
sources; ELISA 2 BMSC (N=4) and DF (N=4) and ELISA3 UMBT (N=8) and DF 
(N=4). The samples were collected at T=24hours and run in duplicates. A standard 
 88 
 
curve of known concentrations was prepared in GenStat 64-bit Release 18.1 and 
plotted for each cytokine. 
 Bio Activation Assay Run1  
-Activated BMSC vs. DF 
The first experiment evaluated six cytokines; IL-1b; IL-6; IL-10; TGF-β1, TNFα 
and PGE2. Cryopreserved cell supernatant samples from eight horses from two 
different sources (BMSC (N=4) and DFs (N=4)) obtained from the Activation 
experiment were used. The samples were analysed at time point T=24h. The 
ELISAs were run as per manufacturers’ instruction as previously described in 
section and all samples were run as duplicates. The absorbance data was analysed 
on Minitab and GenStat 64-bit statistical software. 
 Bio Activation Assay Run2 
-Activated UMBT vs. DFs 
The second experiment evaluated the following cytokines; IL-10; TGF-β1, TNFα 
and PGE2. Cryopreserved cell supernatant samples from twelve horses from two 
different sources (UMBT (N=8) and DFs (N=4)) obtained from the Activation 
experiment were used. The samples were analysed at time point T=24hours. The 
same dermal fibroblast cell lines (N=4) as tested previously in experiment 1 were 
tested again. The ELISAs were performed as per manufacturers’ instruction 
(Genorise Scientific, USA). The assay was repeated twice and each sample was run 
in duplicates. A standard curve was created and had a general logistic fitted:   
Equation 5 Fitted logistic ELISA Standard curve 
 
 (Y= absorbance and X= predicted concentration)  
The predicted concentrations of each cytokine produced by each cell line were 
calculated and graphed. Data were expressed as mean ± SD of the secreted factor. 
Then using population growth data the cytokine production per 104 cells were 
calculated and graphed. 
 Bio Activation Assay Run3; 
-Activated BMSC vs. UMBT vs. DFs 
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The third experiment evaluated only IL-10. Cryopreserved cell supernatant samples 
from three different sources; DFs (N=4), BMSC (N=5) and UMBT (N=8) obtained 
from the Bio Activation assay experiment were used. The samples were analysed 
at time point T=24hours. The ELISAs were performed as per manufacturers’ 
instruction (Genorise Scientific, USA). The assay was repeated twice and each 
sample was run in duplicates. A standard curve was created and had  
a Michaelis- Menten function fitted: 
Equation 6 Fitted logistic ELISA Standard curve 
   
(Y= absorbance and X= predicted concentration)  
The predicted concentrations of each cytokine produced by each cell line were 
calculated and graphed. Data were expressed as mean ± SD of the secreted factor. 
Then using population growth data, the cytokine production per 104 cells was 
calculated and graphed. 
 
2.3 STATISTICAL ANALYSIS  
A number of different experiment were performed and a repeated measures model that 
recognised multiple observations as belonging to the same horse was used to test for 
differences in proliferation, differentiation as well as cytokine production after 
activation, between treatment groups and time points. Numerical data and residuals 
were graphed as histograms for each subset, to visualise the distribution of data to 
assess frequency distribution and normality. An a priori analysis of sample size was 
done with G* Power calculator, 3.1.9.2 for Windows XP, (HH University of 
Dusseldorf, Germany). 
 
Experiment 1 Population doubling times; GraphPad Prism software version 7.02 
for Windows (GraphPad Software Inc, La Jolla, CA, USA) was used in the 
statistical analyses. The cell populations from all five tissue sources were counted 
at seeding and again at 80% confluence at passage 4. Duplicates samples were 
counted per cell line. The residuals of means for each tissue source were plotted in 
histograms to view the frequency distribution and the data was confirmed to be 
normal Gaussian distribution at 95% confidence interval (Appendix 4). The 
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D'Agostino & Pearson normality test also confirmed the data to be normally 
distributed (alpha= 0.05). One-way ANOVAs were performed to test the inter-
group variability of means. The data is presented as Means ± SD 
 
Experiment 2 Flow Cytometry  
FlowJo V7.6.5 analytical software (TreeStar, Ashland, USA) was used for 
statistical analysis of flow cytometry data. Quadrant markers to determine marker 
expression were set according to negative control stains, including ‘‘ﬂuorescence 
minus one’’ (FMO) controls that used all antibodies except that to the marker in 
question. Each run recorded 100,000 events. The data for each cell line is presented 
as dotplots and individual histograms for each CD marker. 
 
Experiment 3 Trilineage Differentiation; The GraphPad Prism software version 
7.02 for Windows (GraphPad Software Inc, La Jolla, CA, USA) was used in the 
statistical analyses. Cell populations from three tissue sources were induced to 
undergo differentiation in two separate replications of the experiment. Subjective 
scoring using a semi-quantitative scale, was performed on triplicate samples from 
each cell populations. The residuals of means for each differentiation potential 
(adipo, chondro and osteogenic) were plotted in histograms to view the frequency 
distribution and the data was confirmed to be normally distributed at 95% 
confidence interval (Appendix 4). The D'Agostino & Pearson normality test also 
confirmed the data to be normally distributed (alpha=0.05). One-way ANOVAs 
were performed to test the inter-group variability of means. The data is presented 
as Means ± SD. 
 
Experiment 4 Synovial Fluid Model 
The GraphPad Prism software version 7.02 for Windows (GraphPad Software Inc, 
La Jolla, CA, USA) was used in the statistical analyses. Three culture conditions 
were applied. A temporal analysis was performed at three different time points (24, 
48 168h), for data collected within source (intra-source) for the control and two 
culture conditions. A subjective estimate of the percentage of confluence was 
recorded on duplicate samples per treatment and cell line. The mean for each cell 
line was added to the source data and graphed as Means ± min-max. For each time 
 91 
 
point a paired t-test was run to compare the means within source for control vs each 
culture condition.  
 
Experiment 5 Bio Activation Assay 
GenStat 64-bit Release 18.1 (PC/Windows 7, VSN International Limited, Hemel 
Hempstead, United Kingdom), was used for the generation of standards curves and 
fitted equations, as well as one-way ANOVA analysis using absorbance and 
predicted concentrations as response variables. Student Newman Keuls was used 
as a post-hoc test to distinguish means between treatment groups. GraphPad Prism 
software version 7.02 for Windows (GraphPad Software Inc, La Jolla, CA, USA) 
was also used to calculate and graph concentrations per 104 cells. The data was 
plotted in histograms to confirm a normal Gaussian distribution (Appendix 4). 
Student paired t-test were performed for inter-source data to compare the effect of 
each of the two activation groups vs control per cytokine. The data is expressed as 
the Mean ± Standard Deviation. 
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CHAPTER 3: RESULTS 
3.1.1 EXPERIMENT 1: MORPHOLOGICAL STUDY 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have equivalent morphological characteristics as 
dermally derived fibroblasts 
 
Cell lines from five equine sources were used during this study; adipose (ADSC; 
N=4), bone marrow (BMSC; N=6), peripheral blood (pBSC N=4), umbilical cord 
matrix (UMBT; N=8) and skin dermis (DF; N=4). All cell lines showed a fibroblast-
like morphology and plastic adherence. The cells were spindle shaped, slender and 
elongated. After seeding in plastic culture flasks, the cells formed distinct colonies 
and with increasing time in culture a monolayer. Figure 15 below shows a 
representation of each cell source. For DFs and BMSC this phenotype was 
maintained across all the passages, P0 to P6, (P16 for the commercial DF cell line). 
From passage P2 to P6, there was a small difference noted in the morphology of the 
UMBT cell lines; cells appeared slightly smaller and acquired a more triangular to 
polygonal shape with shorter cytoplasmic extensions compared to the elongated 
swirls of the DF and BSMC cells. Still they were identified as a mesenchymal 
phenotype. 
 
When cultures were left more than two weeks without passaging a mesenchymal-
epithelial transition (MET) was observed in the DF cell lines. Figure 16 shows 
examples of the cellular morphology after two weeks in culture of two DF cell lines 
and two BMSC cell lines. The cells comprising the two DF monolayers are 
polygonal in shape with more regular dimensions and grow attached to the substrate 
in discrete patches, here in a monolayer. This is typical for an epithelial phenotype. 
The BMSC cells still has a mesenchymal morphology although cells are slightly 
more expanded than a monolayer that has had less time in culture. 
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Figure 15 Representation of selected stromal cell lines and dermal derived 
fibroblasts displaying both individual cell morphology and monolayer formation 
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Figure 16 Mesenchymal-epithelial transition of two DF and two BMSC cell lines 
at P4 after >2 weeks in culture with no passaging of cells 
 Population Doubling Times 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have equivalent population dynamics as measured 
by population doubling times, as dermally derived fibroblasts  
Table 17 below represents the Mean ± SD and SEM of the populations doubling 
times for each cell source. There were no statistical significant differences (P=0.78) 
in population doubling time between the five tissue sources noted at P4. 
Population  
Doubling Times  
(hours) at P4  
BMSC 
(N=6) 
UMBT 
(N=8) 
DF 
(N=4) 
ADSC 
(N=2) 
PBSC 
(N=4)  
Mean 26.70 33.32 30.18 31.70 25.61 
 
Std. Deviation 8.58 10.13 18.20 6.08 16.20 
 
Std. Error of Mean 3.24 3.38 9.10 4.30 8.10 
 
Table 17 Mean of Population Doubling times for all tissue sources at P4 
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Figure 17 below is a graphical representation of the data in Table 17 showing the 
Mean ± standard deviation of hours taken for cell populations from each tissue 
source to double in numbers.  
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Figure 17 Population Doubling times (hours) per tissue source at passage 4 
expressed as Mean ± SD. There was no significant inter-source difference (P=0.78) 
for population doubling times 
The exponential growth could also be assessed for each tissue source over a 72 hour 
time period as displayed in Figure 18. The growth curves were calculated using the 
population doubling means from each tissue source over the time period of 72 hours 
post seeding, since the experiments were carried out during this time point (24hours 
post activation agent removal). 
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Figure 18 Exponential growth of all MSC and DF populations at passage 4 
 Mycoplasma PCR   
All cell samples submitted for mycoplasma testing had excellent DNA recovery. 
The DNA concentrations of the samples as measured with NanoDrop, (Nanodrop 
1000 V3.7, Thermo Scientific) were in the range of 113.8 -889.8ng/µl (N=12). 
Figure 19 shows the electrophoresis results of the Mycoplasma PCR reaction. 
Figure 19 Electrophoresis gel Mycoplasma negative BMSC and DF (lane 5 and 7) 
Lane 1 represents the negative control and thus indicates that there is no 
contamination but primer dimers are evident. The band for the Internal DNA is seen 
in lane 2 and the positive control (Mycoplasma) in lane 3, with the two combined 
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(Internal DNA plus positive control) seen in lane 4. The two samples (BMSC and 
DF) are in lanes 5 and 7, showing no bands, thus, no Mycoplasma contamination 
was detected. All the cell lines used in this experiment were found to be negative 
for Mycoplasma species. 
 
3.1.2 EXPERIMENT 2: IMMUNOPHENOTYPING OF MSC & DFS  
 Immunocytochemistry (ICC)  
H0: The hypothesis is that stromal cells from adipose and bone marrow have the 
same qualitative expression of cell surface markers, Positive for; CD29, CD44, 
CD90 and Negative for; CD45, MHC-II, as dermally derived fibroblasts  
 
The optimal dilution for these selected primary monoclonal antibodies was 
determined to 1:20-1:40 and for the secondary fluorescent labelled antibody the 
optimal dilution was 1:50-1:100. Subjective staining scores displayed in Table 18. 
 
Antibody 
Primary antibody dilution series 
1:20 1:40 1:80 1:160 1:320 
Negative 
control 
CD29 1.5 1.5 0.5 0.5 0.0 0.0 
MHC-II 0.2 0.0 0.0 0.0 0.0 1.5 (MNC) 
Antibody 
Secondary antibody dilution series 
1:50 1:100 1:200 1:400 
Negativ
e control 
Positive 
control 
CD29 1.5 1.0 0.5 0.5 0.0  
MHC-II 0.5 0.5 0.0 0.0 0.0 1.5 (MNC) 
Table 18 Subjective staining score of Primary and secondary monoclonal antibody 
dilution series. Mean (N=2, triplicate samples). Subjective staining score ranged 
from 0 (no fluorescence observed) to 3 (intense green signal). 
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Figure 20 Morphology and cell surface marker expression for two equine cell types. 
Dermal fibroblasts: A.) confocal microscopy at 40X magnification B.) Positive 
staining for CD29, secondary antibody rat anti-mouse FITC at 490nm. Adipose 
stromal cells C.) Confocal microscopy at 40X magnification D.) Positive staining 
for CD29, secondary antibody rat anti-mouse FITC at 490nm. Scale bar = 50 M. 
 
Positive immunofluorescence for CD29 was shown in equine ADSC (N=2), BMSC 
(N=2) and as well as in DF cell lines (N=2) as depicted in Figure 20. The fixed cells 
in the samples stained uniformly; if the sample was positive for stain, all of the cells 
stained. The same proportions applied for the negative marker MHC-II for which 
no staining was detected in either of the MSC or DF cell lines. However, the ICC 
results for MNC samples (positive control) showed positive results for both of the 
negative MSC markers; MHC-II and CD45, which confirms the antibodies are 
working. A more extensive investigation of the immunophenotypes of selected 
BMSC and DF cell lines were performed, and the results displayed in Figure 21. 
There was no difference in the morphological appearance of BMSC or DF 
populations and no apparent difference in distribution of CD markers on the cell 
C D 
A B 
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surface. Mononuclear cells were included as positive controls for the negative MSC 
markers; MHC-II and CD45.   
Figure 21 CD marker expression comparison for two equine cell types; DF and 
BMSC: confocal microscopy at 40x magnification, immunofluorescence viewed at 
490nm. 
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 Flow cytometry  
H0: The hypothesis is that stromal cells from adipose and bone marrow have the 
same qualitative expression of cell surface markers, Positive for; CD29, CD44, 
CD90 and Negative for; CD45, MHC-II, as dermally derived fibroblasts  
 
The CD marker analysis of the selected cell populations was performed with ﬂow 
cytometry using the gating strategy shown in Figure 22. Top row of dot plots. The 
cells were ﬁrst gated by Forward Scatter–A (FSC-A) and Sideways scatter–A 
(SCC-A) followed by doublet exclusion using FCS-A/FSC-H and SSC-A/SSC-H. 
Nonviable (DAPI+) cells were excluded by the use of DAPI staining. 
 
The MSC cell populations were shown to have the following immunophenotype; 
CD29+, CD44+ and CD90+ and CD45  ̅ and MHC-II  ̅. As displayed in Table 19. 
Source 
Horses tested 
(N) CD29 CD44 CD90 CD45 
MHC-
II 
BMSC 5 + + + - - 
ADSC 3 + + + - - 
pBSC 4 + + + - - 
UMBT 4 + + Weak + - - 
DF 4 + + + - - 
Table 19 Flow cytometry results for MSC and DF, + Positive result, - Negative 
result 
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Figure 22 A representation of a typical mesenchymal stromal cell dot plots and 
histograms. Here a BMSC cell line is representing all of the stromal cell populations. 
 
The results of this experiment demonstrated that equine stromal cells from adipose 
tissue, bone marrow and peripheral blood have the same immuno-phenotype as 
previously reported in the literature (DeSchauwer et al. 2011).  
 
MSC 
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The equine dermally derived fibroblast cell lines (N=4) had the same immuno-
phenotype as the MSC cell lines; CD29+, CD44+ and CD90+ and CD45  ̅ and  
MHCII  ̅. The positive immuno-phenotype noted for CD90 were not expressed as 
strongly on UMBT cells (N=4), as for other MSC, which will be discussed further. 
For a positive result the shift in intensity between negative control and a positive 
sample well separated as per the schematic below in Figure 24. 
DF 
Figure 23 Typical dotplots and histograms obtained for DF cell populations 
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Figure 24 Illustration showing how to interpret the peaks obtained from flow 
cytometry data. Retrieved online on 2/2/17 http://www.abcam.com/protocols/ 
introduction-to-flow-cytometry. 
 
For UMBT cell populations labelled with CD90, the sample peaks were 
overlapping to a certain degree with the isotype control and although a positive 
result, it was not as clear demarcation in fluorescence intensity of these samples in 
comparison to the other MSC and DF cell populations (Figure 25, middle row, 
graph on right, CD90).  
 
 104 
 
 
Figure 25 Typical dotplots and histograms obtained for UMBT cell populations, 
immune-phenotype; CD29+, CD44+ and CD90+ and CD45  ̅ and MHC-II  ̅note for 
CD90 there is overlapping of the peaks for fluorescence intensity 
 
Equine peripheral blood mononuclear cells (pMNC) were used as the positive 
control for the negative markers; CD45 and MHC-II. The flow cytometry results 
from these cell lines are displayed in Table 20. Thus, a positive result was expected 
for CD45 and MHC-II as shown with the previous immunocytochemistry results. 
However, only three out of four (75%) horses were positive for MHC-II and only 
one out of four horses (25%) was positive for CD45.  
 
 
 
CD90 
UMBT 
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Source Horse CD29 CD44 CD90 CD45 
MHC-
II 
pMNC 1 + + - - + 
pMNC 2 + + - - + 
pMNC 3 + + weak + + + 
pMNC 4 + + + - - 
Table 20 Flow cytometry results for equine peripheral blood mononuclear cells (P-
1) 
3.1.3 EXPERIMENT 3: TRILINEAGE DIFFERENTIATION 
POTENTIAL  
H0: The hypothesis is that stromal cells from bone marrow and umbilical cord tissue 
have an equal potential for trilineage differentiation as dermally derived fibroblasts  
 
All cell lines were observed to undergo differentiation under the defined induction 
protocols using commercial StemPro mesenchymal induction media. The isolated 
cell lines have the capacity to differentiate into adipocytes, chondrocytes and 
osteocytes, respectively. Figure 26 is a representative example of differentiation for 
each cell population. There was no significant difference between the cell sources 
for adipogenic differentiation scores (P=0.5006) and the range of Means were 5.1-
5.3 (out of 9); BMSC=UMBT=DFs. However, both chondrogenic and osteogenic 
differentiation scores showed significant differences; P<0.0001 and P=0.0096 
respectively, between the sources as presented in Figure 29. 
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Figure 26 Representation of results obtained after trilineage differentiation of three 
different tissue sources, stained with Oil-Red-O (adipogenic), Alcian blue 
(chondrogenic) and Alizarin Red (osteogenic) as viewed on brightfield microscope 
(Olympus IX71) at 10x and 40x magnification 
 
The first column in Figure 26 represents the adipogenic potential of each tissue 
source; DF, BMSC and UMBT. There has been a phenotypic change from a 
fibroblastic cell type into adipocytes and there are lipid globules, stained red with 
Oil Red-O, within the cell cytoplasm. The results showed that all the cell types 
investigated in this study, including dermal ﬁbroblasts, have the potential to 
differentiate into adipocytes. The second column in Figure 26 represent 
chondrogenic differentiation potential of DF, BMSC and UMBT. The cells in a 
micromass culture system have formed a tertiary structure in the form of a firm 
cartilaginous pellet. The cells have a chondrogenic phenotype and visible lacunae 
have formed within the pellet. Chondrocytes produce GAGs and alcian blue stain 
is shown by blue coloration of the matrix. The third column is a representation of 
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osteogenic differentiation of DF, BMSC and UMBT. The cells formed aggregates 
and mineralised material, which stained red with Alizarin red stain. 
 
Figure 27 shows the results obtained from trilineage differentiation for the 
commercial equine dermal fibroblast line (Equus caballus E.Derm (NBL6, CCL-
57™ ATCC, USA). The cells were stained as described in previous section. This 
cell line was at passage 16 for the experiments and trilineage differentiation was 
confirmed even in this cell line, which is far later passage than most studies would 
ever perform differentiation experiments.  
 
Figure 27 Representation of results obtained after trilineage differentiation of the 
commercial equine fibroblast cell line; Equus caballus E.Derm (NBL6, CCL-57, 
stained with Oil-Red-O (adipogenic), Alcian blue (chondrogenic) and Alizarin Red 
(osteogenic) as viewed on brightfield microscope (Olympus IX71) at 10x and 40x 
magnification. 
 
For chondrogenic induction three different culture systems were trialled. The 
micromass culture system in the round bottom 96-well plates was found to be the 
most successful method in our laboratory conditions. The cells formed a dense 
pellet, white to off-white in colour, which was attached to a cellular base layer at 
the bottom of the well. The shapes of the pellets were mainly spherical, and the size 
varied slightly between replications (intra-cell) and between cell lines (inter-
source), range between 20µm-100µm. The StemPro media appeared cloudy white 
soon after induction (T=48-72h) of each culture, but no bacterial nor fungal 
contamination was detected. The conical tube culture system was unsuccessful in 
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all of the attempts (r=6); the cells did not form a firm pellet structure and each 
culture media change resulted in disruption to the cells despite careful pipetting 
technique.  
 
After 21days in the micromass culture system, the pellets were prepared using the 
cryostat sectioning technique and the sections were stained with Alcian blue to 
confirm the presence of GAGs, with a counter stain of H&E applied for 
visualisation of the cell nuclei. The initial run of samples only had Alcian blue stain 
applied and no H&E. As seen in Figure 27, the second column; BMSC, UMBT and 
DF cell lines were all able to differentiate into chondrocytes. The chondrogenic 
potential varied between the groups P<0.001. BMSC (7.5 ± 1.2 SD) and UMBT 
(6.3 ± 0.9 SD) showed a greater differentiation potential compared to DFs. The DF 
populations had a mean chondrogenic score of (4.6 ± 0.8 SD) and distinct pellets 
were formed, which stained positively with alcian blue, indicating formation of 
GAGs. The overall differentiation score was lower, nonetheless positive 
chondrogenic differentiation was confirmed for DFs in this culture system. 
 
Osteogenic differentiation of the cells lines into osteoblasts with the associated 
calcium deposits produced by the cells were also observed. During osteogenic 
induction the cells formed monolayers that stained positive with Alizarin Red, see 
Figure 27, third column. There was a high rate of cellular death noted during the 
osteogenic incubation. The cultures were not able to be maintained for more than 
10-14days before complete detachment of the cells from the culture plates were 
observed. No bacterial nor fungal contamination was observed as proven with 
negative culture on sheep blood agar, at 48hours. The osteogenic potential varied 
between the groups; multiple comparison ANOVA analysis revealed BMSC had a 
significantly higher osteogenic score (P<0.01) than the other cell sources; BMSC > 
UMBT > DF and the range of means were; 4.7-6.3 (out of 9). 
 
Figure 28 shows the differentiation scores for adipo, chondro and osteogenic 
induction using commerical StemPro media by cell source. We also observed an 
induced chondrogenic phenotype in the synovial fluid trial and this is discussed 
further in this section. 
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Figure 28 Semi-quantitative trilineage differentiation scores for adipogenic, 
chondrogenic and osteogenic potential for DF, BMSC and UMBT cell populations. 
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3.1.4 EXPERIMENT 4. SYNOVIAL FLUID MODEL 
H0= The hypothesis is that stromal cells from bone marrow, umbilical cord tissue 
and dermally derived fibroblasts have the equivalent morphological characteristics 
when grown in standard culture conditions or culture containing 50% normal 
synovial fluid or culture containing 50% inflammatory synovial fluid 
 
Mesenchymal stem cells from various sources (BMSC, UMBT) as well as dermally 
derived fibroblast (DF) have the ability to grow and proliferate in various 
concentrations of normal, healthy joint fluid for seven days. 
 Pilot trial 
The initial pilot trial was performed with UMBT cells. Normal SF in concentrations 
0%, 50% and 90% were used and the 0% group (CM) served as the internal control 
as depicted in Figure 29. The growth of cells in culture media supplemented with 
synovial fluid appeared growing more rapidly compared to control. The cells 
formed aggregations and the morphology of cells were more elongated. These 
observed effects served as reasoning for carrying out a follow-on experiment, which 
evaluated the effects of adding different concentrations of synovial fluid to the 
culture system.  
 
Initially (T=24-48h), the UMBT cell lines grown in various concentrations of SF 
showed an increase in proliferation compared to control. With time >T=72h the 
growth rate slowed down and a phenotypic change was observed, the cells acquired 
a more elongated shape. A change in pH was also observed; SF containing media 
had a higher pH recorded at T=168h compared with control, Figure 30. 
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Figure 29 Pilot Trial. The effect of three different culture conditions on the 
percentage of confluence at T= 24hours and 48h of culture, (mean ± SD, (N=4, r=3) 
for treatment group CM and 50/50; (N=4 r=2) for treatment group 10%CM/90%SF) 
 
Figure 30 The effect of three different culture conditions on UMBT viability and 
pH of the cell supernatant after 168h of culture 
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The pH levels were measured at start of culture (T=0h); the pH of prepared and 
sterile filtered basal culture media was measured at 7.68, while pH of the normal 
synovial fluid (100%, pooled sample) was measured to 8.62 and 50% culture media 
and 50% Synovial fluid was measured to 8.1. However, the results still 
demonstrated a 12% variability in mean pH levels between the control group and 
treatment group 3. At T= 168hours pH levels were greater in treatment group 3 that 
had the higher concentration of SF added, Table 21 shows the mean pH levels. All 
groups (1-3) had a start pH level that were lower than the pH at T=168hours.  
 
Group 
Culture media 
composition 
Initial 
pH 
Mean pH at 168h 
(N=4, r=2) 
% Difference in pH 
(T=168h /T=0h) 
1 100% CM control 7.68 7.09 -8.7% 
2 50% CM/ 50% SF 8.11 7.74 -5.6% 
3 10% CM/ 90% SF 8.38 8.08 -3.6% 
Table 21 pH levels and percentage difference between treatment groups. 
For the main experiment, the effects of both i.) Normal SF and ii.) Inflammatory I-
SF were evaluated. Samples of both normal and inflammatory synovial fluid were 
sent to an independent laboratory for Serum Amyloid-A (SAA) and Total Protein 
(TP) measurements. Results were: 
SF  Normal synovial fluid; SAA 2mg/L, TP 10g/L 
I-SF Inflammatory synovial fluid; SAA 3mg/L, TP 12g/L.  
An attempt to minimise the effects of pH was made by the addition of HEPES buffer 
to the synovial fluid enriched media, at same molarity (0.25mM) as the basal culture 
medium. At the end of the culture period T=168hours, no significant difference 
between the control (CM) of SF/ I-SF groups were noted (P=0.08). Figure 31 below 
shows the measured pH levels in control (CM) vs. SF and I-SF at T=168h. 
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Figure 31 Synovial Fluid experiment; SF and I-SF compared to control. pH levels 
after buffering with HEPES (0.25mM) as measured at T= 168 hours for DF, BMSC 
and UMBT cell populations grown in three different culture conditions, P=0.08. 
The collection of graphs below in Figure 32, are a temporal representation (T=24-
168h) of the percentage of confluence reached by cell populations from the three 
different sources; DF, BMSC and UMBT. The normal synovial fluid experiment, 
Figure 34 A, B, C shows the results from cell populations grown in culture media 
(control) vs. 50% SF (treatment1). The Inflammatory synovial fluid experiment, 
Figure 34, D, E, F, shows the results from cell populations grown in culture media 
(control) vs. 50% I-SF (treatment2). A comparative analysis was made i.) within 
each source (intra-source; CM vs. 50/50 SF or I-SF) and ii.) between sources (inter-
source; DF vs. BMSC vs. UMBT) at each of the time points. The data is presented 
as Means ± Min-Max. P values presented on the graphs are intra-source correlations 
from paired t-tests. 
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Figure 32 Synovial Fluid Experiment; Growth characteristics as expressed in 
percentage of confluence (%) Control vs. SF vs I-SF. ****P < 0.0001. **P < 0.0023. 
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Analysis of this data was undertaken using two separate subgroups:  
• Intra-sample variation between control and treatment, and 
• Inter-source variation between sources.  
The results for the Normal Synovial fluid experiment Figure 32 A, B, C, showed 
that dermal fibroblasts have similar growth rates in the treatment group (50% SF) 
compared to control (CM) at T=24h. However, at T=48 and 168h the growth rate 
was reduced in the 50% SF group (P<0.001) compared to control (CM). This 
correlates with the phenotypic change where the cells aggregated to form clusters 
Figure 33, in the SF compared to the control group (CM) where cells formed a 
monolayer. With increasing time, the clusters became denser and formed a tertiary 
structure similar to the pellets seen during the chondrogenic induction protocol, 
Figure 34 A. The pellets were positive to alcian blue stain Figure 34 B indicating 
formation of GAGs and a change of the DF and MSC cell populations into a 
chondrogenic phenotype. This phenotypic change was noted at T=48h for the SF 
group.  
 
 
Figure 33 Phenotypic change cluster formation A.) StemPro Chondrogenic Culture 
Media B.) 50% I-SF culture media 
A B 
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Figure 34 Phenotypic change dense cluster, A.) Pellet formation B.) Alcian blue 
positive  
 
The two MSC populations, BMSC and UMBT initially showed an increased growth 
rate in the 50% SF group compared to control (P<0.0001), however at T=48h the 
confluence of BMSC populations were significantly less than control (P<0.0001), 
while the opposite was seen for UMBT, which expressed an increased growth rate 
in the 50% SF group. T=168h there were no difference between control and the SF 
group for BMSC and UMBT cell populations, however for DF there was a negative 
effect on growth rate (P<0.0001). This negative effect as measured in percentage of 
confluence correlated with a change in phenotype and induction of chondrogenesis. 
The results show that DF, BMSC and UMBT populations can survive well and 
proliferate in 50% normal allogeneic synovial fluid.  
 
Figure 35 depicts phenotypic change during the synovial fluid experiment. 
 
A B 
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 Figure 35 Synovial Fluid experiment. Phenotypic change noted in the SF and I-
SF groups compared to control (CM) by cell source. 
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During the Inflammatory Synovial Fluid Experiment, the cell populations showed 
more consistent performance, Figure 36; Inflammatory synovial fluid graphs. 
Percentage confluence were decreased in the 50% I-SF groups compared to 
controls, DF (P=0.0023) and BMSC and UMBT (P<0.0001) at T=24. However, at 
T=168h the opposite was seen to the Normal Synovial Fluid Experiment; DF 
populations had the same percentage of confluence (near 100%) in the 50% I-SF 
group as compared to control (CM) vs. BMSC and UMBT that now showed a 
decrease in proliferation (P<0.0001) in the 50% I-SF group. The negative effect 
seen on confluence correlated with change in phenotype and induction of 
chondrogenesis. A phenotypic change was noted earlier (T=24h) in the I-SF 
experiment and the number of clusters and tertiary pellets were increased compared 
to the SF group, except for one group; BMSC at T=168 the number of clusters were 
increased in the SF group compared to the I-SF group. As the time in culture 
progressed (T48-168h), the clusters became denser and formed a tertiary structure 
similar to the pellets we see in the chondrogenic induction protocol. These pellets 
were positive to alcian blue staining, indicating a change of the cell populations into 
a chondrogenic phenotype. Thus, cellular viability and proliferation rates (as 
measured as percentage confluence) were only mildly affected with both normal 
and inflammatory allogeneic synovial fluid incorporated into the culture system and 
chondrogenesis was observed in all of the studied equine cell populations.  
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3.1.5 EXPERIMENT 5: BIO ACTIVATION ASSAY 
 Cytokine Analysis by Enzyme linked immunoassay (ELISA) 
H0: The hypothesis is that activated stromal cells from bone marrow and umbilical 
cord tissue have equivalent cytokine production as activated dermally derived 
fibroblasts  
 
H0: The hypothesis is that activation with TNF alpha of stromal cells from bone 
marrow or umbilical tissue or dermal tissue derived fibroblasts equals the effect of 
activation of the same cell populations with inflammatory synovial fluid, 
as measured by the production of cytokines after activation 
 
Figure 36 Synovial Fluid Experiment; Phenotypic change in Control (CM) vs. SF 
vs. I-SF groups at T=24, 48 and 168hours. 
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The results for PGE2 showed that both the TNFα and I-SF activated groups 
produced less PGE2 compared to the control group (CM). It was observed that for 
three of the ELISA plates; IL-1β, IL-6 and IL-10 there was only very small values 
of absorbance detected, that were not within the range of detection for the ELISA 
test kits. This was true for all of the samples from either of the three treatment 
groups (CM, TNFα and I-SF) Figure 37. It was deduced from this data that there 
was no detectable production of these cytokines from the tested BMSC and DF cell 
lines. The TNFα assay could not be validated in either of the two experiments. The 
initial run for IL-10 showed minimal absorbance from the DF and BMSC samples, 
however the next plate resulted in useful data. 
 
Figure 37 Schematic overview of range of absorbance obtained from initial run 
(Run1). A, B and C and F.) Samples were not within the range of detection within 
the standard curve for IL-10, IL-1b, IL-6 and TNFα. D and E.) Samples are within 
the range of detection of the standard curve and useful for analysis. 
 
The culture media and synovial fluid samples were tested in duplicates for each 
cytokine. The results are presented in Table 22 below and shows the concentration 
in picogram/ml. 
 
 
A B C 
D E F 
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Sample 
TGF-b1 PGE2 IL-10 TNFa 
Culture Medium 95.27 0.83 22.47 3.87 
Normal SF 254.68 1.11 28.89 6.03 
Inflammatory SF 223.22 0.76 23.84 23.26 
50/50 CM and I-SF 117.64 0.74 20.57 10.34 
Table 22 ELISA result for media, concentration in picogram/ml. Numbers in red 
are below the limit of detection for the test kit. 
 
The standard curves and the fitted logistics for three of the cytokines tested; TGF-
β1 and PGE2 and Il-10 as displayed below in Figures 38-40. 
 
 
Figure 38 Standard curves for cytokine TGF-β1 for two different ELISA plates at 
two different time points February 2016 (Run) and May 2016 (Run2). 
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Figure 39 Fig Standard curves for cytokine PGE2 for two different ELISA plates at 
two different time points February 2016 (Run) and May 2016 (Run2) 
Figure 40 Standard curves for cytokine IL-10 for two different ELISA plates at two 
different time points May 2016 (Run2) and September 2016 (Run3) 
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Figure 41 Concentration TGF-β1 pg/ml per source; (DF, BMSC and UMBT) after 
activation; TNFα or I-SF vs. control (CM) A.) Concentrations obtained for 
activated BMSC cells, range 340-630pg/ml B.) Concentrations obtained for 
activated DF and UMBT cells range, 200-1500pg/ml. 
 
For TGF-β1 (Figure 41) the trend lines for all three sources; DF, BMSC and UMBT 
were the same; activation with either I-SF or TNFα caused an increase in TGF-β1 
production compared to control (CM). However, when separating the source and 
activation agent no significance could be identified (P=0.06). The range of 
concentrations detected were 320-630pg/ml (Run1), vs. 180-1500pg/ml (Run2). 
 
In contrast the PGE2 concentrations varied greatly between the two runs (Figure 
42); the range was 0-900pg/ml for BMSC and DFs (Run1) compared to 1.0-
4.5pg/ml for UMBT (Run2). Thus, for UMBT (Run2), the PGE2 concentrations 
were 100-fold less compared to results obtained at Run1. These concentrations are 
below the lower limit of sensitivity as the detection range for this PGE2 ELISA test 
was 15-1000pg/ml.  There were some negative results recorded for DF, which 
means that the concentrations of these samples were below that of the standards 
used. These samples were not included in the analysis. For BMSC; activated cells 
showed an increase in production of PGE2 compared to control, No significant 
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difference between activation agents could be determined (I-SF=TNFα) for BMSC 
(P=0.4). For the DF cell populations, the control group (CM) produced higher 
concentrations of PGE2 than each of the two activated groups (I-SF and TNFα) 
P=0.008. This is in opposite to the BMSC results.  
 
 
Figure 42 Concentration of PGE2 pg/ml per source; DF, BMSC, UMBT after 
activation; TNFα or I-SF vs. Control (CM). A.) Concentrations obtained for 
activated DF and BMSC cell populations, range 0-900pg/ml B.) Concentrations 
obtained for activated UMBT cell populations, range 1.0-4.5pg/ml. 
 
The result for IL-10 (Figure 43) when the three sources (DF, BMSC and UMBT) 
are analysed together in a one-way ANOVA, separating the sources and activation 
agents (I-SF and TNFα), significant results were obtained for DF and UMBT but 
not BMSC. DF results showed that activation with I-SF induced the cells to produce 
higher concentrations of IL-10 (I-SF>CM) (P=0.02) and the same for UMBT cells 
after activation with I-SF cells also produced more IL-10 compared to controls (I-
SF>CM) (P=0.03). No significant result was obtained for BMSC. Nor for TNFα 
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activation groups when compared to control (P=0.57). However, the overall trend 
line for BMSC was similar to the other two groups, see Figure 43. 
 
Figure 43 Figure Concentration of IL-10 in pg/ml per Source; DF, BMSC and 
UMBT after activation; TNFα or I-SF vs. control (CM), range 700-1900pg/ml 
 
  DF BMSC UMBT 
TGF-β1 CM TNFα I-SF CM TNFα I-SF CM TNFα I-SF 
Mean 500.0 658.9 781.1 436.6 544.9 552.2 1063.1 1024.0 1154.1 
Std. 
Deviation 221.8 456.9 421.6 118.2 50.0 90.4 254.5 235.8 129.7 
SEM 78.4 161.5 149.1 59.12 25.0 45.2 90.0 83.4 45.9 
IL-10                   
Mean 1061.0 1033.1 1364.2 906.5 944.1 981.3 927.4 997.9 1182.0 
Std. 
Deviation 114.9 223.8 447.7 162.3 125.3 159.3 185.7 229.6 159.9 
SEM 66.3 129.2 258.5 66.3 51.15 65.0 107.2 132.5 92.3 
PGE2    ,               
Mean 681.6 242.7 173.1 452.4 542.6 712.6 2.1 1.1 1.1 
Std. 
Deviation 114.4 107.5 74.6 308.3 355.1 242.1 1.1 0.1 0.1 
SEM 57.2 53.8 37.3 154.1 177.5 121.3 0.4 0.1 0.1 
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Table 23 Cytokine concentration in pg/ml (Mean with SD and SEM) per source and 
activation agent. The UMBT cells produced PGE2 concentrations that were below 
the detection range for the test kit (marked in red) 
 
The bio assay activation experiments were performed with cells at P4. To estimate 
the amount of cytokine produced per 104 cells, the number of cells present after T= 
60h of incubation was calculated with population doubling times from previous 
growth and culture characteristics experiment, Table 24. 
 
Population doubling at P4 data BMSC (N=6) UMBT (N=8) DF (N=4)  
Number of cells present   
at T=60h (Mean) 9.5x104  7.0x104 7.9x104 
 
Table 24 Population doubling times at T=60hours for BMSC, UMBT and DF at P4 
 
The cytokine production per 104 cells are expressed as Mean ± SD. The assays were 
repeated twice and each sample was run in duplicates. The only significant intra-
source result was found for DF cell populations for PGE2 concentrations; cells in 
the control group (CM) produced more PGE2 compared to activated groups; control 
(CM) >TNFα (P=0.0124) and control > I-SF (P=0.0027). The cytokine production 
per 104 cells expressed in picograms/ml, as represented below in Figure 44. 
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Figure 44 Cytokine production per 104 cells expressed in picograms/ml. per 
cytokine and source (DF, BMSC and UMBT) after activation agent (TNFα and I-
SF) vs CM. *P < 0.05. **P < 0.005. 
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Because of the noticeable plate effect the concentrations of cytokine produced after 
activation could only be compared intra-source (DF vs BMSC vs UMBT) for IL-
10, as all of the samples were run on the same plate at the same time, a non-
significant intra-source result was obtained (P=0.811).  
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CHAPTER 4: DISCUSSION 
Study design and sample collection 
The selection of horses that the samples were collected from was biased with 
respect to sex. This was due to mares were the only available sex at Equibreed NZ, 
where the author was performing the research and could easily obtain samples. The 
samples obtained ex vivo were from horses that were destined for pet food. These 
horses were of mixed breed, sex and age. No attempt was made to match the 
samples for breed, sex or age. Carter-Arnold et al., (2014) showed that even when 
donors (N=6) were matched for age and gender there were donor-to-donor 
variability noted in both proliferation and differentiation ability of the cell 
populations. Schnabel et al., (2014) were biased using only TB horses and specified 
the age of the horse but not sex. Ranera et al., (2012) gave a range of age (8-12years) 
and range of weight (400-450kg) but did not mention breed or sex of the five horses 
in this study. Guest et al., (2010) used eight TB geldings at the age of 3-4years in 
an attempt to standardise these variables. In an ideal study design the donor horses 
would have been matched for breed, sex, age and tissues from all sources would 
have been collected from each donor. However, it is not possible to eliminate the 
effects of individual donors. An a priori sample size analysis revealed that the 
minimum number of donors required for a statistical power of 80% was 42 horses, 
when performing repeated measures within-between multiple group comparisons 
(one-way Anova). 
 
The normal group of synovial fluid samples were collected ex vivo. An attempt was 
made to categorise the sample as normal by performing a clinical exam of the horse 
at walk to detect any lameness and palpation of the joints for any effusion. However, 
there could have been joints affected by disease that went undetected. The 
inflammatory synovial fluid samples were collected during arthroscopic surgery 
and they were confirmed to be abnormal by radiographs and intra operative 
visualisation of the joint. However, some developmental joint problems may have 
varying degree of inflammatory mediators present. The synovial fluid was analysed 
for SAA and TP, as well as for each cytokine that were used in the bio assay 
experiment. A more extensive analysis could have been carried out as there are 
 130 
 
many more cytokines and growth factors present in synovial fluid. Synovial fluid 
from different animals and different joints were pooled to create a larger sample to 
eliminate donor and site variability. Other studies by Hegewald et al. (2004) used 
autologous and Boone (2013) allogenic synovial fluid. Boone (2013) used fluid 
from carpal and tarsal joints and pooled a total sample from 25horses. If using 
allogenic synovial fluid in an experiment it is necessary to pool a number of smaller 
samples together to get a uniform sample that can be used in the experiment. 
 
To my knowledge no equine studies have fully addressed the relationship between 
fibroblasts and mesenchymal stem cells; such as morphology, presence of cell 
surface markers and potential for trilineage differentiation. Lack of clarification of 
the similarities and/or differences between these cell types confounds the evaluation 
of the efficacy of these cells in clinical situations. In human medicine there are 
recent studies that have acknowledged the relationship between mesenchymal stem 
cells and fibroblasts, Hematti (2012) and Ullrich et al., (2012) reviewed the 
literature to find little evidence on methods to distinguish the two cell populations 
from one another. This is in agreement with the present study, which showed that 
equine mesenchymal stromal cell populations from adipose, bone marrow and 
peripheral blood were indistinguishable from dermal fibroblasts with respect to; 
cellular morphology and culture characteristics in vitro and cell surface antigens 
(CD markers). During trilineage differentiation there were a significant difference 
in scores obtained for the chondro and osteogenic potential, but since dermal 
fibroblasts were shown to undergo trilineage differentiation this method cannot 
distinguish stromal cells from fibroblasts. 
 
Morphological study and growth characteristics 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have equivalent morphological characteristics as 
dermally derived fibroblasts 
 
The hypothesis was proven to be correct as no differences in morphology and 
growth characteristics using conventional culture methods could be detected 
between equine MSC and DF. However, when cultures were left at confluency for 
longer time; 2 weeks, there were differences in morphology noted. 
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A standardised culture medium was used for all experiments to reduce variability. 
It has been mentioned that serum origin and content; foetal bovine serum or equine 
serum, or serum free medium, can affect the growth of cells (Ho et al. 2008). The 
molecular profile and function of the cells may also change with passages and time 
in culture. For the experiments in this study, passage four was selected and all 
experiments were carried out with cells at this passage. This was done to eliminate 
passage number as a variable. This was especially true also for the 
immunophenotyping experiment as discussed later. Trypsinisation and 
cryopreservation of cells could potentially alter the biological function, the cells 
were all treated the same way and all cells used in experiments were cryopreserved 
and thawed. 
 
-Standard culture conditions  
Morphology and growth characteristics of the equine mesenchymal stromal cell and 
dermal fibroblast cell populations were shown to be indistinguishable under 
standard culture conditions. The typical spindle shaped morphology, plastic 
adherence and formation of monolayer are all typical characteristics of MSC and 
are well recorded in the equine literature. Dermally derived fibroblasts are also 
described to have the same characteristics (Blasi et al., 2012). The only study to our 
knowledge to record some data for an equine DF cell lines is Schnabel et al. (2013). 
 
If cells were left at confluency for 2 weeks, dermal fibroblast cultures underwent 
mesenchymal to epithelial transition. This was not observed in BMSC cultures. It 
would’ve been an interesting follow up to passage the dermal fibroblast cells after 
this transition had occurred to see if stem characteristics and plasticity and even 
multipotency were preserved or if the cells had terminally differentiated into an 
epithelial phenotype.  
 
Cells within certain epithelia appear to be plastic and thus able to move back and 
forth between epithelial and mesenchymal states via the processes of epithelial to 
mesenchymal or mesenchymal to epithelial transitions (Kalluri and Weinberg 
2009). Three distinct subtypes of epithelial to mesenchymal differentiation are seen 
(Jordan et al. 2011); i.) Developmental EMT events occur in a temporally controlled 
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setting and contribute to embryonic morphogenesis and tissue remodelling during 
development ii.) The second EMT subtype is associated with wound healing and 
tissue regeneration in adult tissue and occurs in response to inflammation. Persistent 
inflammatory signals produce continuous activation of EMT resulting in organ 
fibrosis iii.) The third EMT subtype occurs during the progressive stages of 
neoplasia, whereby EMT in epithelial neoplastic cells produces cells that can invade 
other tissues and with increased metastatic capacity.  
 
The observation of cells undergoing MET is likely to have occurred due to space 
constrictions and close cell to cell interactions as a reversal of the second EMT 
subtype. Mesenchymal to epithelial transition and the reverse thus seem to be an 
important function of stromal and fibroblastic cell populations as a response to 
changes in their environment in vivo and therefore a clear distinction between the 
two cell types would be difficult to make. Any given stromal cell population is 
likely to be heterogenous (Corradetti et al. 2011).Which means it contain both 
multipotent progenitor cells and more terminally differentiated fibroblastic type 
cells. The state which the cells are in are determined both by stage in cell cycle 
(Nakamura-Ishizu et al. 2014) and by the external stimuli from local tissue 
environment (Prockop 2013) and its’ not a constant but a dynamic relationship.  No 
equine studies to our knowledge have tried to evaluate or reported the degree of 
heterogenicity of their proposed stem cell populations. It seem plausible that each 
MSC cell line contain a mixed population of cells and morphology and growth 
characteristic studies fail to distinguish these cells apart. 
 
Immunophenotyping by Immunocytochemistry and Flow cytometry 
H0: The hypothesis is that stromal cells from adipose, bone marrow, peripheral 
blood and umbilical cord tissue have the same qualitative expression of cell surface 
markers, CD29, CD44, CD90 positive and CD45, MHC-II negative as dermally 
derived fibroblasts  
 
This hypothesis was found to be true for this specific CD marker panel. It 
acknowledges the limitation of the number of cell surface markers included in the 
analysis. The two conventional methods evaluated for immunophenotyping were 
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immunocytochemistry and flow cytometry. The method of flow cytometry was far 
superior as both qualitative and quantitative results were obtained for a larger 
number of cells (1x105) as compared to immunocytochemistry where only a smaller 
number of cells could be subjectively evaluated. 
 
When evaluating cell surface markers there are several factors that can contribute 
to variability in results (Ulrich et al. 2012); i.) The initial processing involve the use 
of proteolytic enzymes for adipose, umbilical and dermal tissue or a density 
gradient system for bone marrow and peripheral blood  (Redmond Hubbard 2014; 
Sabatini et al. 2005), These enzymes and the in vitro culture conditions (method 
and media) can affect cell surface protein expression (Ulrich et al. 2012). In addition 
the specificity of antibodies or inappropriate or prolonged fixation can significantly 
diminish the antibody binding capability (Williams et al. 1997). One of the main 
difficulties with ICC staining is to overcome specific or non-specific background 
and to optimise fixation methods and times. Time for the incubation of antibodies 
and optimisation of post-antibody wash buffers and wash times are all important 
for obtaining high quality immunostaining (Freshney 2010). All these factors were 
considered and trialled to produce satisfying immunofluorescence result for the 
equine MSC and DF in this present experiment. However, the initial protocol had 
to be modified several times before the process could be optimised for the selected 
antibodies. In addition, the presence of positive and negative controls for staining 
are essential for determining specificity. Equine peripheral blood mononuclear cells 
were used for the positive control for the two MSC negative markers; CD45 and 
MHC-II. A fluorescent nuclear stain (DAPI) could have been used to make visible 
the cellular morphology of the MSC, when the negative markers were evaluated 
(Xing et al. 2007). The immunofluorescence result obtained for the stromal cells 
for the negative markers without the nuclear stain was just a plain black field of 
view when the fluorescent light was applied. If DAPI had been used a photographic 
evidence could have been produced also of the two negative markers (CD45 and 
MHC-II). The results obtained were purely observational in the form of photos 
displaying the immunofluorescence of cells. For this method there were no 
objective measures of the intensity of the fluorescence nor quantification of the 
number of CD markers present on each cell. The production of a colorimetric scale 
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for intensity of fluorescence would have been useful. The ICC technique can still 
be useful to prove the presence of a certain CD marker on the cell surface, but as a 
method for distinguishing sub populations of stromal cells it was found not 
adequate. 
 
Flow cytometry was shown to have several advantages over the 
immunocytochemistry method. It was more time-efficient and cryopreserved cells 
could be used without cell culturing steps and there were no fixation agents applied 
that could damage or alter the cell surface protein epitopes. Flow cytometry has the 
ability to define distinct cell populations by their size and granularity combined 
with the capacity to gate out dead cells and thus improved sensitivity (Brown and 
Wittwer 2000). The new flow cytometers can do multi-colour analysis, which allow 
for several antigens to be measured simultaneously (Baumgarth and Roederer 
2000). More importantly, the data output is objective and thus a large number of 
cells can be processed, which produce a more accurate result compared to 
immunocytochemistry.  
 
In this present flow cytometry study the same immunophenotype was determined 
for the equine DF cell lines as compared to adipose, bone marrow and peripheral 
blood stromal cells The flow cytometry obtained results for the mesenchymal 
stromal cell populations were in agreement with other equine studies (De Schauwer 
et al. 2011; De Schauwer et al. 2012; Dias et al. 2016; J. H. Spaas et al. 2013b), 
except for a small variance in the umbilical tissue derived stromal cells. In the 
umbilical tissue derived cells, the CD90 expression was a weak positive result. This 
was in contrary to previous studies by Iacono et al. (2012) and Carrade et al. (2012) 
where the umbilical cord cells showed a normal positive result for CD90 on flow 
cytometry. It could possibly be explained by the fact that our cells had been 
cryopreserved prior to flow cytometry. Dias et al. (2016) showed a reduction in 
CD90 expression after cryopreservation as compared to fresh isolated equine 
umbilical derived MSC. It suggests that the CD90 epitope on UMBT may be 
sensitive to the effects of cryopreservation. Immunocytochemistry could not be 
performed for CD90 due to lack of a suitable primary monoclonal antibody 
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sensitive to equine epitopes not being readily available commercially for this 
application. 
 
This present study was not able to effectively distinguish equine mesenchymal 
stromal cells from adipose, bone marrow or peripheral blood from dermal 
fibroblasts with the methods of immunocytochemistry and flow cytometry. This is 
in agreement with Ulrich et al. (2012) who presented a short review of human 
mesenchymal stromal cells and fibroblasts where they discussed the inability of 
studies to establish a panel of markers to separate human mesenchymal stromal 
cells and dermal fibroblasts. They suggested Raman Spectroscopy as a highly 
sensitive method to discriminate between closely related cells. 
 
Trilineage Differentiation 
H0: The hypothesis is that stromal cells from bone marrow and umbilical cord tissue 
have an equal potential for trilineage differentiation as dermally derived fibroblasts  
 
This hypothesis was rejected. Positive trilineage differentiation was observed in all 
cell populations of the three sources evaluated, (bone marrow, umbilical tissue and 
dermal fibroblast). The potential for differentiation however, varied between the 
sources. 
 
The differentiation potentials of MSC is reported to decline with increasing number 
of passage (Baer and Geiger 2012). All of the cell lines in this study were shown to 
have the capacity to differentiate at P4, even the commercial equine dermal 
fibroblast line at P16. To our knowledge only Schnabel et al., 2014 have reported 
an attempt to induce trilineage differentiation of an equine dermally derived 
fibroblast cell line (N=1). They also used the StemPro® induction media, however 
they reported unsuccessful trilineage differentiation in this cell line. Given the 
donor effect (inter-horse) (Colleoni et al. 2009), which could confound results, 
using only one sample donor, seem to be inadequate for the Schnabel et al. (2013) 
study. Rohart et al. (2016) showed that most of the differences in human 
mesenchymal stem cells attributed to tissue source could be explained by donor 
genotype in an integrative secretome analysis. They also suggested that cultured 
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mesenchymal stem cells share a common phenotype that is intermediate between a 
quiescent perivascular progenitor and a differentiated cell type; the fibroblast. If 
mesenchymal stromal cells from multiple tissues from the same animal were used 
the “intra-horse” effect could be reduced. However, it was not practical to collect 
multiple tissue samples from each donor as some were client animals, some samples 
were cryopreserved stock from a previous study as well as the commercial cell line 
only had one tissue source collected from the donor horse. Some samples were 
collected ex vivo and although attempts were made to collect bone marrow samples 
ex vivo the author was unsuccessful. The umbilical cord samples were also a special 
category as peripheral blood could have been reasonably easily collected from 
mares and foals at time of birth, however no stud master would have agreed to 
collect bone marrow or adipose or skin dermis from newborn foals or mares. It is 
not possible to correct for differences in genotype between horses. An ideal study 
design would be to have samples from multiple sources from the same animal to 
eliminate genotype as a variable. 
 
Colleoni et al. (2009) showed that for equine adipose and bone marrow there were 
a donor effect noted on cell yields obtained from raw material but no difference in 
differentiation potentials. Carter‐Arnold et al. (2014) showed intra-donor variability 
despite matching horses for sex and age, of bone marrow derived cells for both 
proliferation rates and chondro- and osteogenic differentiation. These two studies 
did not perform any test for Mycoplasma contamination, which is another possible 
factor to consider. In the present study all of the cell lines were tested and proven 
free from Mycoplasma contamination. Mycoplasma contamination of cultures can 
extensively affect cell physiology and metabolism (Nikfarjam and Farzaneh 2011). 
 
In the present study the bone marrow stromal cells were as expected superior at 
chondrogenic and osteogenic differentiation (Vidal. et al. 2008), while there were 
no significant inter-source difference noted for adipogenic differentiation. 
Youngstrom (2015) and also Vidal et al. (2011) discuss that some cells are pre-
primed for a certain tissue type as they are already existing in a similar environment, 
for example bone marrow derived stromal cells would have a predisposition for 
osteogenic differentiation and tendon derived stromal cells would have a 
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predisposition for tenogenesis. A recent study by Zayed et al. (2017) compared 
BSMC and Synovial fluid derived MSC from the same donor to minimise the intra-
horse effect. They used five horses in total with matched BMMSCs and SFMSCs, 
which were found to be similar in respect to cellular morphology, viability, and 
immunophenotype, but varied in their chondrogenic potential, and expression of 
the key chondrogenic proteins. They found there were considerable donor-to donor 
(inter-horse) variation.  
 
Despite that some cell populations achieved higher differentiation scores, the 
method of trilineage differentiation is not selective to distinguish equine 
mesenchymal stromal cells from dermal fibroblasts. Trilineage differentiation has 
been a hallmark feature of identification of stem cells (Hematti 2012). However, 
the question can and should be asked regarding the usefulness of its application, as 
the results obtained after induction under supra-physiological conditions in vitro 
likely does not reflect the behaviour of the cell populations in vivo and the fact that 
fibroblasts can effectively undergo trilineage differentiation as shown in several 
human studies (Alt et al. 2011; Brohem et al. 2013; Sabatini et al. 2005). It is 
unknown if MSC after injection into a live animal undergoes the same process of 
differentiation as produced in vitro. The results by Guest et al. (2008) suggest the 
opposite as poor survival post 10days of injected BMSC was reported. This means 
that an alternative mechanism of action rather than differentiation of the injected 
cells and incorporation into the architecture of the neo-tissue need to be considered.  
 
At present, mesenchymal stromal cells are mainly used to treat musculoskeletal 
diseases in equine veterinary medicine based on their ability to differentiate into 
various tissues of mesodermal origin (De Schauwer et al. 2013). De Schauwer et al. 
(2013) also points out that this is in marked contrast to human medicine, where 
mesenchymal stem cell therapies are primarily focused on immune-mediated, 
inﬂammatory, and ischemic diseases. It appears that the trilineage differentiation 
potential is irrelevant when considering cells for treatment. Since the in vivo effects 
seem to be produced by chemical messengers produced by the cells rather than the 
actual transformation and incorporation of cells into neotissue to repair the injured 
tissue.  
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Synovial fluid enriched culture conditions  
H0= The hypothesis is that stromal cells from bone marrow, umbilical cord tissue 
and dermally derived fibroblasts have the equivalent morphological characteristics 
when grown in standard culture conditions or culture containing 50% normal 
synovial fluid or culture containing 50% inflammatory synovial fluid 
 
This hypothesis was rejected. A difference in growth potential was noted between 
control and the two treatment groups; SF and I-SF. There was also a difference in 
phenotypic change noted between normal and inflammatory synovial fluid 
treatment, a faster induction of phenotypic change was noted for the I-SF group and 
more clusters of cells and pellets were formed on average independent of source of 
MSC or DF. 
 
For the main experiment 50% concentration was selected based on results from 
(Hegewald et al. 2004), who studied the effects of autologous synovial fluid on 
equine bone marrow derived stromal cells. They found that chondrogenesis was 
induced with the addition of synovial fluid into the culture system. Boone (2013) 
was of the same conclusion that bone marrow derived stromal cells can survive and 
proliferate well in allogenic synovial fluid.  In the present study a chondrogenic 
phenotype was noted as early as 24hours. One theory proposed would be that 
synovial fluid is more viscous than standard basal culture media, the cells were less 
free to move around before cellular attachment was achieved and consequently 
were more likely to form aggregates. This close cell to cell contact then likely 
induced the rapid change in phenotype due to more efficient cell communication 
and niche effects (Koch et al. 2008).  
 
The bone marrow derived, and umbilical tissue derived stromal cells showed an 
initial increase in proliferation rates (as measured as percentage of confluence) in 
the normal synovial fluid group (SF) compared to matched controls (same cells 
grown in basal culture media, (CM)). Synovial fluid can be considered an 
ultrafiltrate of plasma (Blewis et al. 2007). It also contain high levels of hyaluronic 
acid, sulphated and non-sulphated glycosaminoglycans, proteolytic enzymes, 
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cytokines and growth factors. (McIlwraith 2005). The total composition of the 
pooled synovial fluid was not known, and was beyond the scope of this study to 
fully documnet the synovial fluid composition.  
 
For the dermal fibroblast populations the percentage confluence between control 
(CM) and synovial fluid groups were the same at T=24h, then at T=48h the 
percentage confluence was decreased in the synovial fluid group.  Overall the 
proliferation rates (measured as percentage of confluence) were affected by the 
addition of both normal synovial fluid and inflammatory synovial fluid to the 
culture systems. A morphologic change was induced that involved cluster formation 
and differentiation of the mesenchymal stromal cells and dermal fibroblasts towards 
a chondrogenic phenotype. The bone marrow and umbilical tissue stromal cells 
showed an earlier and more marked response; there were increased number of 
clusters and pellets formed, as compared to dermal fibroblasts.  
 
The result that fibroblasts showed a lesser degree of phenotypic change could 
support the theory described by Covas et al. (2008) that a fibroblast is a more 
terminally differentiated version of a stem cell. As discussed previously in section 
1.4.2, any given cell population show some heterogenicity; either from 
contamination of other cell types or the same type of cells that are at different stages 
of the cell cycle (Baer and Geiger 2012). In the present study the dermal fibroblast 
cell populations showed a lesser degree of phenotypic change compared to MSC in 
the synovial fluid experiments, as well as attaining significantly less chondrogenic 
and osteogenic scores during the trilineage differentiation experiment. Thus, it 
could be that dermal fibroblast cell populations have a higher proportion of cells 
that are terminally differentiated and therefore has a lesser multipotent potential as 
compared to bone marrow derived and umbilical tissue stromal cells. However, 
dermal fibroblasts populations do still express multipotency as shown in this 
experiment. Therefore, percentage confluence attained and phenotypic change (as 
quantified by number of clusters and pellets formed) induced by synovial fluid 
incorporation in culture system are not suitable as a measure to clearly define nor 
distinguish these cell populations from one another.  
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Activation Experiment 
H0: The hypothesis is that activated equine stromal cells from bone marrow and 
umbilical cord tissue and dermally derived fibroblasts have equivalent cytokine 
production as the same cell populations grown in culture media. 
 
This hypothesis was rejected. Activation of MSC and DF resulted in an increase in 
production of the selected cytokines. There was one exception; after activation DF 
cell populations decreased production of PGE2 as compared to the control.  
 
It was hypothesised that the functional behaviour of equine mesenchymal stromal 
cells versus dermal fibroblasts in standard culture conditions versus activated 
conditions may be a way to distinguish the cell populations apart. Blasi et al (2011) 
showed that functional bioassays were required to enable to distinguish between 
human mesenchymal stem cell and fibroblast cell lines. To our knowledge this the 
first study to attempt to clarify the functional similarities and/or differences between 
equine mesenchymal stromal cells and dermal fibroblasts.  
 
H0: The hypothesis is that activation with TNF alpha of stromal cells from bone 
marrow or umbilical tissue or dermal tissue derived fibroblasts equals the effect of 
activation of the same cell populations with inflammatory synovial fluid, 
 
The activation agents TNFα was selected based on Blasi et al. (2011). We 
hypothesised that inflammatory synovial fluid would be a biological substance that 
would activate MSC and DF in line with the discussion by Prockop (2013) on tissue 
products as natural inducers. Other activation agents mentioned in the literature are; 
IFN-γ (Carrade et al. 2012; Paterson et al. 2014) and phytohemagglutinin (PHA) 
(Carrade et al. 2012) and lipopolysaccharide (LPS) (Blasi et al. 2011). One 
limitation of this study was that we could not fully quantify all of the components 
of the pooled inflammatory synovial fluid as discussed previously. Future studies 
could compare the degree of activation exerted by the different agents in vitro 
and/or evaluate the in vivo effect of mesenchymal stromal cells injected intra-
articular (activation) on change in cytokine concentrations in synovial fluid.  
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A panel of six cytokines were selected, based on the current literature on equine 
arthropathy (Bertone et al. 2001; Kamm et al. 2010; McIlwraith 2005) and tendon 
injuries (Hosaka et al. 2002). Enzyme linked immunosorbent assay was selected as 
the method for cytokine evaluation and equine specific ELISA kits were found to 
be commercially available from Genorise, USA. In contrast to an earlier study by 
Kamm et al. (2010) who used human ELISA kits or manufactured their own. Each 
kit had a specific detection range (picograms/ml) and standards supplied for 
manufacturing of a standard curve. It was surprising that during the initial 
experiment, results for absorbance could only be obtained for two of the secreted 
cytokines; TGF-β1 and PGE2. The remainder four cytokines (Il-1β, IL-6, IL-10 and 
TNFα) were outside the range of detection. The selection of IL-1β can be 
questioned and the receptor antagonist protein, IRAP may have been more 
appropriate. Carrade et al. (2012) found IL-6 only to be produced by mesenchymal 
stromal cells (ADSC, BMSC, UMBT and UMBB) after activation with PHA or T-
cells enriched PBMNC. Kamm et al. (2010) evaluated TNFα levels successfully 
with ELISA, their values were in the range of 10-40pg/ml. The Nori Equine TNFα 
kit used in the present study had a detection range of 31-2000pg/ml, hence the 
amount produced was too low to be interpreted with this kit. Kamm et al. (2013) 
did report a similar problem for IL-1β and MMP13. Despite the non-detectable 
results obtained for IL-10 during Run1, additional plates were acquired and in the 
following experiments results were produced within the correct range and within 
the limit of detection. 
 
The result from this present study showed that for the anti-inflammatory cytokines; 
TGF-β1 was produced at higher levels after activation with I-SF compared to 
control (culture media) and compared to TNFα activation. This was significant for 
umbilical tissue stromal cells (P=0.03) and dermal fibroblasts (P=0.02) but not for 
bone marrow derived cells (P=0.57), the trend line was the same but non-
significant. The results obtained in the present study for PGE2 showed both TNFα 
and I-SF activated bone marrow stromal cells did increase their production of PGE2, 
however the result was non-significant, P=0.40. For the dermal fibroblast cell 
populations, the control group (CM) produced higher concentrations of PGE2 than 
each of the two activated groups, P=0.008. This was in opposite to the BMSC 
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results. The umbilical cord tissue cell population had concentration values that were 
below the lower limit of sensitivity for the test kit, so no result was recorded for this 
source. From a clinical point of view there is the potential to utilise this anti-
inflammatory and immunomodulatory effect of mesenchymal stromal cells and 
dermal fibroblasts. If allogenic stromal cells and also dermal fibroblasts like our 
results show, are injected into an inflammatory environment in an injured equine 
synovial joints (in vivo), in theory they should upregulate the IL-10 and TGF-β1 
production, which could promote beneficial anti-inflammatory effects in the joint 
and the synovium. Prockop (2013) suggest that Prostaglandin E2 plays a large role 
as part of a negative feedback loop regulating inflammation. The proposed 
mechanism of action is that TNFα activated stromal cells produce PGE2 that drives 
resident macrophages with an M1 pro-inﬂammatory phenotype toward an M2 anti-
inﬂammatory phenotype. In the present study activated bone marrow derived MSC 
increased their production of PGE2 while dermal fibroblasts did not. Hence the 
conclusion is drawn that BSMC would be preferable to use as a therapy. 
 
An a priori sample size analysis for the cytokine experiment revealed that the 
minimum number of samples required for a statistical power of 80% was 64 
matched samples when performing paired t tests intra-source between control and 
the two activation agents (treatment groups). This number of samples was not 
achievable for this study. 
 
The plate effect was noticeable and only for the IL-10 and TGF-β1 kits, were the 
absorbances recorded in a similar range for both replicates. For PGE2 there were a 
100-fold difference noted in absorbance for the UMBT cells and the concentrations 
obtained were below the detection range of the test kit, thus for UMBT it was not 
possible to analyse nor compare the results with the other two sources. A more 
accurate comparison across the three sources was obtained for IL-10 concentrations 
(Run3), as the plate effect was eliminated. The other two ELISAs for TGF-β1 and 
PGE2, were run on two different plates on two separate occasions (Run1 and Run2). 
The results for TGF-β1 concentrations were still comparable, the range was 320-
620pg/ml for BMSC (Run1) compared to 200-1400pg/ml for DF and UMBT 
(Run2). The large inter-test variability of these equine specific ELISA kits, 
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unfortunately make the results less reproducible so a different method of analysis 
should be considered for future cytokine evaluation.  
 
Determination of the tissue source that produce the highest levels of cytokines 
associated with anti-inflammatory action and tissue repair could enable the 
selection of the best cell type for clinical applications. Ideally a more complete 
panel of cytokine and chemokines should be tested to further determine the 
differences between mesenchymal stromal cells and dermal fibroblasts. The 
antibody array method can simultaneously measure up to several hundreds of 
proteins (Hoogduijn et al. 2010). Compared to the ELISA method, antibody arrays 
are also highly cost-effective and consume less sample volumes. It can provide a 
broader perspective with the possibility to unveil other relevant molecules that may 
not have been previously considered. Bead-based assays confer savings in time and 
costs because they allow multiplexing, which is the simultaneous detection of 
multiple targets (Wagner and Freer 2009). Multiplexing allows for smaller sample 
volumes and high-throughput automation. However, the bead systems are not yet 
commercially available for equine specific cytokines. This signalling system by 
cytokine and chemokine expression is intriguing; MSC and DFs can influence the 
local tissue environment where they are applied. The plausible mechanism to 
explain the effects seen in tissues after MSC treatment, are that they provide 
regulatory function and immuno-modulation via secreted mediators; PGE2, TGF-
β1, IL-10, TSG-6 to control inflammation and aid in the repair and regeneration. 
Many equine musculo-skeletal injuries increase in severity due to excessive 
inflammation post the initial trauma. Mesenchymal stromal cells and dermal 
fibroblasts both acquired anti-inflammatory properties after activation (a simulated 
inflammatory environment), as shown in this study by the increased production of 
anti-inflammatory cytokines. Future research efforts should aim to characterise the 
full secretome of equine mesenchymal stromal cells and dermal fibroblasts when 
activated and applied in various clinical conditions. If their full potential could be 
evaluated, then treatments could ultimately be targeted to suit a specific 
inflammatory niche or type of injury.  
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Conclusion 
It appears that the definition of equine mesenchymal stromal cells and dermal 
fibroblasts is purely an academic matter as suggested by Ulrich et al. (2012). Is a 
fibroblast a terminally differentiated form of a stromal cell? Or is it a dynamic 
process involving the mesenchymal to epithelial transition and the reverse process; 
epithelial to mesenchymal transitioning? Both which are commonly occurring in 
tissues as a response to the local environment. This combined with cell cycle events 
make it seem impossible to elucidate their relationship. It seems more important to 
define functionality of each cell population in vitro and in vivo to optimise the 
potential use for clinical applications. The goal of stem cell therapy in horses is to 
regenerate tissues that are inherently difficult to heal naturally with completely 
restored functionality. Any treatment which is able to restore the architecture of the 
damaged tissue and potentially reduce the time to recovery and rate of re-injury, 
would greatly help to reduce wastage of horses as well as overall costs incurred to 
the equine industry in New Zealand.  
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APPENDIX 1: MEDIA, SOLUTIONS AND BUFFERS 
Basal Culture Media for MSC – To make total volume of 300ml  
Ingredients Volume Source 
DMEM low glucose 355ml LifeTechnologies 
FBS 40ml Gibco 
Antibiotic-Antimycotic 4ml Sigma Aldrich 
Fungizone 400μl Sigma Aldrich 
Gentamicin 500μl ProPharma 
Filter sterilised 0.22μm stock ingredients 
 
Cryogenic medium 
Ingredients Volume (20ml stock) Source 
75% DMEM  15ml Thermofisher 
20% FBS 4ml Life 
Technologies/Gibco 
5% DMSO 1ml Thermofisher 
Filter sterilised 0.22μm stock ingredients 
 
Collagenase 
Ingredients Quantity/volume (10ml) Source 
Collagenase, Type 1A, 
125 CDU/mg solid 
0.02g Sigma Aldrich 
PBS 10ml Thermofisher 
Filter sterilised 0.22μm stock ingredients 
 
2% Agarose gel 
Ingredients Quantity Source 
Agarose powder .67g Ngaio Diagnostics 
1xTAE buffer 33ml Waikato University 
 
30% Sucrose solution 500ml   
Ingredients Quantity/volume 500ml Source 
Sucrose 150g Sigma Aldrich 
PBS 10x 50ml Thermofisher 
Sterile dH20 To 500ml Waikato University 
Filter sterilised 0.22 μm and stored at 4°C 
 
50x TAE buffer 1000ml
Ingrediants Quantity Source 
Tris 242g Sigma Aldrich 
glacial acetic acid 57.1ml Sigma Aldrich 
0.5M EDTA 100ml Sigma Aldrich 
dH20 To 1L Waikato University 
1 x TAE (20ml 50x TAE into 980 ml dH20) 
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1X PHEM buffer 100ml pH 6.9
Ingredients Quantity Source 
60mM PIPES 1.81g Sigma Aldrich 
25mM HEPES 0.60g Sigma Aldrich 
0.5M EGTA 0.38g Sigma Aldrich 
2mM MgCl2 0.02g Sigma Aldrich 
 
 
APPENDIX 2: CONSUMABLES, CHEMICALS, 
DRUGS 
 
Consumables      
Product Supplier Catalogue number 
Cell strainer - Green Lifetechnologies MILSLGV100RS 
Cell strainer - Orange Ray Lab, NZ GR542070 
Centifugation tubes 
15ml Interlab, NZ KJ324 
Centifugation tubes 
50ml Interlab, NZ KJ326 
Coverslips Thermo Fisher Scientific FSHMNJ-500-010G 
Cryovial Greiner 1ml 
blue Mediray, NZ GR123279 
Cryovials Greiner 2ml 
green Mediray, NZ GR126277 
Falcon tube, 15ml 
sterile Thermo Fisher Scientific LBSCN8CT15 
Falcon tube, 50ml 
sterile Thermo Fisher Scientific LBSCN8CT50 
Filter papers Thermo Fisher Scientific LBS0001.070 
Nunclon flasks 25cm Thermo Fisher Scientific NUN156340 
Nunclon flasks 75cm Thermo Fisher Scientific NUN156499 
Parafilm Thermo Fisher Scientific TS3800 
Pipette bulbs Thermo Fisher Scientific C-P24820-60 
Pipette tips 1ml Interlab, NZ LC1057-965 
Pipette tips 200ul Interlab, NZ LC1059-965 
Sterile disposable 
pipettes Ray Lab, NZ RL200CS01 
Syringe filter - 22μm Lifetechnologies MILSLGV025RS 
Syringe filter - 45μm Minisart, Sartorious Stedim 16555 
Surgipath Apex 
Cryostat Slides 
Thermo Fisher Scientific 
NC0884931 
Surgipath® 
Frostbite® Spray Leica Biosystems 3803100 
0.5ml straws Minitub, Australia  13408/0010 
24 well plate nunclon Thermo fisher Scientific NUN142475 
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4 well plates nunclon Thermo Fisher Scientific NUN144444 
6 well plate nunclon Thermo Fisher Scientific NUN145380 
96 well plate round 
low cell binding 
surface Thermo fisher Scientific NUN145397 
      
Chemicals general     
Acetic acid solution 
CH3COOH 0.1M Sigma- Aldrich NZ A9967 
Acetone CH3COCH3 Sigma- Aldrich NZ 90872 
Ethanol ETOH Sigma- Aldrich NZ E7023 
Isoproponol Sigma- Aldrich NZ 563935 
Methanol MeOH Sigma- Aldrich NZ M1770 
Paraformaldehyde  Sigma- Aldrich NZ 158127 
Phosphate buffered 
saline 10x solution Thermofisher FSBBP399-1 
Sodium Acetate 
NaOAc Sigma- Aldrich NZ S3272 
Sodium azide 0.1M 
NaAz Sigma- Aldrich NZ 8591 
Sucrose C12H22O11 Biolab AJA530-5KG 
      
Cell Culture     
Preparation     
Collagenase type 1A Sigma- Aldrich NZ C9891-500MG 
Lymphoprep Mediray N-1114545 
Vigro Embryo flush 
media Minitub, Australia  19982/6202 
Culture     
Antibiotic -
antimycotic Lifetechnologies 15240-062 
Dexamethasone Sigma- Aldrich NZ D8893-1MG 
Dimethyl sulfoxide 
C2H6OS Sigma- Aldrich NZ D8418 
DMEM low glucose, 
hepes, L-glut Lifetechnologies 12320-032 
Fetal bovine serum Lifetechnologies 10091148 
Fungizone 
(amphoterecin B) Lifetechnologies 15290-026 
Gentamicin 80mg in 
2ml ProPharma   
Glutamax Thermo Fisher Scientific 35050061 
HEPES sodium salt 
C8H17N2O4S Sigma- Aldrich NZ H3784 
Trypan blue 0.2um 
filtered Hyclone Thermo Fisher Scientific HYCSV30084.01 
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Trypsin-EDTA Lifetechnologies 25200-056 
      
Mycoplasma PCR     
HyAgarose  Hydragene  9012-36-6 
I-Taq,  2 PCR 
mastermix iNtRON 
Biotechnology Ngaio Diagnostics 25027 
PCR DNA ladder Genescript M106R 
Proteinase K 
recombinant PCR 
grade Sigma-Aldrich, NZ 
EO0491 
Redsafe, iNtRON 
Biotechnology Ngaio Diagnostics 21141 
      
Antibodies     
Immunocyto-
chemistry     
CD105 reactive 
against horse  
Abacus 
SEMCA1557  Clone 
SN6 
CD29 mouse anti-
human 
Norrie 
303001 Clone 
TS2/16 
CD44 rat anti-
mouse/human 
Norrie 103001 Clone IM7 
CD45 mouse anti-
human 
Abacus 
SEMCA87A Clone 
F10-89-4 
MHC-II mouse anti-
human Abacus 
SEMCA1085GA 
Clone CVS20 
2nd ab goat anti-
mouse FITC  Norrie Biotech/Biolegend 405305 
2nd AB rat anti-
mouse IgG 
ALEXA488 Abacus JI415545166 
Flow cytometry     
CD90+ Gentaur 
YV0298-01 Clone 
DH24A 
CD105-RPE+ AbD Serotec 
MCA1557PET 
Clone SN6 
CD45-Alexa488- AbD Serotec 
MCA87A488T 
Clone F10-89-4 
CD79a_Alexa647- AbD Serotec 
MCA2538A647T 
Clone CVS36 
(HM57) 
MHC-II- AbD Serotec 
MCA1085PE Clone 
CVS20 
7-AAD- Sigma- Aldrich NZ A9400-1MG 
Dapi AbD Serotec BUF061 
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Differentiation     
Stempro Adipose kit Thermo Fisher Scientific A10070-01 
Stempro 
Chondrogenic kit Thermo Fisher Scientific A10071-01 
Stempro Osteogenic 
kit Thermo Fisher Scientific A10072-01 
Stains     
Alcian Blue  Sigma- Aldrich NZ A5268 
Alizarin Red Sigma- Aldrich NZ A5533 
Oil Red O Sigma- Aldrich NZ O0625 
Organo-limonene 
mount Sigma- Aldrich NZ O8015-30ML 
Harris Hematoxylin & 
eosin Sigma- Aldrich NZ HHS16 
OCT Jung tissue 
freezing media Leica Biosystems 14020108926 
      
Bio Activation Assay     
TNF alpha Sigma- Aldrich NZ H8916-1006 
allogenic synovial 
fluid     
ELISA plates     
GSI Equine IL-1b Genorise USA 106041-SF 
GSI Equine IL-10 
ELISA jf Genorise USA 106003-SF 
GSI Equine IL-6 
ELISA Kit jf Genorise USA 106001-SF 
GSI Equine TGFb1 
ELISA Kit jf Genorise USA 106123-SF 
GSI Equine TNF-
alpha ELISA Kit jf Genorise USA 106004-SF 
Nori Equine PGE2 
ELISA Kit Genorise USA GR106222-SF 
 
PCR equipment and enzymes 
Equipment/enzymes Supplier Specifications 
Ethidium bromide  10mg/ml 
100bp Ladder GenScript M102R 500ul 
I-Taq 2 PCR Ngaio 
Diagnostics 
25027 
MgCl2 2M and 4M  
Electrophoresis unit Owl tank and 
power packs 
 
Thermal cycler BioRad T100 
Real Time PCR 
machine 
Corbett Research Rotor-Gene 6000 
UV illuminator Gibco BRL UV-TFX-35M 
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Spectrophotometer Nanodrop 2000  
PCR eppendorfs  200ul, 500ul 
Redsafe, iNtRON 
Biotechnology 
Ngaio Diagnostics 21141 
PCR DNA ladder Genescript M106R 
Proteinase K 
recombinant PCR grade 
Sigma-Aldrich, NZ EO0491 
 
 
APPENDIX 3: EQUATIONS 
Equation 1 ............................................................................................................. 65 
Equation 2 Haemocytometer count ....................................................................... 65 
Equation 3 Population/Cell Doubling time (DT) .................................................. 66 
Equation 4 Cell numbers at T=X hours ............................................................. 66 
Equation 5 Fitted logistic ELISA Standard curve ................................................. 88 
Equation 6 Fitted logistic ELISA Standard curve ................................................. 89 
 
APPENDIX 4: HISTOGRAMS  
 
 
 163 
 
 
 164 
 
 
 165 
 
 
 166 
 
 
